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ABSTRACT 
 Natural product total synthesis provides an alternative method for obtaining 
medicinally relevant compounds in a more efficient process with higher yields than what 
nature can provide. Natural products pose significant synthetic challenges due to the 
unique heterocyclic skeletons with fused and spirocyclic ring systems. Therefore, it is 
paramount to develop efficient reaction methodologies targeting substructures such as 
cyclic ureas and spiro[4.5]decanes which are prominent among marine natural products 
and Lycopodium alkaloids, respectively. Presented here is a compilation of research 
seeking to develop synthetic methods for the construction of cyclic moieties such as those 
previously mentioned. The objectives that are addressed include: 1) Investigating the 
vinylogous enolate reactivity of phenols to undergo intramolecular para-allylation with 
pi-allyl palladium complexes to form functionalized spiro[4.5]decanes 2) The 
development of synthetic strategies for the preparation of tri-substituted quinoline 
scaffolds and subsequent derivatization toward establishing a library of heterocyclic 
candidates for HIV-1 integrase inhibition and 3) Investigating a new synthetic tool for the 
creation of carbon-nitrogen bonds to afford 1,2-diamines as the protected cyclic urea via 
vinyl sulfoxide/carbodiimide annulation and sigmatropic rearrangement. 
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CHAPTER I - INTRODUCTION 
1.1 Natural Product Isolation 
Throughout history and within various cultures, humans have utilized natural 
remedies for treatment of a variety of ailments ranging from acute illnesses to chronic 
conditions. Medicinally, these remedies have proven useful which has led to increased 
interest in isolation of the specific compounds in naturally occurring species that exhibit 
these properties. This process has been valuable for the discovery of a plethora of 
molecules containing biologically relevant indications. Although isolation techniques 
have revealed significant information about what nature can provide, there are two 
limitations with harvesting these compounds from their native plants: 
1. Extensive isolation procedures requiring considerable time, labor, and 
resources. 
2. Total plant composition comprising low percentages of the target 
compound which leads to waste and endangerment of the plant. 
In response to these issues, the chemical community has embarked on a myriad of 
synthetic endeavors to mimick the complicated synthesis that nature has been able to 
acheive. 
 Natural product total synthesis provides an alternative method for obtaining 
medicinally relevant compounds in a more efficient process with higher yields than what 
nature can provide. In addition, the synthetic methods developed can be utilized for a 
myriad of applications including pharmaceutical research where the preparation of 
analogues from a single key precursor is implemented for drug discovery. Among the 
plethora of natural products that are known, a substantial amount contain unique 
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heterocyclic skeletons with fused and spirocyclic ring systems which present significant 
challenges to the synthetic chemist. The ultimate goal is to discover efficient 
methodologies for the synthesis of substructures within natural products. By doing so, the 
total synthesis of natural products can become the desired alternative to harvesting from 
natural sources. 
1.2 Total Synthesis Milestones 
In pursuit of these goals, the field of organic synthesis has made significant 
progress over the past decades. A variety of synthetic acheivements that laid the 
foundation for modern organic chemistry include the preparation of multicyclic 
compounds such as morphine,1 quinine,2 penicillin V,3 and strychnin4 (Figure 1.1). Of 
course, these select examples do not encompass all the classical syntheses that have 
defined the field as it exists today. 
 
Figure 1.1 Select classic natural product total syntheses. 
One common theme shared among all of these natural products is the presence of 
cyclic features. There are a variety of conformations presented which include 
carbocycles, heterocycles, aromatics, fused and spirocyclic ring systems, and varying 
stereochemical complexity. While some appear to contain higher complexity than others, 
each molecule presents unique challenges that test the ingenuity and creativity of the 
 3 
organic chemist. At times, the simplest molecule in appearance can harbor the most 
significantly challenging synthetic task. 
1.3 The Necessity for Cyclization Reactions 
With it clear that cyclic moieties comprise a high percentage of structural features 
among a multitude of chemical targets, it is paramount that methodolgy for the 
construction of cyclic structures be continuously developed and refined. From the onset, 
key cyclization reactions that have continued to influence the synthetic community 
surfaced. An example can be found by the work of Otto Diels and Kurt Alder when they 
discovered the [4+2] cycloaddition;5 a reaction that is still implemented in modern 
synthesis. Additionally, the Stork-Eschenmoser hypothesis which stated the development 
of exclusively trans polycyclic ring systems can be developed stereoselectively from 
polyunsaturated trans olefins, serving as a foundation for the development of steroid 
synthesis.  
Other notable developments include the discovery of alkene6 and alkyne7 
metathesis. Following the seminal publications, both systems were expanded into what is 
now generally referred to as “ring closing metathesis”. Following these reports, J.E. 
Baldwin established a set of guidelines for intramolecular ring closing reactions which 
have sense been termed “Baldwin’s Rules”.8 The purpose of these rules was to establish 
defining factors that govern both plausibility of a ring closure to occur and predicted 
stereochemical outcomes. Although this select set of examples is not exhaustive, they are 
preseneted as a highlight to the major contributions in the field and serve as an 
introduction to the continued demand for novel alternative methods for constructing 
cyclic molecules. 
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With the understanding that cyclization reactions hold a significant component for 
the synthesis of natural products, this dissertation seeks to implement and expand on 
these concepts. In the proceeding chapters, three individual projects are presented. 
Although each section contains a unique and specialized niche, a broadened examination 
reveals that all three ideas seek to expand on current applications of cyclization reactions 
and contribute to the collective knowledge found within this widespread topic. 
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CHAPTER II - APPLICATION OF TSUJI-TROST VARIANT OF THE WINSTEIN-
MASAMUNE REACTION TOWARD THE SYNTHESIS OF MAGELLANINE 
2.1 Introduction 
2.1.1 Cyclopiane Terpenes 
 Terpenes are a class of natural products that are prominent among plants and 
fungi and are often isolated from the essential oil extracts. Terpenes consist of only 
hydrocarbons and follow a pattern of containing five-carbon units.9 In the late 1800s it 
was observed by Otto Wallach that the building block for these units was isoprene which 
contains the molecular formula C5H8 which is now referred to as the isoprene rule.
10 
Though examples containing oxygen in the form of alcohols, ketones, and aldehydes 
have also been reported these are instead referred to as terpenoids due to diversion from 
the established rule. 
Though a wide variety of sub-classes for terpenes have been established, two are 
of particular interest for this research (Figure 2.1): 
1. Cyclopianes: Conidiogenone 2.3 
2. Acoranes: Colletoic Acid 2.4 
 6 
 
Figure 2.1 Spiro[4.5]decane architecture in natural products. 
The reason for this selection resides in both the biological activity for these 
families as well as the structural scaffold shared among each. To begin, the first report of 
terpenes within the cyclopiane family was published by Roncal and co-workers in 2002 
wherein conidiogenone was isolated from the fermentation broth of Penicillium 
cyclopium.11 It was recognized that this terpene had the capability to induce 
conidiogenesis (the aerial or aquatic transfer of spores via conidia) which could be 
utilized to further understand this biological process of fungi. Following this initial 
report, a variety of new cyclopianes have been discovered and have shown to have 
diverse biological activity including antimicrobial indication against Staphylococcus 
aureus,12 cytotoxicity against human Leukemia cells,13 and antiallergenics.14 
In pursuit of synthetic preparations of desired cyclopianes, Hou and co-workers 
recently reported a convergent synthesis of three cyclopianes via a key directed 
semipinacol rearrangement step which afforded construction of both the C ring and the 
quaternary carbon shared by ring C and A (Scheme 2.1).15 Through the previously stated 
 7 
Lewis acid mediated cycloenlargement semipinacol rearrangement, tetracycle 2.6 was 
developed from 2.5. An additional three steps which included an aldol cyclization 
succeeded in the production of the tetracyclic core in 2.7. 
 
Scheme 2.1 Construction of the tetracyclic core found in cyclopianes. 
2.1.2 Acorane Terpenes 
Acoranes present a unique family of sesquiterpenes due to the bicyclic 
spiro[4.5]decane scaffold. The first reported discovery of the acorane family was by 
Sorm and co-workers during their investigation of sweet flag oil wherein degradation 
experiments of acorone 2.9 revealed the spirocyclic structure.16 Since this discovery, a 
variety of spiro[4.5]decanes have been isolated and reported. In early studies, it was 
postulated that acoranes acted as a key intermediate for the biosynthesis of tricyclic 
skeletons such as cedrene 2.10 (Scheme 2.2).17 
 
Scheme 2.2 Biosynthesis of cedrane. 
Colletoic acid 2.4 (Scheme 2.3) presents a prime example of the utility for 
medicinal applications of an acorane sesquiterpenoid. Following its discovery in 2008 
and subsequent application as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor for 
the treatment of type 2 Diabetes and metabolic syndrome,18 both the Rivas and Nakada 
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research groups have shown successful synthesis of the molecule.19-20 In pursuit of a 
more effective treatment for metabolic syndrome, Rivas and co-workers utilized a late 
stage palladium mediated intramolecular Heck coupling to furnish the spirocyclic carbon. 
This served as the groundwork to produce an extensive table of colletoic acid derivatives 
for inhibition studies.21  
 
Scheme 2.3 Synthetic approaches to colletoic acid 2.4. 
2.1.3 Lycopodium Alkaloids 
Lycopodium alkaloids are a classification of structurally similar natural products 
isolated from the species of club moss, Lycopodium. The first isolated Lycopodium 
alkaloid, lycopodine 2.17, was discovered by Bödeker in 1881.22 This same alkaloid was 
again isolated and structurally elucidated in 1938 by Achmatowicz and Uzieblo.23 
Following these first reports, the interest in the lycopodium alkaloids significantly 
increased. Throughout the past several decades, the isolation and elucidation of over 200 
Lycopodium alkaloids have been reported. During the period of 1986-1990, a variety of 
isolated Lycopodium alkaloids were discovered to possess potent acetylcholinesterase 
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inhibition activity. The most potent of these is huperazine A which was isolated from 
Huperzia serrata.24 
 The structures of the Lycopodium alkaloids have the same basic skeleton of two 
2-propylpiperidine units and are divided into four major classes: lycodine, lycopodine, 
fawcettimine, and the miscellaneous group which are represented by lycodine, 
lycopodine, fawcettimine, and phlegmarine, respectively (Figure 2.2).25 It is important to 
recognize that among the over 200 Lycopodium alkaloids isolated, there are a plethora of 
variations to these core structures and further detail into these variations are outlined in a 
review by Gang, et al.26 
 
Figure 2.2 Major lycopodium alkaloid classes. 
2.1.4 Isolation of Magellanine and the Structure Elucidation 
Magellanine, a member of the fawcettimine class, was first isolated from 
Lycopodium magellanicum by Castillo and coworkers in 1976 and was fully elucidated 
utilizing NMR, IR, MS, and UV-Vis techniques27. The molecular formula was 
determined to be C17H25NO2 through combustion analysis and mass spectrometry. The IR 
spectrum contained noteworthy signals at 3330, 3150-2400, and 1650 cm-1 which implied 
the presence of both an alcohol and ketone functionality. It was further confirmed that the 
ketone was α,β-unsaturated from the UV-Vis spectrum containing λmax at 237 nm. 
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 A 1H NMR spectrum (220 MHz) identified the presence of an N-methyl group as 
a singlet integrating to three protons at 2.23 ppm and a vinylic methyl group integrating 
for three protons at 1.94 ppm. Furthermore, a proton geminal to a secondary hydroxyl 
group was located at 4.21 ppm with an integration of one proton. Decoupling 
experiments successfully confirmed the presence of the vinylic methyl group to be 
located on the β position of the α,β-unsaturated ketone. It was also determined via 
decoupling that the secondary hydroxyl was located between a methine and methylene 
unit. 
 The mass spectrum was then utlilized to identify fragmentation patterns of the 
molecule. The daughter tree was compared to that of paniculatine and found to have 
significant similarities. Of particular note is the nitrogen containing ions with m/z at 57, 
58, 70, 71, 96, 97, 110, and 111 which were representative of the piperidine ring 
fragmentations also found with paniculatine (Figure 2.3). Finally, X-Ray crystallography 
was utilized to confirm spectroscopic observations and determine relative 
stereochemistry. 
 
Figure 2.3 Key daughter ions of magellanine and paniculatine. 
2.1.5 Prior Total Syntheses of Magellanine 
Following the isolation and structural elucidation of magellanine, a variety of 
methods have been reported for the preparation of this Lycopodium alkaloid. The first 
account of a successful total synthesis came from Overman and co-workers wherein a 25-
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step sequence was implemented consisting of a key stereocontrolled tetracycle formation 
via a Prins-Pinacol spirocyclization (Scheme 2.4).28 
 
Scheme 2.4 Overman total synthesis. 
Shortly after the first synthesis, Paquette and co-workers described the second 
successful preparation of magellanine in seventeen steps. The utility of this report is 
found in the construction of the tricyclic core via a tandem Michael addition diquinane 
synthesis (Scheme 2.5).29 
 
Scheme 2.5 Paquette total synthesis. 
In the early 2000s two research groups utilized a Pauson-Khand reaction as a 
method for installation of two cyclic portions in a single step. The first report by Ishizaki 
in 2005 produced the tricyclic core from enyne 2.35 with a total step count of thirteen to 
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develop magellanine (Scheme 2.6).30 Two years later, the Mukai group implemented 
similar chemistry for the construction of the tetracyclic precursor 2.38.31 
 
Scheme 2.6 Ishizaki and Mukai total syntheses. 
The prevalent feature of all prior examples is the construction of the piperidine 
ring (ring D) in a late-stage synthetic strategy. With the intention of developing a concise 
preparation of magellanine-type alkaloids, Sarpong and co-workers implanted a synthesis 
which incorporates the D ring as a dimethoxypiperidine. The power of this design resides 
in the palladium catalyzed pyridine C-H functionalization for the completion of the 
tetracyclic core (Scheme 2.7).32 A similar construction strategy was implemented by the 
Yang group wherein the D ring was delivered from readily available arecoline and a sight 
selective aldol condensation was performed as the key tetracycle-forming step.33 
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Scheme 2.7 Sarpong and Yang total syntheses. 
2.2 Research Hypothesis 
It is hypothesized that a Tsuji-Trost variant of the Winstein-Masamune 
dearomatization can be implemented as an approach to the synthesis of the stereogenic 
quaternary carbon present within Lycopodium alkaloids. Furthermore, the development 
of a terminal alkene from this process can supply a functional handle for construction of 
the tricyclic core. 
2.3 Research Design and Methods 
2.3.1 New Methodology Proposed by Our Research 
With previous attempts at the synthesis of magellanine, we sought to design a 
novel method toward the preparation of the tricyclic core contained within the 
Lycopodium alkaloids. Shown in Scheme 2.8 is the retrosynthetic analysis of the key 
steps to our proposed methodology. It was envisioned that the core could be prepared via 
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free radical cyclization of halohydrin 2.45 which could be prepared via reaction of 
spirocycle 2.46 and a halogen electrophile. Synthesis of 2.46 to develop the stereogenic 
quaternary carbon would be achieved via a Tsuji-Trost variant of the Winstein-
Masamune phenolic allylation of para-substituted phenol 2.47. Preparation of 2.47 could 
be achieved from the alkylation of malonate 2.48 with prepared bis-electrophile 2.49. 
 
Scheme 2.8 Retrosynthetic analysis of the tricyclic core. 
2.3.2 Winstein-Masamune Phenolic Dearomatization 
The first of two key steps in the forward synthesis of our method is the Tsuji-
Trost variant of the Winstein-Masamune phenolic allylation. Therefore, it is pertinent to 
briefly discuss the original work by Winstein and the proceeding extension of the 
conditions by Masamune (Scheme 2.9). In the first attempt by Winstein, a para-
substituted phenol 2.50 was reacted with potassium tert-butoxide in tert-butanol to afford 
spiro[4.5]decane 2.51. This concept was further extended by Masamune when tricyclic 
structure 2.53 was successfully prepared from tetrahydronapthalene 2.52. This reaction 
presents several chemical aspects that prove the power of this transformation. First, there 
is a unique observation that the aromatic portion of the molecule is being treated as a 
vinylogous enolate. Second, this vinylogous enolate reactivity treats the para position as 
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the nucleophilic component for an intramolecular SNAr
- displacement reaction. The third 
and most significant aspect is the loss of aromaticity to produce a sterically congested 
quaternary carbon. Accompanying these strengths is one notable limitation that the 
displacement reaction is performed on a sp3 hybridized carbon which prevents 
proceeding functionalization at that location. 
 
Scheme 2.9 Winstein-Masamune phenolic dearomatization. 
2.3.3 Tsuji-Trost Variant for Phenolic Dearomatization 
To address this shortcoming, a Tsuji-Trost variant can be implemented. Seminal 
work by Tsuji showed the ability to substitute π-allylpalladium chloride with 
nucleophiles such as enamines, diethyl malonate, and ethyl acetoacetate.34 With this 
discovery, Trost and co-workers were able to demonstrate alkylation of π-allylpalladium 
complexes with soft nucleophiles (Scheme 2.10).35 
 
Scheme 2.10 Tsuji-Trost allylation. 
The power of this discovery portrays the ability to now perform nucleophilic addition to 
allylic positions. Therefore, it was postulated that developing a hybrid of both reactions 
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could provide a remedy for the shortcoming previously discussed in para-phenolic 
alkylations. 
 Recently, two independent publications by the Hamada36 and You37 groups 
utilizing palladium (2.57→2.59) and iridium catalysis (2.58→2.60) have effected a Tsuji-
Trost 5-exo-trig allylation variant of the classic Winstein-Masamune reaction. The use of 
phenol nucleophiles as vinylogous enolates in the intramolecular Tsuji-Trost allylation 
had been relatively unexplored over the past half century. Therefore, a Tsuji-Trost 
Winstein-Masamune (TTWM) phenolic allylation would be an ideal solution for the 
syntheses of molecules such as 2.59-2.60 (Scheme 2.11) as a vinyl group is deposited at 
the electrophilic carbon for post-cyclization modifications. 
 
Scheme 2.11 Hamada and You variant of the Tsuji-Trost allylation. 
Shown in Scheme 2.12 is the proposed catalytic cycle for the development of 
spiro[4.5]decanes. The proposed mechanism is based on that of known mechanism for 
the Tsuji-Trost reaction and begins with the formation of the pi-allyl complex 2.61 
resulting in the loss of carbon dioxide and methoxide ion. Methoxide then re-enters the 
cycle and deprotonates phenol 2.62. With the palladium complex forming a Zimmerman 
Traxler chair-like transition state (2.63), the para-carbon of the phenoxide attacks at the 
electrophilic center and produces the desired spirocycle 2.46. 
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Scheme 2.12 Catalytic cycle for Pd(0) mediated phenolic allylation. 
2.4 Results and Discussion 
2.4.1 Preparation of the Spirocyclic Precursor 
Outlined in Scheme 2.13 is the synthesis of the spirocyclic precursor. All 
synthetic steps preceding the spirocyclization of 2.47 to 2.46 have been successfully 
performed with minimal optimization or troubleshooting required. Briefly, Knoevenagel 
condensation of 4-hydroxybenzaldehyde 2.65 with dimethylmalonate was carried out in 
toluene in the presence of piperidine and catalytic acetic acid at reflux to afford 
benzylidene malonate 2.66 in 99% yield. Subsequent hydrogenation of the olefin with 
hydrogen gas in the presence of 10% palladium on carbon in methanol smoothly afforded 
reduced malonate 2.48 in 97% yield. The phenol was protected as the tert-
butyldimethylsilyl ether with TBSCl, imidazole and catalytic DMAP in DMF giving silyl 
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ether 2.67 in 95% yield. At this stage the allylic carbonate was installed via alkylation of 
the sodium enolate with the bis-electrophile 2.49. The silyl protecting group of 2.68 was 
quantitatively cleaved with TBAF in THF at ambient temperature giving the desired 
phenol 2.47 in 96% yield. Preparation of the TTWM precursor was achieved in five steps 
with an overall yield of 86%. 
 
Scheme 2.13 Synthesis of the spirocyclic precursor 2.47 and bis-electrophile 2.49. 
2.4.2 Synthesis of the Spiro[4.5]decane 
With gram quantities 2.47 in hand, the main focus of this research began with 
screening of conditions for optimal spirocyclization using a Pd(0) catalyst. Initial 
conditions for spirocyclization utilized a Pd(0) catalyst with triphenylphosphine as a 
ligand. Dichloromethane proved to be an effective solvent and was utilized for most 
attempts during the initial reaction screening. Although the spirocyclization successfully 
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showed progression to the expected product, the low conversion prompted further 
examination of conditions. Due to difficulty in separation of starting material and 
product, it was necessary for full conversion. 
In addition to palladium, we also examined iridium (I) and (II) catalysts. These 
catalysts were less effective and were therefore not considered in further investigations. 
Consequently, screening of available palladium (0) complexes was implemented to 
identify the catalyst that yielded the quickest and highest conversion (Table 2.1). All 
reactions were performed for six hours at room temperature on a 50 mg scale in order to 
maintain standard conditions and ensure accurate percent conversions were observed by 
crude NMR. The conversions observed from the six hour period could then be 
extrapolated in order to estimate a necessary reaction time to achieve full conversion. 
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Table 2.1  
Catalyst screening for spirocyclization 
 
Entry Catalyst Vendor/Lot Solvent Ligand Temp. %Conv.a 
1 Pd2(dba)3 Strem/30047 CH2Cl2 PPh3 ambient 37% 
2 Pd2(dba)3•CHCl3 Aldrich/30036 CH2Cl2 PPh3 ambient 19% 
3 Pd(PPh3)4 Aldrich/30026 CH2Cl2 PPh3 ambient 9% 
4 Pd2(dba)3 Strem/40101 CH2Cl2 PPh3 ambient 42% 
5 Pd2(dba)3•CHCl3 Aldrich/30058 CH2Cl2 PPh3 ambient 29% 
6 Pd(PPh3)4 Aldrich/30046 CH2Cl2 PPh3 ambient 13% 
7 Pd2(dba)3 Aldrich/30031 CH2Cl2 PPh3 ambient 39% 
8 Pd2(dba)3 Aldrich/40101 MeCN PPh3 ambient 38% 
9 Pd2(dba)3 Aldrich/40101 CHCl3 PPh3 ambient 28% 
 
aNote: All entries were reacted for six hours prior to filtration and NMR analysis. Crude NMR analysis was utilized to determine 
percent conversion via comparison of starting material peak at 4.65 ppm (1H) and product peak at 5.00 ppm (1H). 
The percent conversion of the spirocyclization was measured via NMR, HPLC, 
and GC with NMR proving to be the preferred method. Other techniques proved either 
less accurate or more time consuming than NMR. HPLC analysis indicated that the 
product and starting material exhibited different extinction coefficients at different 
wavelengths which resulted in inaccurate comparisons. A GC method for identification of 
the product peak was difficult to determine and was considered time consuming. NMR 
showed to have both the needed accuracy via signal integration and resulted in the quick 
acquisition time making it the preferred technique. 1H NMR was utilized for 
determination of the percent conversion by choosing peaks associated with the starting 
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material (4.65 ppm, allylic CH2) and the product (5.00 ppm, vinyl CH2) that both 
integrated for two protons. 
 Through these experiments, Pd2(dba)3 was the most effective catalyst and was 
therefore used in a solvent screen to determine the best reaction media for the 
spirocyclization. The solvents examined included: dichloromethane, chloroform, 1,2-
dichloroethane, THF, acetonitrile, toluene, and 1,4-dioxane. By selecting these solvents, a 
wide range of polarity and dielectric constants were explored. Dichloromethane was 
identified as the most suitable solvent and was therefore implemented in all proceeding 
experiments. 
 With the catalyst chosen and suitable solvent identified, a reaction was performed 
at an increased scale of 200 mg and was stirred at ambient temperature for twenty four 
hours. It was believed that with a 42% conversion at six hours, twelve hours would be 
sufficient to approach 100% conversion. A conversion of 55% was observed, so the 
reaction was allowed to continue for the full twenty four hours. No further conversion 
occurred after twenty four hours so the reaction was stopped. It was likely that the 
palladium was being inactivated with residual oxygen in the solvent and reaction flask, 
preventing continuation of the catalytic cycle. 
 With this conclusion, it was pertinent to identify another method that may allow 
for shorter reaction times to minimize the effect that residual oxygen may have on the 
reaction. Therefore, the reaction was irradiated via microwave conditions with the 
Biotage® Initiator+ microwave reactor. Within five minutes at 80°C, TLC analysis 
showed complete consumption of starting material with a product spot appearing at the 
same location as previously seen with the reactions performed at ambient temperature. 
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NMR analysis revealed that the product was neither starting material nor the desired 
product. Two-dimensional NMR techniques and LRMS were implemented to provide 
insight into the structure of the unknown product. It was determined via NMR that the 
carbonate functionality had been lost due to absence of the proton signal at 54.9 ppm 
associated with the methyl protons and absence of the carbon signal at 155.9 ppm 
associated with the sp2-hybridized carbonyl carbon (Figure 2.4). 
 
Figure 2.4 NMR evidence for loss of carbonate functionality in intermediate 2.47. 
It was postulated that a Claisen-type [3,3]-sigmatropic rearrangement catalyzed 
by the heat of the reaction (Scheme 2.14). Following this rearrangement, the palladium 
catalyst would then insert between the new C-O bond resulting in the expected 
elimination of the carbonate as carbon dioxide and methoxide. A subsequent β-hydride 
elimination then occurs to form diene 2.74. 
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Scheme 2.14 Mechanistic hypothesis for formation of diene 2.74. 
Both 1-dimensional and 2-dimensional NMR techniques were utilized to elucidate 
the structure of 2.74. Proton NMR provided evidence of the presence of five alkene 
protons located at 6.35 ppm, 6.15 ppm, 6.04 ppm, 5.24 ppm, and 5.15 ppm. The presence 
of the terminal alkene was confirmed from the signals at 5.24 and 5.15 ppm (H10) via 
HSQC which proved both signals were coupled with the same carbon. Further 
confirmation was found in the coupling constants with a cis-coupling of 16.8 Hz and 
trans-coupling of 10.1 Hz for the proton at 5.24 and 5.15 ppm, respectively. The 
assignment of C8 and C9 required the use of HMBC which showed long range coupling 
of H8 with C6 while H9 did not express this coupling. Therefore, it was concluded that 
the connection sequence was C10-C9-C8. This conclusion has been further supported by 
mathematical calculation through Spartan prediction software utilizing the Hartree-Fock 
3-21G method which indicates complimentary splitting patterns and peak shifts. 
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Figure 2.5 HMBC correlation confirming connectivity of diene 2.74. 
Based on the development of the undesired diene, the microwave conditions were 
altered. The reaction was heated to 40°C to prevent the thermally initiated Claisen 
rearrangement. After 20 minutes of microwave radiation, complete cyclization occurred. 
Having established appropriate conditions, the reaction scale was increased to 500 mg to 
confirm reproducibility. Larger scale batches required extended reaction times of 40 
minutes and contained minor amounts of diene 2.47 after purification. 
 Despite using sufficiently degassed solvent, the efficiency of the microwave 
reaction with Pd2(dba)3 was diminishing with every new reaction. Over a twenty minute 
period in the reactor, the color of the solution was changing from an orange yellow color 
to a deep amber or green yellow. Eventually, no changes were observed via TLC and 
crude NMR showed no loss of starting material or the formation of the spirocycle 
intermediate. To address the issue with diminishing efficiency of the palladium catalyzed 
spirocyclization, new procedures were implemented. To ensure that the Pd (0) catalyst 
was not quenched, the reaction vial was loaded with triphenylphosphine and the catalyst 
then immediately sealed. The vial was then evacuated via syringe through the septum and 
charged with dry nitrogen. Phenol 2.47 was prepared in a separate recovery flask that was 
also evacuated and charged with dry nitrogen. Dichloromethane was degassed for twenty 
minutes with dry nitrogen and 2.47 was then dissolved in the solvent and transferred to 
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the reaction vial via syringe. The vial was then heated at 40°C for 40 minutes in the 
Biotage® Initiator+ microwave reactor. 
This new procedure proved to be successful in achieving 100% conversion of 
starting material. Of note is the color difference of the crude solution with a successful 
reaction against the color of a crude solution of a reaction with poor conversion. When 
100% conversion is achieved, the solution appears to be a golden yellow color while 
unsuccessful reactions appear purple-dark amber colored. In response to this success, all 
bottles containing Pd2(dba)3 were tested with this new procedure and all catalyst batches 
achieved full conversion of starting material. The next issue to be addressed is the percent 
recovery of product. At best, a 50% recovery has been achieved on a 50 mg scale (40% 
was also achieved with a 250 mg scale). Table 2.2 outlines all conditions attempted with 
the microwave reactor. 
Table 2.2  
Microwave reactor conditions for spirocyclization 
Entry Catalyst Vendor/Lot Scalea Time (min) Temp. %Yieldb 
1 Pd2(dba)3 Strem/40101 100 mg 5 80ºC 24% 
2 Pd2(dba)3 Strem/40101 75 mg 20 40ºC n/a 
3 Pd2(dba)3 Strem/40101 1.5 g 20 40ºC 28% 
4 [Ir(cod)Cl]2 Aldrich/30068 50 mg 10 50ºC n/r 
5 [Ir(cod)Cl]2 Aldrich/30068 50 mg 10 60ºC n/r 
6 [Ir(cod)Cl]2 Aldrich/30068 50 mg 10 70ºC n/r 
7 [Ir(cod)Cl]2 Aldrich/30069 50 mg 150 120ºC n/a 
8 [Ir(cod)Cl]2 Aldrich/30069 50 mg 90 70ºC n/r 
9 Pd2(dba)3 Strem/40101 50 mg 40 40ºC 60% 
10 Pd2(dba)3 Aldrich/30031 50 mg 40 40ºC 98%
c 
11 Pd2(dba)3 Aldrich/30047 50 mg 40 40ºC 60%
c 
12 Pd2(dba)3 Strem/40101 250 mg 40 40ºC 40% 
13 Pd2(dba)3 Strem/40101 500 mg 40 40ºC 40% 
14 Pd2(dba)3 Strem/40101 500 mg 40 40ºC 40% 
15 Pd2(dba)3 Strem/40101 500 mg 40 40ºC 5% 
16 Pd2(dba)3 Strem/40101 1.0 g 40 40ºC 20% 
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Table 2.2 (continued) 
17 Pd2(dba)3 Aldrich/30047 250 mg 40 40ºC 11% 
18 Pd2(dba)3 Aldrich/30047 250 mg 40 40ºC 36% 
19 Pd2(dba)3 Aldrich/30047 250 mg 40 40ºC 39% 
20 Pd2(dba)3 Aldrich/30047 660 mg 40 40ºC 25% 
 
Note: aScale based on milligrams of phenol 2.47 added. bIsolated via purification on a silica column eluted with hexanes-ethyl acetate 
solvent gradient. cContains diene byproduct. 
An issue with product isolation was being observed in the spirocyclization 
reaction at 50, 250, and 500 mg scales resulting in complete conversion but an isolated 
yield of 40% or less. Several methods to probe for the disappearance of the remaining 
60% of material were conducted. First, all material was flushed through the Cellite® plug 
that acted as the palladium filter. This was done by first flushing as normally performed 
using dichloromethane. This filtrate was then collected and a separate flush using ethyl 
acetate was collected in a separate flask. Both filtrates were checked for presence of 
product and only the dichloromethane flush contained product. It was postulated that the 
spirocycle was binding to the Cellite® so this step of the workup was removed. Removal 
of this step and subsequent addition of a saturated ammonium chloride quench and water 
extraction again afforded only a 40% yield. A complete list of attempted conditions for 
improved recovery of product is described in Table 2.3. 
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Table 2.3  
Spirocyclizations with alternative Pd (0) catalysts and conditions 
Entry Catalyst Vendor/Lot Scale Conditions Workup %Recovery 
1 Pd(PPh3)4 Strem/40101 274 mg µw; 40 min; 
40ºC 
hexane precipitation 50%a 
2 Pd(PPh3)4 Strem/40101 200 mg µw; 40 min; 
40ºC 
n/a 48%a 
3 Pd(PPh3)4 Oakwood 170 mg µw; 40 min; 
40ºC 
Et2O precipitation 50%
a 
4 Pd(PPh3)4 Oakwood 531 mg 2.5 hr; 50ºC n/a n/a 
5 Pd2(dba)3•CHCl3 Aldrich/30036 282 mg µw; 40 min; 
40ºC 
Celite filtration 29% 
6 Pd2(dba)3•CHCl3 Aldrich/30036 168 mg 12 hr; 
ambient 
Celite filtration 46%b 
7 Pd2(dba)3•CHCl3 Aldrich/30036 210 mg µw; 40 min; 
40ºC 
Celite filtration n/a 
8c Pd2(dba)3•CHCl3 Aldrich/30036 221 mg µw; 40 min; 
40ºC 
Celite filtration n/ad 
9 Pd(dba)2 Aldrich/30051 265 mg 16 hr; 
ambient 
Celite filtration 20% 
10 Pd(dba)2 Aldrich/30051 241 mg 45 min; 
ambient 
Celite filtration 40% 
11 Pd(dba)2 Aldrich/30051 522 mg 24 hr; 
ambient 
Celite filtration 27% 
 
aContains reagent impurities. bReported as percent conversion: calculated via qNMR with DMF as an internal standard. cReacted in 1,4-dioxane. dContains presence of diene byproduct as 
impurity. 
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A qNMR study was implemented to determine what the percent composition of 
the spirocycle was in the crude mixture. To perform this, a sample containing a known 
amount of crude residue was dissolved in 600 µL of CDCl3 and 10 µL of DMF was 
added to the solution. The singlet at 8.1 ppm associated with DMF was compared to the 
terminal alkene signal of the spirocycle located at 5.0 ppm. 
 With no success in yield improvements with workup procedures and the 
observation that increasing reaction scales resulted in diminished yields, several reactions 
were prepared at once and combined in bulk for purification. Implementing this batch 
approach resulted in a significant decrease of the isolated yields and implied that product 
loss may be occurring at the purification stage. Therefore, all collected fractions were 
concentrated and the contents were analyzed via NMR. A total of three separate fractions 
were collected during the purification of one of the 500 mg reactions. The first fraction 
contained triphenylphosphine (55 mg), the second contained product (150 mg) and the 
third fraction, obtained via 10% methanol in dichloromethane flush, contained residual 
Pd2(dba)3 and coordinated triphenylphosphine ligand. 
Knowing this, alternative purification methods were utilized. First, EDTA was 
used as an agent for binding and removing all residual palladium from the crude mixture. 
If successful, it would have been possible to run a shorter silica plug rather than a full 
column length (10-11 cm height). Reduced contact with the silica could have resulted in 
less product loss and higher recoveries. It was also reasoned that treating the silica gel 
with 1% triethylamine may prevent product loss on the column. 
 Performing these alternative purification methods did not result in improved 
purification. Scavenging for residual palladium still resulted in a 40% yield while base 
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treating silica with trimethylamine caused complete degradation of material on the 
column. Therefore, a final attempt at completely avoiding purification via 
recrystallization attempts included precipitation of the crude material into either hexanes 
or cold diethyl ether. Both systems resulted in a white, tacky precipitate while keeping 
the spirocycle product in solution. The yields were not further improved via these 
precipitation methods and residual triphenylphosphine still remained following NMR 
analysis. 
 Despite the issue of isolation, enough product was produced to perform a 
complete structural elucidation. This was achieved with the aid of 2D NMR techniques. 
COSY was used to identify the cyclohexenone (Hc-Hf, Hd-Hg) and cyclopentane (Hh-
He-Hj-Hn) spin systems (Figure 4). The diastereotopic protons of the cyclopentane ring 
(Hm and Hn) were identified via COSY coupling and confirmed via HSQC and the 
geminal coupling constants (1J = 14.7, 14.0). To determine the stereochemistry at Cj, 
NOESY was utilized. Correlation of Hj with Hc confirmed Hj to be located on the bottom 
face of the cyclopentane (Table 2.4). 
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Table 2.4  
Structural elucidation of spirocycle 2.46 
 
Position δC δH COSY HMBC (H to C) NOESY 
a 185.9 - - - - 
b 172.4 - - - - 
b’ 172.1 - - - - 
c 153.0 6.73 d,f a, d, l, m f, j, n1 
d 148.9 6.85 c,g a, d, l, m g, n2 
e 133.8 5.41 h1, h2, j l, n h 
f 130.1 6.29 d,f g, l c 
g 129.3 6.27 c,g f, l d 
h 117.8 h1: 5.01 e e, j e 
h2: 4.99 e e, j e 
i 58.5 - - - - 
j 53.5 2.84 e, n1, n2 c, d, e, h, l, m, n c, n1, n2 
k 53.3 3.80 - b, b' - 
k’ 53.2 3.79 - b, b' - 
l 52.1 - - - - 
m 43.6 m1: 2.68 m2 b, b', c, d, i, j, k, k', n - 
m2: 2.45 m1 b, b', c, d, i, j, k, k', n n1 
n 38.6 n1: 2.67 j, n2 b, b', e, i, j, k, k', m c, j 
n2: 2.56 j, n1 b, b', e, i, j, k, k', m d, j 
 
Additional evidence supporting the structure of the spirocycle can be found in the 
1H NMR splitting tree (Figure 2.6). Specifically looking at the coupling of Hg with Hi it 
was realized that one of the two proton signals was not contributing to the splitting 
pattern located at 2.6 ppm. Further investigation of the structure via 3-dimensional 
modeling revealed that a dihedral angle of 90º existed between Hg and Hi. According to 
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the Karplus equation, a 90º dihedral angle prevents coupling between the associated 
protons which explains the observed splitting pattern. 
 
Figure 2.6 1H analysis of spirocycle 2.46. 
2.4.3 Formation of the Tricyclic Core 
With the obtained product, several reactions were attempted towards the synthesis 
of the tricyclic core of Magellanine. It was envisioned that formic acid may be able to 
perform this cyclization in one step. Protonation of 2.46 at the unsaturated ketone would 
activate position d on the cyclohexenone ring (Table 2.5). The resulting formate ion 
would then attack the internal carbon (position e) of the alkene, pushing electon density 
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to the terminal carbon (position h). This would then incur an intramolecular nucleophilic 
attack on the electrophilic carbon of the cyclohexenone ring. All attempted reaction 
conditions for this process are outlined in Table 2.5. 
Table 2.5  
Attempted acid promoted intramolecular polyolefin cyclization 
 
Entry Reagent Solvent Temp. Time 
1 none THF ambient 24 hr 
2 sodium formate formic acid ambient 24 hr 
3 sodium formate formic acid 78ºC 24 hr 
4 sodium formate formic acid 100ºCa 20 min 
5 sodium formate formic acid 100ºCa 40 min 
 
Note: a Reactions performed in a microwave reactor. 
Another process was a two-step method which first involves a stereoselective 
halohydrin or selenyhydrin formation. Next, via free radical chemistry, the cyclization 
will occur. A summary of conditions for the selenylhydrin formation is provided in Table 
2.6. 
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Table 2.6  
Conditions for selenylhydrin formation 
 
Entry Equivalents Solvent Temp. Time %Yield 
1 1.0 THF/H2O ambient 24 hr 50% 
2 1.0 THF/H2O 95ºC
a 11 min 0% 
3 1.0 THF/H2O 50ºC 24 hr n/a
b 
4 2.0 MeCN/H2O ambient 24 hr 62% 
5 1.5 MeCN/H2O ambient 4 hr 87% 
6 2.0 MeCN/H2O ambient 6 hr 42% 
7 1.5 MeCN/H2O ambient 10.5 hr 35% 
 
Note: a Reaction performed in a microwave reactor. b crude material was used immediately in proceeding reactions without 
purification 
Success was observed in the selenylhydrin formation which resulted in focus 
diverting from the halohydrin conditions and optimizing the work with phenyl selenyl 
chloride. NMR analysis showed key changes with the upfield shift of the terminal alkene 
sp2 proton signals of x located at 5.4 ppm to 3.2 ppm and the sp2 carbon signal at 117.7 to 
the sp3 hybridized carbon signal at 35.7 ppm. Both diastereomer products were produced, 
resulting from the chiral center formed at the secondary alcohol. Although the 
diastereomers were separable by chromatography, little effort was made to do this 
because later oxidation of the alcohol to the ketone will remove the stereochemistry and 
an enantioselective reduction can then be performed to afford only the desired 
stereoisomer. To provide further proof that only diastereomers were formed, the products 
were separated via chromatography and analyzed via HRMS.  
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 With selenylhydrin 2.45a in hand, focus turned to the final step in the synthesis of 
the tricyclic core using free radical chemistry. Both thermal and light induced conditions 
were examined with the initial experiments utilizing tributyltin hydride and AIBN as the 
initiator (Scheme 2.15). 
 
Scheme 2.15 Proposed free radical cyclization of 2.45a with tributyltin hydride and 
AIBN. 
With no success in production of the tricycle via free radical initiated chemistry of 
the selenylhydrin, efforts returned to the implementation of halohydrins for the free 
radical chemistry. Starting with NBS, the reaction was performed according to the 
conditions in Table 2.7. 
Table 2.7  
Conditions for halohydrin formation 
 
Entry Reagent Equivalents Solvent Temp. Time %Yielda 
1 NBS 1.0 THF ambient 23 hr 19% 
2 NBS 2.0 Acetone/H2O 0ºC-ambient 22 hr 50%
b 
3 NBS 2.0 MeCN/H2O 0ºC-ambient 22 hr 50%
b 
4 NBS 1.5 THF/H2O 0ºC-ambient 25 hr 14% 
5 NBS 2.0 MeCN/H2O 0ºC-ambient 22 hr 55% 
6 NIS 3.0 MeCN/H2O 0ºC-ambient 22 hr 56% 
7 NIS 3.0 MeCN/H2O 0ºC-ambient 22 hr 32% 
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Table 2.7 (continued) 
8 NIS 3.0 MeCN/H2O 0ºC-ambient 18 hr n/a
c 
9 NIS 3.0 MeCN/H2O 0ºC-ambient 1.5 hr n/a
c 
 
Note: a All reported yields contain a mixture of diastereomers. b Entries were combined and purified as a single sample. c The crude 
residue was utilized in the proceeding reactions without purification 
With the bromohydrin in hand, an attempt at the tricycle formation via free radical 
conditions was performed. The initial conditions utilized thermally initiated 
azaisobutyronitrile and tributyltin hydride. Although complete conversion to product 
occurred within 45 minutes, NMR analysis implied the desired tricyclic structure was not 
produced. Upon complete analysis via 1D and 2D NMR, ESI-MS, and IR, it was 
determined that re-aromatization of the cyclohexadienone and subsequent formation of a 
trans-alkene afforded 2.76 (Figure 2.7). 
 
Figure 2.7 2-D NMR correlations for allylic alcohol 2.76. 
During the reaction screening using tin hydride reagents, we observed smooth 
conversion of the starting material to a more polar spot by TLC (Rf = 0.30 (1:1 hexanes-
acetone) but examination of the 1H NMR revealed a different structure containing an 
internal alkene functionality (implied from 1H NMR signals at 5.74 and 5.62 ppm). The 
byproduct was fully elucidated with 2D NMR and was determined to be a rearomatized 
phenol containing an allylic alcohol. COSY was used to identify the spin systems in the 
structure located at the alkene (Hl → Hf → Hc → Hh) and the phenol (Hg → Hd). HSQC 
 36 
and HMBC confirmed the connectivity of the phenol. The trans conformation of the 
conjugated diene was established based on the coupling constants (3Jc,f = 15.7 Hz). 
Additionally, 13C chemical shifts supported the presence of the phenol (155 ppm) and 
primary alcohol (63 ppm). 
It was postulated that attack of the tin radical to the ketone oxygen results in 
rearomatization of the molecule. Subsequently, the spirocycle is ring opened and 
ultimately the hydroxyl group was transferred to the primary location and a trans alkene 
was formed. With this understood, free radical conditions free of the tin radical were 
necessary. Therefore, triethylborane was implemented to perform the radical chemistry. 
This resulted in product that showed no presence of rearomatization and loss of the 
iodohydrin proton signals. The resultant product was fully characterized via NMR 
techniques to reveal the presence of a tricyclic core. 
 
Figure 2.8 Possible product structure from triethylborane conditions. 
The spin systems were confirmed via COSY which showed the presence of four 
unique systems: (1) n→k→p→g, (2) f→o, (3) e→d→f, and (4) m. The long range 
coupling of d→f can be explained by the w coupling as denoted in Figure 2.8. One 
distinction with the COSY spectrum is the lack of correlation with g→f which, upon 
observation, should show a coupling interaction. 
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Further analysis via HSQC and HMBC provided the necessary evidence to label 
all carbons appropriately and to identify long range C-H interactions. The HMBC is 
particularly crucial in confirming the appropriate connectivity. Specifically, 2J correlation 
with Hg→Cf confirms the connectivity where COSY had implied separated systems. 
Furthermore, no correlations to Ce, though Ho→Ce would be expected and Hk and Hl 
show all expected correlations confirming the location of those signals at centralized 
positions in the system. 
 The main issues remaining to be resolved include signal p which has a H signal at 
4.2 ppm but a C signal at 21 ppm which implies presence of an electronegative group for 
the proton spectrum but no such chemical environment for the carbon. Also, several of 
the proton signals are shifted further downfield than would be expected and no 
explanation has been identified for this phenomena. Ultimately, it was clear this reaction 
would not produce the desired product and therefore was no further analysis was 
performed for the structure’s elucidation. 
Independent reports from the Beckwith and Clive groups have demonstrated the 
utility of tri-n-butylgermanium hydride to selectively generate carbon radicals from alkyl 
iodides in the presence of cyclohexadienones.38 We were pleased that treatment of iodide 
2.45c with tri-n-butylgermanium hydride and AIBN in refluxing toluene furnished the 
desired tricyclic compound in 43% yield. 
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Scheme 2.16 Comparison of tin and germanium hydride products 
Given the geometrical constraints of this system, the primary carbon radical is 
forced to add to the electron deficient -carbon of the proximal alkene of the 
spiro[4.5]cyclohexadienone from the bottom face. This addition forces cis ring fusion in 
the bicyclo[4.3.0]nonane, whereas addition from the top face would give a strained trans 
ring junction. The ensuing stabilized radical is then quenched by nBu3GeH and 
concomitantly sets the correct desired trans relationship between Hf and Hk. Based on the 
stereochemistry of the spirocycle 2.46, the stereochemistry of Hk (pointing down) is 
conserved. It should be noted that the radical addition to the distal olefin would result in 
an energetically disfavored trans ring junction about the bicycle[3.3.0]octane 
substructure.  
 
Scheme 2.17 Stereochemical outcome during tricycle formation 
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The structure of 2.44 was fully elucidated using extensive 1D and 2D NMR 
experiments. 1H NMR gave initial indication of successful conversion based on the loss 
of the proton signal associated with cyclohexenone protons at 6.30 ppm. A total loss of 
two protons was observed from that region implying successful addition to that location. 
In addition, COSY correlations were able to identify two isolated spin systems located at 
the α,β-unsaturation (He→Hd) and tracing around the tricyclic system 
(Hg→Hf→Hn→Hh→Hk→Ho) (Figure 2.9). Support for the stereochemistry at position f 
was found through “W” coupling of Hf with Hd which would only be possible with Hf in 
the cis conformation. 
 
Figure 2.9 COSY correlations for tricycle 2.44. 
Note: Structure of the major diastereomer is shown. 
2.5 Future Work 
With a proof of concept established utilizing the Tsuji-Trost variant of the 
Winstein-Masamune phenolic allylation, a total synthesis of magellanine is proposed 
(Scheme 2.18). In this proposal, the D ring is present from the outset via use of 
isonicotinic acid. As designed, the A ring can be installed and the precursor to the 
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spirocyclization reaction can be constructed within six steps with a total of eight steps to 
afford the tetracyclic core. 
 
Scheme 2.18 Proposed synthetic route to magellanine. 
2.6 Summary and Conclusion 
This chapter presented a methodology study for the development of palladium 
catalyzed phenolic allylation. The resultant spiro[4.5]decane was then applied as the 
synthetic precursor for the synthesis of the tricyclic core present within natural products 
of the Lycopodium alkaloid family. At both key stages, intermediates were fully 
characterized via spectroscopic methods and structure, connectivity, and three-
dimensional orientation were confirmed. Through the described method, a new route to 
the production of spirocyclic terpenes and magellanine-type alkaloids has been presented. 
This report provides the foundation for an alternative route to the development of desired 
biologically active natural products. 
  
 41 
2.7 Experimental 
2.7.1 General Methods 
2.7.1.1 Experimental Techniques 
Unless otherwise noted, all reactions were carried out using flame-dried glassware 
and standard syringe, cannula, and septa techniques, when necessary. Tetrahydrofuran 
(THF), diethyl ether (Et2O), hexanes, dichloromethane (CH2Cl2), and toluene (PhCH3) 
were dried by passage through a column of activated alumina on an mBraun SPS. 
Triethylamine (Et3N), N,N-dimethylformamide (DMF), and acetonitrile (MeCN) were 
dried by passage through a column of activated alumina on an Innovative Technologies 
system. Trimethylsilyl chloride and Hunig’s base were distilled from calcium hydride 
under argon. Pyridine was distilled from potassium hydroxide under nitrogen. Analytical 
thin layer chromatography was performed using Sorbent Technologies 250 m glass-
backed UV254 silica gel plates. The plates were first visualized by fluorescence upon 254 
nm irradiation then by iodine chamber. The plates were then dipped in one of the 
following stains followed by heating: p-anisaldehyde, phosphomolybdic acid, vanillin, 
ceric ammonium molybdate, potassium iodoplatinate, ninhydrin or bromocresol green. 
Flash column chromatography was performed using Sorbent Technologies 40-63 μm, 
pore size 60 Å silica gel with solvent systems indicated. Solvent removal was effected 
using a Buchi R3 rotary evaporator with a V900 diaphragm pump (~ 10 mmHg).  All 
yields refer to isolated material that is chromatographically (TLC or HPLC) and 
spectroscopically (1H NMR) homogenous. 
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2.7.1.2 Characterization 
All melting points were taken with a Thomas Hoover melting point apparatus and 
are uncorrected. Infrared spectra were recorded on a Nicolet Nexus 470 FTIR 
spectrometer as neat liquids, oils, solids or as thin films formed from evaporation of 
NMR solvent over the ATR plate. HPLC were recorded on an Agilent 1260 Infinity using 
a Poroshell 120 EC-C18 (3.0 x 50 mm, 2.7 micron) column with a binary gradient of 
0.1%TFA in H2O (A) and 0.1%TFA in CH3CN (B):  [0 min: A (95%), B (5%); 7 min: A 
(5%), B (95%); 8 min: A (5%), B (95%)] monitoring 214, 254, and 280 nm. Low-
resolution mass spectra were recorded on a ThermoFinnigan LXQ ESI-LCMS by use of 
chemical ionization (CI). High-resolution mass spectra were recorded either at the Old 
Dominion University College of Science Major Instrumentation Center (COSMIC) on a 
Bruker 12 Tesla APEX-Qe FTICR-MS with an Apollo II ion source or The Ohio State 
University Campus Chemical Instrumentation Center (CCIC). Combustion analysis was 
performed at Atlanitic Microlabs on samples taken from the bulk of the material.  
2.7.1.3 NMR Parameters 
Proton nuclear magnetic resonance spectra were recorded on a Bruker UltraShield 
Plus 400 MHz spectrometer and are recorded in parts per million from internal 
chloroform (7.26 ppm), benzene, or dimethylsulfoxide on the  scale and are reported as 
follows: chemical shift [multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, 
qu=quintet, m=multiplet), coupling constant(s) in hertz, integration, interpretation]. 13C 
NMR data were recorded on a Bruker UltraShield Plus 400 MHz spectrometer and are 
reported as follows: chemical shift (multiplicity as determined from DEPT (CH, CH3 up 
and CH2 down) and/or HSQC experiments. 
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2.7.2 Synthesis of Intermediates 
dimethyl 2-(4-hydroxybenzyl)malonate (2.48): To a degassed solution of 
dimethyl 2-(4-hydroxybenzylidene)malonate (5.0 g, 21.2 mmol, 1.0 equiv) 
dissolved in methanol (60 mL) was added palladium, on 10% carbon (100.0 
mg, 0.8 mmol, 0.04 equiv).  Hydrogen gas was bubbled through the solution until 
reaction completion was observed via TLC. The suspension was filtered through a 
Büchner funnel filled with Cellite® and rinsed with methanol (four 50-mL portions). The 
yellow filtrate was collected and concentrated in vacuo to yield 4.9 g of reduced malonate 
2.48 as a brown-yellow oil (97% yield). No further purification was performed. 1H NMR 
(CDCl3, 400 MHz) δ: 7.03 (dd, J = 8.4 Hz, 2H), 6.73 (dd, J = 8.4 Hz, 2H), 3.70 (s, 6H), 
3.64 (t, J = 7.9 Hz, 2H), 3.14 (d, J = 7.8 Hz, 1H). 
dimethyl 2-(4-((tert-butyldimethylsilyl)oxy)benzyl)malonate (2.67): To a 
solution of dimethyl 2-(4-hydroxybenzyl)malonate (9.8 g, 41.1 mmol, 1.0 
equiv.) dissolved in dimethylformamide (100 mL) was added tert-
butyldimethylsilyl chloride (6.2 g, 41.2 mmol, 1.0 equiv.) and 4-
dimethylaminopyridine (10.0 g, 82.3 mmol, 2.0 equiv.). The reaction was stirred at 
ambient temperature for one hour and thirty minutes before an additional equivalent of 
tert-butyldimethylsilyl chloride was added. After an additional one hour and thirty 
minutes, the reaction was diluted with ethyl acetate (100 mL) and was washed with water 
(three 100-mL portions). The aqueous phase was extracted with ethyl acetate (200 mL). 
The combined organic phase was dried over magnesium sulfate, vacuum filtered, and 
concentrated in vacuo to yield 30 g of a crude brown liquid. The residue was 
chromatographed over 200 g of silica gel (13 cm height by 5 cm diameter) eluted with 
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hexanes-ethyl acetate (500 mL 9:1 in 50 mL fractions → 250 mL 4:1 in 50 mL fractions 
→ 200 mL 1:1 in 75 mL fractions → 600 mL 100% ethyl acetate in 200 mL fractions): 
fractions 5-8 contained protected malonate 2.67 as a yellow oil (13.8 g, 95% yield. IR 
(Thin Film) 1736, 1608 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 7.04 (dd, J = 8.4 Hz, 2H), 
6.74 (dd, J = 8.4 Hz, 2H), 3.68 (s, 6H), 3.62 (t, J = 7.8 Hz, 1H), 0.97 (s, 9H), 0.17 (s, 6H); 
13C NMR (CDCl3, 100 MHz) δ: 169.3 (s), 154.5 (s), 130.4 (s), 129.8 (d), 120.1 (d), 53.9 
(d), 52.5 (q), 34.1 (t), 25.6 (q), 18.2 (s), -4.4 (q); LRMS (ESI), m/z calc. for C18H28O5Si 
[M+Na]+ 375.16, found 375.27. 
(Z)-dimethyl 2-(4-((tert-butyldimethylsilyl)oxy)benzyl)-2-(4-
((methoxycarbonyl)oxy)but-2-en-1-yl)malonate(2.68): To a 
suspension of sodium hydride (340.4 mg, 8.5 mmol, 1.5 equiv.) in 
tetrahydrofuran (5.0 mL) was added a solution of dimethyl 2-(4-
((tert-butyldimethylsilyl)oxy)benzyl)malonate (2.0 g, 5.7 mmol, 1.0 
equiv) in tetrahydrofuran (5.0 mL) via cannula. The reaction was stirred at ambient 
temperature for fifteen minutes before a solution of (Z)-4-((methoxycarbonyl)oxy)but-2-
en-1-yl methanesulfonate (1.6 g, 7.1 mmol, 1.25 equiv.)  in tetrahydrofuran (5.0 mL) was 
added via cannula. The solution became highly viscous,  and additional tetrahydrofuran 
(10 mL) was added. After one hour the reaction was diluted with ethyl acetate (25 mL) 
and washed with water (two 25-mL portions). The aqueous phase was extracted with 
ethyl acetate (25 mL). The combined organic phases were dried over magnesium sulfate, 
vacuum filtered, and concentrated in vacuo to yield 2.8 g of a crude yellow oil. The 
residue was chromatographed over 40 g of silica gel (13 cm height by 3 cm diameter) 
eluted with hexanes-ethyl acetate (200 mL 10:1 → 100 mL 4:1 → 50 mL 1:1 → 50 mL 
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100% ethyl acetate) in 10 mL fractions. The product rich fractions were pooled and 
evaporated to afford 2.68 as a clear, colorless oil (1.7 g, 62%). IR (Thin Film) 1734, 1604 
cm-1; 1H NMR (CDCl3, 400 MHz) δ: 6.91 (dd, J = 8.5 Hz, 2H), 6.72 (dd, J = 8.5 Hz, 2H), 
5.72 (dt, J = 11.4, 6.4 Hz, 1H), 5.63 (dt, J = 11.2, 7.2 Hz, 1H), 4.63 (d, J = 6.5 Hz, 2H), 
3.79 (s, 3H), 3.71 (s, 6H), 3.19 (s, 2H), 2.59 (d, J = 7.0 Hz, 2H), 0.97 (s, 9H), 0.17 (s, 
6H); 13C NMR (CDCl3, 100 MHz) δ: 171.1 (s), 155.7 (s), 154.8 (s), 130.8 (d), 128.7 (d), 
128.1 (s), 126.7 (d), 120.0 (d), 63.5 (t), 58.8 (s), 54.8 (q), 52.5 (q), 37.8 (t), 30.3 (t), 25.7 
(q), 18.2 (s), -4.5 (q); LRMS (ESI), m/z calc. for C24H36O8Si [M+Na]
+ 503.21, found 
503.32. 
(Z)-dimethyl-2-(4-hydroxybenzyl)-2-(4-
((methoxycarbonyl)oxy)but-2-en-1-yl)malonate (2.47): To a 
solution of (Z)-dimethyl 2-(4-((tert-butyldimethylsilyl)oxy)benzyl)-2-
(4-((methoxycarbonyl)oxy)but-2-en-1-yl)malonate (3.0 g, 6.2 mmol, 
1.0 equiv) in tetrahydrofuran (100 mL) was added tetrabutylammonium fluoride (1M in 
tetrahydrofuran) (7.5 mL, 7.5 mmol, 1.2 equiv.) over three minutes at 0°C. The reaction 
was stirred for ten minutes then concentrated in vacuo. The residue was chromatographed 
over 50g of silica gel (7 cm height by 3 cm diameter) eluted with hexanes-ethyl acetate 
(100 mL 4:1 → 100 mL 2:1 → 50 mL 1:1 → 200 mL 100% ethyl acetate) in 10 mL 
fractions. Product rich fractions were pooled and evaporated to afford   2.47 as a yellow 
oil (1.3 g, 53% yield). 1H NMR (CDCl3, 400 MHz) δ: 6.91 (dd, J = 8.5 Hz, 2H), 6.71 
(dd, J = 8.5 Hz, 2H), 5.72 (dtd, J = 11.2, 7.2 Hz, 1H), 5.65 (dtd, J = 11.2, 6.5 Hz, 1H), 
4.63 (dd, J = 6.5 Hz, 2H), 3.79 (s, 3H), 3.80 (s, 3H), 3.73 (s, 6H), 3.19 (s, 2H), 2.60 (dd, J 
= 7.0 Hz, 2H); 13C NMR (CDCl3, 100 MHz) δ: 171.3 (s), 155.9 (s), 154.7 (s), 130.9 (d), 
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128.6 (d), 127.2 (s), 126.7 (d), 115.4 (d), 63.5 (t), 58.9 (s), 54.9 (q), 52.6 (q), 37.8 (t), 
30.2 (t); LRMS (ESI), m/z calc. for C18H22O8 [M+Na]
+ 389.12, found 389.24. 
(E)-dimethyl 2-(buta-1,3-dien-1-yl)-2-(4-hydroxybenzyl)malonate 
(2.74): To a 0.5-2.0 mL Biotage microwave reactor vial containing (Z)-
dimethyl 2-(4-hydroxybenzyl)-2-(4-((methoxycarbonyl)oxy)but-2-en-1-
yl)malonate (75.0 mg, 0.20 mmol, 0.2 equiv), triphenylphosphine (11.0 
mg, 0.04 mmol, 0.2 equiv), and tris(dibenzylideneacetone)dipalladium (0) (19.0 mg, 0.02 
mmol, 0.1 equiv) in dichloromethane (1.0 mL).  The vial was sealed and heated to 80°C 
for five minutes in a Biotage® Initiator+ microwave reactor. The suspension was filtered 
through a Pasteur pipette filled with Celite® and rinsed with dichloromethane (2.0 mL). 
The filtrate was collected and concentrated in vacuo. The residue was chromatographed 
over 50 g of silica gel (1.25 cm diameter by 11.0 cm height) eluted with hexanes-ethyl 
acetate (50 mL 10:1 → 50 mL 8:1 → 25 mL 4:1 → 25 mL 2:1 → 25 mL 1:1 → 25 mL 
1:2) in 5 mL fractions. The product rich fractions were pooled and evaporated to afford 
2.74 (24 mg, 40% yield) as a yellow oil. 1H NMR (CDCl3, 400 MHz) δ: 6.92 (d, J = 8.5 
Hz, 2H), 6.67 (d, J = 8.5 Hz, 2H), 6.33 (ddd, J = 16.9, 10.0, 10.0 Hz, 1H), 6.15 (dd, J = 
16.0, 10.0 Hz, 1H), 6.04 (d, J = 16.0 Hz, 1H), 5.20 (dd, J = 16.8, 10.1 Hz, 2H), 3.73 (s, 
6H), 3.33 (s, 2H); 13C NMR (CDCl3, 100 MHz) δ: 170.7 (s), 154.8 (s), 136.2 (d), 132.6 
(d), 131.2 (d), 130.3 (d), 127.3 (s), 118.5 (t), 115.1 (d), 61.0 (s), 52.8 (q), 41.6 (t). 
dimethyl 8-oxo-4-vinylspiro[4.5]deca-6,9-diene-2,2-dicarboxylate 
(2.46): To a sealed 0.5-2.0 mL Biotage microwave reactor vial 
containing triphenylphosphine (36.0 mg, 0.14 mmol, 0.2 equiv) and 
tris(dibenzylideneacetone)dipalladium (0) (60.0 mg, 0.07 mmol, 0.1 
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equiv) under nitrogen was added a degassed solution of (Z)-dimethyl 2-(4-
hydroxybenzyl)-2-(4-((methoxycarbonyl)oxy)but-2-en-1-yl)malonate (250 mg, 0.68 
mmol, 1.0 equiv) in dichloromethane (1.5 mL) via syringe.  The reaction was heated to 
40°C for forty minutes in a Biotage® Initiator+ microwave reactor. The suspension was 
filtered through a Pasteur pipette filled with Celite® and rinsed with dichloromethane 
(2.0 mL). The orange-yellow filtrate was collected and concentrated in vacuo. The 
residue was chromatographed over 160 g of silica gel (10.5 cm height by 2.25 cm 
diameter) eluted with hexanes-ethyl acetate (150 mL 10:1 → 100 mL 8:1 → 75 mL 6:1 
→ 75 mL 4:1 → 50 mL 2:1 → 50 mL 1:1) in 10 mL fractions. The product rich fractions 
were pooled and evaporated to afford 2.46 as a white solid (80 mg, 40% yield). IR (Thin 
Film) 1728, 1662, 1624 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 6.85 (dtd, J = 10.3, 3.0 Hz, 
1H), 6.73 (dd, J = 10.0, 3.0 Hz, 1H), 6.29 (dtd, J = 10.1, 1.9 Hz, 1H), 6.27 (dd, J = 10.1, 
1.9 Hz, 1H), 5.41 (m, 1H), 5.01 (dd, J = 18.0, 1.1, 1H), 4.99 (dd, J = 9..3, 1.1 Hz, 6H), 
3.80 (s, 3H), 3.79 (s, 3H), 2.84 (dd, J = 6.8, 6.0, 1H), 2.68 (d, J = 14.6 Hz, 1H), 2.67 (d, J 
= 14.0 Hz, 1H), 2.56 (dd, J = 13.9, 13.9 Hz, 1H), 2.45 (d, J = 14.8 Hz, 1H); 13C NMR 
(CDCl3, 100 MHz) δ: 185.9 (s), 172.4 (s), 172.1 (s), 153.0 (d), 148.9 (d), 133.8 (s), 130.2 
(d), 129.3 (d), 117.8 (t), 58.5 (s), 53.5 (q), 53.3 (q), 53.2 (t) 52.1 (t), 43.6 (t), 38.6 (t); 
HRMS (CI), m/z calc. for C24H36O8Si [M+Na]
+ 313.1046, found 313.1053; Elemental 
Analysis calc. C-66.19, H-6.25, found C-65.99, H-6.25. 
dimethyl 4-(1-hydroxy-2-(phenylselanyl)ethyl)-8-
oxospiro[4.5]deca-6,9-diene-2,2-dicarboxylate (2.45a): To a 
solution of dimethyl 8-oxo-4-vinylspiro[4.5]deca-6,9-diene-2,2-
dicarboxylate (57.0 mg, 0.2 mmol, 1.0 equiv) in acetonitrile (0.5 mL) 
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was added water (0.1 mL, 0.5 mmol, 2.8 equiv) and phenyl selenyl chloride (43.0 mg, 0.2 
mmol, 1.1 equiv). The reaction was stirred at ambient temperature for six hours before an 
additional equivalent of phenyl selenyl chloride was added. After a total of 18 hours the 
reaction was quenched with saturated ammonium chloride (1.0 mL). The organic phase 
was diluted with ethyl acetate (1.0 mL) and was washed with water (1.0 mL) then brine 
(1.0 ml). The aqueous phase was extracted with ethyl acetate (1.0 mL). The combined 
organic phase was dried over sodium sulfate, vacuum filtered, and concentrated in vacuo 
to yield a brown oil. The crude residue was chromatographed over 10 g of silica gel (1 
cm diameter by 10 cm height) eluted with hexanes-ethyl acetate (50 mL 10:1 → 40 mL 
8:1 → 30 mL 6:1 → 25 mL 4:1 → 20 mL 2:1 → 20 mL 1:1 → 20 mL 1:2) in 20 mL 
fractions for fractions 1-6 and 10 mL fractions for all remaining fractions collected. The 
product rich fractions were pooled and evaporated to afford single diastereomer of 2.45a 
(27 mg, 30% yield) as a brown oil, a mixture of diastereomers of 2.45a (13 mg, 14% 
yield) as a brown oil, and a single diastereomer of 2.45a (16 mg, 18% yield) as a purple 
oil. IR (Thin Film) 3276, 1705 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 7.44 (m, 1H), 7.26 
(m, 2H), 6.90 (dd, J = 10.3, 3.0 Hz, 1H), 6.71 (dd, J = 10.0, 3.0 Hz, 1H), 6.18 (dd, J = 
10.1, 1.9 Hz, 1H), 6.14 (dd, J = 10.1, 1.9 Hz, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 3.77 (m, 
1H), 3.06 (dd, J = 6.6, 1.2 Hz, 2H), 2.94 (dd, J = 9.7, 5.8, 1H), 2.75 (d, J = 6.6, 1.2 Hz, 
2H), 2.68 (dd, J = 14.6, 1H), 2.45 (d, J = 14.8 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ: 
185.4 (s), 172.1 (s), 171.7 (s), 153.1 (d), 148.4 (d), 133.4 (d), 130.1 (d), 129.5 (d), 128.9 
(d), 128.5 (s), 127.9 (d), 60.7 (d), 57.2 (s), 53.5 (d), 53.4 (q), 53.3 (q), 50.5 (s), 44.7 (t), 
34.6 (t), 35.4 (t); LRMS (ESI), m/z calc. for C22H24O6Se [M+Na]
+ 331.12, found 331.24. 
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dimethyl 4-(2-bromo-1-hydroxyethyl)-8-oxospiro[4.5]deca-6,9-
diene-2,2-dicarboxylate (2.45b): To a solution of dimethyl 8-oxo-4-
vinylspiro[4.5]deca-6,9-diene-2,2-dicarboxylate (0.05 g, 0.172 mmol) 
in a cosolvent of acetonitrile (0.285 mL, 0.172 mmol) and water (0.285 mL, 0.172 mmol) 
cooled to 0°C was added N-bromosuccinimide (0.062g, 0.344 mmol). The reaction was 
allowed to warm to ambient temperature overnight. The reaction was determined 
complete via HPLC and TLC (1:1 Hex-EtOAc; UV/I2) after a total of 22 hours. The 
reaction mixture was quenched with 10% aqueous sodium thiosulfate (1 mL) and washed 
with brine (1 mL). The organic phase was filtered through a pipette filled with Celite® 
and sodium sulfate plug. The filtrate was concentrated in vacuo to afford a clear oil. The 
crude residue was purified by flash column chromatography over a 4 g silica column 
using an Isco CombiFash. The product rich fractions were pooled and evaporated to 
afford 2.45b (0.037 g, 55%) as a clear oil. IR (Thin Film) 3404, 1708 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ: 6.95 (dd, J = 10.2, 3.0 Hz, 1H), 6.89 (dd, J =9.9, 3.1 Hz, 1H), 6.35 
(dd, J = 10.1, 1.8 Hz, 1H), 6.29 (dd, J = 9.9, 1.9 Hz, 1H), 3.95 (m, 2H), 3.80 (m, 2H), 
3.78 (s, 6H), 2.88 (m, 1H), 2.75 (d, J = 14.4, 1H), 2.72 (m, 1H), 2.59 (m, 1H), 2.29 (d, J = 
14.6, 1H); 13C NMR (CDCl3, 100 MHz) δ: 185.5 (s), 172.0 (s), 171.8 (s), 154.7 (d), 
147.1 (d), 130.1 (d), 129.1 (d), 66.2 (t), 57.6 (s), 56.6 (d), 53.5 (q), 53.4 (q), 52.6 (d), 51.0 
(s), 44.9 (t), 37.4 (t); HRMS (CI), m/z calc. for C16H19BrO6 [M+Na]
+ 795.0622, found 
795.0626. 
dimethyl 4-(1-hydroxy-2-iodoethyl)-8-oxospiro[4.5]deca-6,9-diene-
2,2-dicarboxylate (2.45c): To a solution of dimethyl 8-oxo-4-
vinylspiro[4.5]deca-6,9-diene-2,2-dicarboxylate (0.051 g, 0.176 mmol) 
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in a co-solvent of water (0.285 mL, 0.176 mmol) and acetonitrile (0.176 mmol, 0.285 
mL) cooled to 0° C was added N-iodosuccinimide (0.119 g, 0.527 mmol).The reaction 
was allowed to warm to ambient temperature and was determined complete after 1.5 
hours. The reaction was quenched with 10% aqueous sodium thiosulfate (1 mL) and 
washed with brine (1 mL). The organic phase was filtered through a pipette filled with a 
Celite® and sodium sulfate plug and concentrated in vacuo to afford 2.45c as a yellow-
brown oil. Due to the instability of this material, the crude mixture was utilized in the 
proceeding step without further purification. 1H NMR (CDCl3, 400 MHz) δ: 6.95 (m, 
1H), 6.88 (m, 1H), 6.32 (m, 2H), 4.03 (m, 1H), 3.72 (m, 1H), 3.78 (s, 6H), 2.88 (m, 1H), 
2.73-2.55 (m, 3H), 2.29 (d, J = 14.6 Hz, 1H). 
(E)-dimethyl 2-(4-hydroxybenzyl)-2-(4-hydroxybut-2-en-1-
yl)malonate (2.76): To a 25 mL roundbottom flask flushed with 
nitrogen was added (E)-2,2'-(diazene-1,2-diyl)bis(2-
methylpropanenitrile) (1.484 mg ,9.04 µmol). A solution of dimethyl 
(4R)-4-(2-bromo-1-hydroxyethyl)-8-oxospiro[4.5]deca-6,9-diene-2,2-dicarboxylate 
(0.035 g, 0.090 mmol) in toluene (1.506 mL, 0.090 mmol) was then added and the 
solution was heated to reflux. Tri-n-butyltin hydride (0.049 mL, 0.181 mmol) was added 
in a single portion and the reaction was stirred at reflux for one hour. The solution was 
cooled to ambient temperature and was concentrated in vacuo. The crude residue was 
purified by flash column chromatography over 4 g of silica gel using an Isco CombiFlash 
eluted with hexanes-ethyl acetate in 8.0 mL fractions. The product rich fractions 39-41 
were pooled and evaporated to afford (E)-2.76 (20 mg, 72%) as a clear oil. IR (Thin 
Film) 3276, 1705 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 6.92 (d, J = 8.5 Hz, 1H), 6.71 (d, 
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J =8.5 Hz, 1H), 6.24 (s, 1H, O-H), 5.74 (dt, J = 15.5, 5.7 Hz, 1H), 5.62 (dt, J = 15.5, 5.7 
Hz, 1H), 4.12 (m, 2H), 3.71 (s, 6H), 3.15 (s, 2H), 2.55 (d, J = 6.8 Hz, 2H),; 13C NMR 
(CDCl3, 100 MHz) δ: 171.4 (s), 155.1 (s), 133.8 (d), 131.0 (d), 127.3 (s), 126.2 (d), 115.3 
(d), 63.2 (t), 59.3 (s), 52.5 (q), 37.4 (t), 34.9 (t); HRMS (CI), m/z calc. for C16H20O6 
[M+Na]+ 331.1152, found 331.1154. 
(3aR,4S,5aR)-dimethyl 4-hydroxy-7-oxo-3a,4,5,5a,6,7-hexahydro-
1H-cyclopenta[c]indene-2,2(3H)-dicarboxylate (2.44): To an oven 
dried 10-20 mL Biotage microwave reactor vial was added AIBN (1.002 
mg, 6.10 µmol). The vial was immediately sealed then evacuated and charged with 
nitrogen three times. A solution of dimethyl (4R)-4-(1-hydroxy-2-iodoethyl)-8-
oxospiro[4.5]deca-6,9-diene-2,2-dicarboxylate (0.053 g, 0.122 mmol) in toluene (12.21 
mL, 0.122 mmol) was added and the reaction heated to 110°C. While the reaction was 
heating, tri-n-butylgermanium hydride (0.067 mL, 0.244 mmol) was added to the vial in a 
single portion. The reaction was stirred at 110°C for 17 hours. The solution was cooled to 
ambient temperature and concentrated in vacuo to afford a yellow oil (55 mg). The 
residue was chromatographed over 4 g of silica gel eluted with hexanes-ethyl acetate (25 
mL 4:1→ 25 mL 2:1→ 25 mL 1:1→ 25 mL 1:2→ 25 mL 1:4) in 3 mL fractions. The 
product rich fractions 16-18 were pooled and evaporated to afford dimethyl 2.44 (16.2 
mg, 43%) as a clear oil. 1H NMR (CDCl3, 400 MHz) δ: 5.87 (dd, J = 10.2, 0.6 Hz, 1H), 
5.44 (dd, J = 10.2, 2.7 Hz, 1H), 3.80 (ddd, J = 12.2, 5.2, 5.2, 1H), 3.60 (tdd, J = 3.0, 3.0, 
3.0 Hz, 1H), 3.53 (dd, J = 11.7, 4.8 Hz, 1H), 3.39 (dd, J = 12.0, 12.0 Hz, 1H), 3.28 (s, 
3H), 3.25 (s, 3H), 2.91 (dd, J = 14.0, 7.1 Hz, 1H), 2.59 (dd, J = 13.6, 13.6 Hz, 1H), 2.43 
(dd, J = 16.8, 3.2 Hz, 1H), 2.36 (d, J = 15.1 Hz, 1H), 2.32 (d, J = 13.4 Hz, 1H), 2.22 (dd, J 
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= 16.8, 3.0 Hz, 1H), 2.08 (d, J = 15.0 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ: 194.1 (s), 
171.8 (s), 171.7 (s), 149.3 (d), 129.7 (d), 73.4 (d), 68.2 (t), 56.1 (s), 52.35 (q), 52.31 (q), 
50.5 (d), 47.9 (s), 42.3 (t), 39.6 (t), 36.9 (t), 22.7 (d); LRMS (ESI), m/z calc. for C16H20O6 
[M+Na]+ 331.1152, found 331.11. 
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CHAPTER III – INVESTIGATION OF SYNTHETIC STRATEGIES FOR THE 
DEVELOPMENT OF HETEROCYCLIC SMALL MOLECULE HIV-1 INTEGRASE 
INHIBITORS 
3.1 Introduction 
3.1.1 The Global and National Health Issue 
Following the first report of Human Immunodeficiency Virus (HIV)39 it has 
remained a global epidemic. Shown in Table 3.1 is the 2017 report from the World 
Health Organization (WHO) outlining several statistics with regard to the virus.40 Of 
particular note is the estimated 36.7 million people living with the virus. In addition, the 
Centers for Disease Control and Prevention (CDC) released a 2017 report outlining 
statistics for the United States. In this report, it was estimated that 39,782 US residents 
were infected and diagnosed with HIV in 2016 with 15,458 HIV related deaths in 2015.41 
Table 3.1  
Global statistics for HIV-1 infections 
 
Estimated number of 
people (all ages) living 
with HIV (million) 
Number of deaths 
due to HIV/AIDS 
(million) 
Number of new 
HIV infections 
(million)  
Africa 
25.6 0.72 1.2  
[22.9−28.6] [0.59−0.89] [0.98–1.3] 
Americas 
3.3 0.054 0.15 
[2.9−3.8] [0.044−0.065] [0.13–0.18] 
South-East 
Asia 
3.5 0.13 0.15 
[2.5−8.2] [0.12−0.22] [0.11–0.18] 
Europe 
2.4 0.049 0.22 
[2.3−2.6] [0.040−0.056] [0.21–0.23] 
Eastern 
Mediterranean 
0.36 0.017 0.37 
[0.29−0.5] [0.014−0.024] [0.029–0.057] 
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Table 3.1 (continued) 
Western 
Pacific 
1.5 0.039 97 000 
[1.2−2.0] [0.025−0.066] [0.046–0.17] 
(WHO) Global 
36.7 1.0 1.8 
[30.8−42.9] [0.83−1.2] [1.6–2.1] 
 
Fortunately, the amount of new infections reported globally is down 40% from 
2000 with the death toll being reduced by 33%.40 Regardless of these diminishing values, 
the virus continues to develop drug resistant strains which requires continued research to 
gain deeper understandings of the virus’ life cycle and potential inhibitors for improved 
treatments of infected patients. 
3.1.2 The Origins of HIV 
The origins of HIV-1 have been geographically traced to equatorial West Africa 
where zoonic transmissions via simian immunodeficiency viruses (SIV) occurred.42 This 
proposed origin is based on several factors including genetic similarities between HIV 
and SIV, geographic coincidence, and plausible occurrences for transmission which 
include hunting and pet ownership.43 With additional simian-derived viruses having been 
recorded for traversing the cross-species line,44-46 it was reasonable to presume HIV was 
capable of performing the same action. 
3.1.3 Life Cycle of the Virus 
Within the life cycle of HIV-1, there are multiple targets with which researchers 
have explored for restriction of viral replication. These targets have spanned across the 
full spectrum of the replication cycle from host-cell entry to release and maturation of 
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new virions. Specific stages currently exploited include: 1) Cell wall fusion/entry, 2) 
RNA reverse transcription, 3) DNA integration, 4) and maturation.47 
HIV-1 integrase (IN), the enzyme responsible for integration of viral DNA 
(vDNA) into the host DNA, is essential for virus replication and represents an important 
multifunctional therapeutic target.48 IN has been determined to contain three main 
sections: the N-terminus domain (NTD), C-terminus domain (CTD), and the catalytic 
core domain (CCD).49-50 These three domains work in conjunction to form a tetramer 
structure where viral DNA and target chromosomal DNA are bound to IN.51-54 
Additionally, a necessary component for tetramer association and viral DNA integration 
is cellular chromatin-associated protein lens epithelium-derived growth factor 
(LEDGF/p75).55 Specifically, LEDGF functions as a tether wherein it binds to both HIV 
and target chromatin to facilitate integration.56-58 
The integration of vDNA occurs in two stages at the active site located within the 
CCD. The first stage forms the target capture complex (TCC) which involves trapping of 
the target followed by subsequent cleavage of the vDNA 3′ ends. Completion of this 
leads to a strand transfer complex (STC) which cleaves the target DNA and covalently 
links the 3′ ends.59 The three amino acid residues required for the strand transfer include 
aspartates 64 and 116 and glutamate 152. In addition, these residues coordinate with two 
divalent magnesium cofactors to perform 3′ processing.60 
3.1.4 Current Available Treatments 
After the development of anti-retroviral treatments, HIV diagnosis transitioned 
from a death sentence to a manageable disease which provided prolonged lifetimes and 
better living conditions for infected patients. Specifically, Highly Active Anti-Retroviral 
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Therapy (HAART) was developed as an effective treatment method. Through this 
therapy, a single pill containing a cocktail of medications is administered. The variety of 
medications target various stages in the viral lifecycle.54 One example of this is Genvoya 
which contains a combination of four individual medications: elvitegravir (integrase 
inhibitor), tenofiovir alafenamide (Nucleoside/Nucleotide Reverse Transcriptase Inhibitor 
(NRTI)), emtricitabine (Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTI)), 
cobicistat (pharmacokinetic enhancer) (Figure 3.1). 
 
Figure 3.1 Contents of Genvoya. 
Currently, there are three FDA approved compounds available for IN via strand 
transfer inhibition: Raltegravir (RAL), Elvitegravir (EVG), and Dolutegravir (DVG). 
RAL was developed by Merck and approved in 2007 making it the first treatment 
available. Following this, Gilead produced EVG and received approval in 2012 with 
GlaxoSmithKline close thereafter with approval of DVG in 2013. Although these 
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treatments are effective, drug resistant strains have emerged against RAL and EVG due 
to HIV’s high turnover and mutation rates.61 Currently, there are no reports of resistance 
to DVG though the development of a mutation is virtually imminent.  
Development of mutations within the active site of HIV IN makes it pertinent to 
pursue alternative inhibition sites on the enzyme. HIV IN functions as a tetramer wherein 
a dimer is formed at the CCD interface for vDNA interaction. Furthermore, LEDGF/p75 
interacts at this CCD dimer within an allosteric binding pocket via the C-terminal 
integrase binding domain (IBD).62-64 This binding pocket has become of significant 
interest as an IN alternative target option.65 Previous studies66-68 have demonstrated that 
the binding of inhibitors to the IN dimer interface at the IBD binding site immediately 
triggers an aberrant multimerization of the enzyme, effectively blocking its functions and 
viral replication. Two reported candidates that target the LEDGF binding pocket include 
quinoline scaffolds 3.569 and 3.6 (BI 224436)70 (Figure 3.2). 
 
 
Figure 3.2 Biaryl multisubstituted quinolines. 
Examination of the crystal structure for 3.5 within the binding pocket reveals the 
amino acids of interest in the northern region of the pocket (Figure 3.3).71 Specifically, 
the northern aromatic component of the substrate resides in proximity to tryptophan 132 
and leucine 102. Therefore, we commenced an investigation to identify relevant 
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stereoelectronic interactions within this pocket. The inhibition data for compounds 3.5 
and 3.6 inspired our research group to further investigate a library of 4-biaryl quinolines 
through systematic structure activity relationship studies. 
 
Figure 3.3 Ribbon representation of the integrase CCD dimer. 
Shown in this crystal structure is 3.6 within the target binding pocket and amino acid W132. The yellow and cyan portions each 
represent a single unit of the dimer. 
3.2 Research Hypothesis 
It was hypothesized that relevant stereoelectronic interactions within the 
hydrophobic region of the binding pocket could be identified through examination of a 
series of 4-biaryl quinolines.  
3.3 Research Design and Methods 
3.3.1 The Quinoline Scaffold 
Quinolines represent approximately 2% of FDA approved prescription drugs,72 
there are numerous methods for synthesizing this heterocycle. Most typically, 
unsubstituted,73 mono-substituted,74 di-substituted,75-77 and tri-substituted rings78-80 have 
been prepared from aniline, indole and isatin derivatives (Figure 3.4). Variations of these 
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methods include: (1) electrophilic,81-82 oxidative,83 and free radical cyclizations,84 (2) 
allene cycloadditions,85[9] and (3) iodine catalyzed,86 and aza-Wittig cascade reactions.87 
 
Figure 3.4 Summary of synthetic methods for construction of quinolines. 
Biaryl quinolines such as 3.5 and 3.6 have been shown to exhibit inhibitory 
activity against the HIV-integrase enzyme.70 Examination of these shows a quinoline 
framework substituted at the 2, 3, 4 and 7 positions. Structure activity relationship studies 
have indicated that the 2-methyl and 3-acetic acid residue are crucial to maintaining the 
potency of this scaffold. Given the lack of commercially available material for the 
quinolines, we sought to modify existing literature methods for preparation of quinoline 
scaffold 3.12 (Figure 3.5). To that end, we envisioned elaboration of the aryl ring. 
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Figure 3.5 Existing literature methods for preparation of the desired quinoline scaffold. 
3.3.2 Retrosynthetic Analysis 
With the target quinoline scaffold set, a retrosynthetic analysis was designed. 
Final stages of the synthesis to produce 3.21 would incorporate cyanohydrin formation 
and hydrolysis followed by tert-butyl ether formation of a secondary alcohol to install the 
acetic acid residue on the eastern fragment. Aldehyde 3.22 could be developed via 
DIBAL-H reduction of an ethyl ester followed by a Parikh-Doering oxidation. 
Installation of the northern aromatic component would be accomplished under standard 
Suzuki coupling conditions. 4-bromoquinoline 3.23 would be developed via bromination 
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of 4-hydroxyquinoline 3.19. Synthesis of quinoline 3.19 could be produced via base 
initiated condensation of ethyl acetoacetate with isatoic anhydride 3.17 which could be 
prepared from reaction of commercially available anthranilic acids 3.20 and triphosgene. 
 
Scheme 3.1 Retrosynthetic analysis of quinoline 3.21. 
3.4 Results and Discussion 
3.4.1 Execution of First Generation Design 
At the onset of this reaction sequence, development of quinoline 3.19 was 
successfully realized utilizing triphosgene as the acylating agent for production of isatoic 
anhydride 3.17 followed by subsequent condensation with ethyl acetoacetate. From this 
point, it was envisioned that bromination with phosphorus tribromide would prepare 
scaffold 3.23 and set the stage for Suzuki coupling with aromatic boronic acids. Initial 
reaction screenings were attempted with para-chlorophenylboronic acid due to a need to 
develop a substrate that could be compared to previously reported quinoline 3.5. Once 
installed, oxidation/reduction chemistry would be performed to first reduce ethyl ester 
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3.24 to primary alcohol 3.25 followed by oxidation to aromatic aldehyde 3.22. This 
would then prepare the scaffold for subsequent cyanohydrin formation and hydrolysis to 
produce the α-hydroxy acetic acid residue 3.27. Finally, ether formation with perchloric 
acid and tert-butyl acetate would install the tert-butyl ether residue to produce the target 
quinoline 3.21. 
 
Scheme 3.2 First generation synthetic scheme 
3.4.2 Challenges of Generation 1 
The synthesis of 3.15 has been published in two-steps from 4-bromoaniline 3.8a 
and diethyl acetylsuccinate 3.16 in 36% yield.88 Our attempts to repeat and scale-up this 
procedure beyond a few hundred milligrams were met with inconsistent results and 
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variable yields. In our experience this route is less advantageous due to: (1) the need for a 
prolonged room temperature condensation reaction time (> 5 days in a dessicator with 
phosphorus pentoxide) to form the initial vinylogous amide; (2) the use of expensive 
diphenyl ether, which has a nauseating odor, at 0.01 molar dilution at reflux (259ºC) to 
effect the ring closure via electrophilic aromatic substitution; and (3) the aqueous workup 
of this method which does not reliably produce a precipitate that can be filtered easily. 
 
Scheme 3.3 Synthetic conditions by Avetisyan and co-workers. 
We therefore sought to employ the Coppola quinoline synthesis method through 
the acylation of active methylene compounds with isatoic anhydrides followed by 
dehydrative intramolecular cyclization.89 The anhydride 3.17 is readily accessed by 
treatment of anthranilic acid 3.20 with one equivalent of triphosgene in tetrahydrofuran. 
This procedure improves upon the existing published protocol which relies on toxic 
phosgene gas90 as the acylating agent replacing it with the non-volatile, easy to weigh 
solid triphosgene. The operationally simple reverse aqueous quench and aging avoids 
extraction with organic solvent and produces 3.17 as solid material that is easily collected 
by vacuum filtration (Table 3.2). 
Table 3.2  
Synthesis and reaction yields of isatoic anhydrides 
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Entry Isatoic Anhydride R1 R2 R3 Yielda 
1 3.17a H H H 81% 
2 3.17b Br H H 90% 
3 3.17c I H H 91% 
4 3.17d OH H H 82% 
5 3.17e NO2 H H 75% 
6 3.17f H Br H 89% 
7 3.17g H NO2 H 91% 
8 3.17h H H Br 81% 
 
Note: a Isolated yield of homogenous material 
The structures of the isatoic anhydrides 3.17a-h were assigned utilizing 2D NMR 
techniques heteronuclear single quantum coherence (HSQC) and heteronuclear multiple 
bond correlation (HMBC). The most deshielded ring proton resonance for 3.17a was 
located at position 5 (7.92 ppm). With this as the benchmark, substitution at position 6 
was compared. Addition of an electron withdrawing group (NO2, anhydride 3.17e) or 
donating group (OH, anhydride 3.17d) had the expected effect of deshielding (Δppm = 
0.64) and shielding (Δppm = -0.70) at position 5, respectively. Additionally, substitution 
at position 7 afforded similar shifts but with diminished effect.
  
6
5
 
Table 3.3  
1H NMR data for isatoic anhydrides in DMSO-d6 
 
Entry 
Isatoic 
Anhydride 
1H Position δ  ppm (J Hz) 
1 2 3 4 5 6 7 8 9 10 
1 3.17a 11.75 - - - 7.92 (7.9) 7.26 (8.1, 0.9) 7.75 (8.0, 7.2, 1.5) 7.17 (8.0) - - 
2 3.17b 11.86 - - - 7.10 (8.7) - 7.89 (8.7, 2.3) 7.99 (2.3) - - 
3 3.17c - - - - 8.13 (1.6) - 8.01 (8.5, 1.8) 6.96 (8.5) - - 
4 3.17d - - - - 8.13 (1.6) - 8.01 (8.5, 1.8) 6.96 (8.5) - - 
5 3.17e 12.35 - - - 8.56 (2.6) - 8.52 (9.0, 2.6) 7.30 (9.1) - - 
6 3.17f 11.83 - - - 7.83 (8.4) 7.42 (8.4, 1.6) - 7.30 (1.6) - - 
7 3.17g 12.09 - - - 8.16 (8.6) 7.96 (8.6, 2.2) - 7.86 (9.1) - - 
8 3.17h 11.08 - - - 7.95 (7.8, 1.4) 7.19 (7.8, 7.8) 8.02 (7.9, 1.4) - - - 
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Table 3.4  
13C NMR data for isatoic anhydrides in DMSO-d6 
 
Entry Isatoic 
Anhydride 
13C Position δ  ppm 
1 2 3 4 5 6 7 8 9 10 
1 3.17a - 147.5 - 160.3 129.4 124.0 137.4 115.8 141.9 110.7 
2 3.17b - 146.7 - 158.8 117.6 114.5 139.3 130.5 140.6 112.4 
3 3.17c - 147.2 - 159.1 136.9 86.5 145.3 118.1 141.4 113.1 
4 3.17d - 147.4 - 160.4 112.8 153.8 126.1 117.2 134.4 111.2 
5 3.17e - 147.0 - 159.1 125.0 142.9 131.7 117.1 146.5 111.6 
6 3.17f - 147.3 - 159.8 131.2 126.9 130.7 118.2 142.9 110.2 
7 3.17g - 147.1 - 159.2 131.4 117.8 152.4 110.7 142.5 115.9 
8 3.17h - 147.0 - 159.6 129.1 125.0 140.6 113.4 140.0 108.4 
 
The Coppola conditions for cyclodehydration reaction employing 3.17a-h with 
the sodium enolate of ethyl acetoacetate in DMA were used to prepare quinolines 3.19a-
h. Operationally the reaction is robust and can be carried out without rigorous exclusion 
of moisture or degassing protocols. To our advantage, product isolation was achieved via 
water precipitation and filtration. Drying of products overnight under high vacuum 
afforded desired quinolines without requiring additional purification. 
Table 3.5  
Synthesis and reaction yields of quinolines 
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Entry Quinoline R1 R2 R3 Yield 
1 3.19a H H H 58% 
2 3.19b Br H H 80% 
3 3.19c I H H 77% 
4 3.19d OH H H 69% 
5 3.19e NO2 H H 82% 
6 3.19f H Br H 97% 
7 3.19g H NO2 H 66% 
8 3.19h H H Br 47% 
 
Analysis of the quinoline NMR data shows strong correlation with previously 
reported observations for substituted quinolines.91 The structures were again assigned 
utilizing HSQC and HMBC. The most deshielded ring proton resonance for 3.19a was 
again located at position 5 (8.06 ppm) and was therefore utilized as the benchmark for 
comparison with the substituted quinolines. Addition of an electron withdrawing group 
(NO2, quinoline 3.19e) or donating group (OH, quinoline 3.19d) at position 6 had the 
expected effect of deshielding (Δppm = 0.73) and shielding (Δppm = -0.68) at position 5, 
respectively. Additionally, substitution at position 7 afforded similar shifts but with 
diminished effect.
  
6
8
 
Table 3.6  
1H NMR data for quinolines in DMSO-d6 
 
Entry Quinoline 1H Position δ  ppm (J Hz) 
1 2 3 4 5 6 7 8 9 10 
1 3.19a - - - - 8.06 (8.1, 1.4) 7.35 (8.0, 7.1, 1.0) 7.68 (8.4, 7.0, 1.5) 7.54 (8.0) - - 
2 3.19b - - - - 8.13 (2.3) - 7.82 (8.8, 2.3) 7.51 (8.8, 1.0) - - 
3 3.19c - - - - 8.34 (2.0) - 7.93 (8.7, 2.1) 7.36 (8.7) - - 
4 3.19d - - - - 7.38 (2.8) - 7.16 (8.8, 2.8) 7.42 (8.8) - - 
5 3.19e - - - - 8.79 (2.6) - 8.44 (9.1, 2.7) 7.71 (9.2) - - 
6 3.19f - - - - 7.97 (8.6) 7.48 (8.6, 1.8) - 7.71 (1.8) - - 
7 3.19g - - - - 8.28 (8.8) 8.08 (8.9, 2.2) - 8.39 (2.0) - - 
8 3.19h - - - - 8.12 (8.0, 1.4) 7.31 (7.8, 7.8) 8.02 (7.8, 1.4) - - - 
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Table 3.7  
13C NMR data for quinolines in DMSO-d6 
Table x. 13C NMR data (DMSO-d6) for Quinolines x 
 
Entry Quinoline 13C Position δ  ppm 
1 2 3 4 5 6 7 8 9 10 
1 3.19a - 149.3 115.3 173.8 125.5 124.2 132.7 118.4 141.9 110.7 
2 3.19b - 149.9 115.5 172.5 127.6 116.8 135.4 121.1 138.5 126.5 
3 3.19c - 150.1 115.5 172.3 133.9 88.6 140.6 121.3 139.3 126.9 
4 3.19d - 147.9 113.7 173.3 108.2 154.5 122.6 120.0 133.0 126.5 
5 3.19e - 151.3 116.7 172.9 127.9 117.8 139.4 114.7 149.8 128.4 
6 3.19f - 150.2 115.7 173.3 127.8 127.1 124.0 121.0 141.0 125.9 
7 3.19g - 151.0 116.5 173.3 122.0 143.5 126.9 120.4 143.4 124.2 
8 3.19h - 150.4 116.5 173.3 125.5 125.2 136.7 126.6 137.5 111.3 
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A plausible mechanism for the formation of the quinoline is shown in Scheme 
3.4. After initial formation of the enolate of ethyl acetoacetate with sodium hydroxide, 
water is generated in the reaction mixture serving as a proton transfer agent. The resultant 
sodium enolate regioselectively attacks the more electrophilic ester carbonyl of the 
isatoic anhydride forming a tetrahedral intermediate 3.28. Subsequent collapse of the sp3 
hybridized carbon to the ketone with concomitant expulsion of carbon dioxide and proton 
transfers affords the amino ketone 3.29. The aniline nitrogen then attacks the ketone 
carbonyl via intramolecular 6-exo-trig cyclization with loss of water to afford the 
quinoline 3.19. 
 
Scheme 3.4 Mechanistic proposal for development of quinoline 3.19. 
With a series of quinoline substrates in hand, we continued forward with the 
installation of the aromatic group on the northern region of the molecule. To begin, the 
unsubstituted quinoline 3.19a was utilized to develop the synthetic route for proceeding 
substrates to follow. 4-bromoquinoline 3.23 was readily prepared in 76% yield via 
bromination of 4-hydroxyquinoline 3.19a with the use of phophorous tribromide. It was 
observed to be a highly exothermic reaction which required dropwise addition on larger 
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scales to prevent extreme exotherms. Suzuki coupling to install the northern aromatic 
residue was readily achieved utilizing tetrakis(triphenylphosphine)palladium (0) catalyst 
at ambient temperatures to produce 3.24 at 66% yield. 
 
Scheme 3.5 Synthesis of biaryl quinoline 3.24. 
Reduction of ethyl ester 3.24 proved to be a challenging chemical transformation 
when utilizing a variety of standard reducing agents including lithium aluminum hydride, 
Red-Al, and sodium borohydride. None of these reagents effectively converted the ester 
to alcohol 3.25. When attempted with diisobutyl aluminum hydride, conversion was 
observed though challenges remained with product isolation which resulted in varied and 
inconsistent yields that showed diminishing returns as scales increased. With primary 
alcohol 3.25 prepared, a Parikh-Doering oxidation utilizing pyridine sulfur trioxide 
complex was successfully performed to convert the alcohol to aromatic aldehyde 3.22. 
 
Scheme 3.6 Synthesis of aromatic aldehyde 3.22. 
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With the aldehyde in hand, examination of the cyanohydrin was pursued (Table 
3.8). Initial conditions utilizing potassium cyanide (Table 3.8, Entries 1-5) proved unable 
to completely convert starting material 3.22 to product 3.26. Upon implementation of 
trimethylsilylcyanide with a zinc iodide catalyst, full conversion was successfully 
observed. Unfortunately, silica gel purification let to reversion to the starting aldehyde. 
Additionally, both acidic and alkaline conditions resulted in development of aldehyde 
starting material. It was postulated that reversion was achieved through an elimination 
mechanism wherein the cyanide was acting as the leaving group to produce the aldehyde. 
Table 3.8  
Reaction conditions for development of cyanohydrin 3.26 
 
Entry CN Source Additive Solvent Time (hr) % Conv.a 
1 KCN HCl EtOH 48 20% 
2 KCN NH4Cl Et2O 16 20% 
3 KCN NaHSO3 EtOAc 48 40% 
4 KCN NaOH THF 22 16% 
5 KCN NaHCO3 THF 21 79% 
6 TMSCN ZnI2 DCM 5.5 100% 
7 TMSCN ZnI2 DCM 16 100% 
 
Note: a Determined via HPLC: Rt 3.22 = 5.3 min; Rt 3.26 = 4.9 min 
To remedy the instability of the cyanohydrin, a one-pot method was attempted 
(Scheme 3.7). It was postulated that conversion to the cyanohydrin in a 
dichloromethane/tert-butylacetate co-solvent followed by subsequent addition of Tf2NH 
could produce the cyanide with the benzylic t-butylether residue installed. Through this 
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method the cyanohydrin would be “trapped”, imparting stability and preventing 
undesired elimination and reversion to the aldehyde. Attempts to perform this chemistry 
were unsuccessful in producing desired cyanide 3.30. 
 
Scheme 3.7 One-pot trapping method for development of cyanide 3.30. 
To this end, it was determined that diminishing reaction yields at the reduction 
stage and stability challenges with the cyanohydrin formation would not make this a 
viable synthetic route for the facile development of an extensive drug candidate library. 
Therefore, an alternative method was designed that involved the formation of acid 
chloride 3.31 (Scheme 3.8). Starting from ethyl ester quinoline 3.24, base hydrolysis and 
subsequent acid chloride formation with oxalyl chloride was performed to develop 3.31 
as a white solid. Proceeding attempts to install the cyanohydrin and hydrolyze to α-keto 
acetic acid 3.32 were unsuccessful as no reaction was observed. 
 
Scheme 3.8 Alternative conditions for cyanohydrin formation. 
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3.4.3 Second Generation Synthesis 
With the previous route having presented significant challenges, we sought to 
employ chemistry from the Boehringer Ingelheim process group as an alternative method 
to install the acetic acid side chain.92 Beginning with 4-hydroxy-2-methylquinoline 
(Scheme 3.9) transformations were performed at positions 3 and 4. Development of 2-
iodo and 2-bromoquinolines (3.34a and 3.34b, respectively) was achieved via addition of 
the associated halo-succinimide in the presence of acetic acid which was readily scaled to 
15 grams. Installation of chlorine at position 4 utilized phosphorous oxychloride in the 
presence of triethylamine with greater success observed with the 3-bromoquinoline and 
could also be easily scaled up to multigram scales. A reverse quench by pouring the crude 
reaction into ice water with vigorous stirring followed by slow addition of solid sodium 
hydroxide effectively neutralized any phosphate intermediates to afford 3.35a and 3.35b 
as solids. 
 
Scheme 3.9 Synthesis of 3-haloquinolines 3.35a-b. 
In the proceeding step, a selective halogen-metal exchange was implemented to 
install the necessary ethyl oxalate at position 3. Specifically, a copper (I) bromide 
dimethylsulfide complex mediated Grignard was implemented (Table 3.9). In our hands, 
this reaction with isopropyl magnesium chloride was unsuccessful using 3-iodoquinoline 
3.35a (Entries 1-11). What was often observed was complete conversion but only a 
development of de-halogenated byproduct 3.40. When performing the same reaction 
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utilizing 3-bromoquinoline 3.35b, we were unable to achieve full conversion to the α-
keto ester 3.39. Additionally, increased scales of this reaction proved problematic as the 
development of the same de-halogenated quinoline by-product became prevalent beyond 
a 500 mg scale.  
Table 3.9  
Condition screening for the Grignard reaction 
 
Entry X Temp. Catalyst Electrophile %Yield Comments 
1 I -4 CuBr•SMe2 3.36 no reaction - 
2 I -4 CuBr•SMe2 3.38 no reaction - 
3 I -54 CuBr•SMe2 3.38 no reaction - 
4 I -54 CuBr•SMe2 3.36 0%a - 
5 I -54 to -4 CuBr•SMe2 3.38 0%a - 
6 I -4 CuBr•SMe2 3.38 0%a - 
7 I -4 CuBr•SMe2 3.38 0%a - 
8 I -4 CuBr•SMe2 3.38 0%a - 
9 I -54 CuBr•SMe2 3.38 0%a - 
10 I -54 none 3.38 0%a - 
11 I -78 none 3.38 0%a used n-BuLi 
13 Br -54 CuBr•SMe2 3.38 no reaction - 
14 Br -54→-4 CuBr•SMe2 3.38 0% - 
15 Br 0→rt CuBr•SMe2 3.38 29%b - 
16 Br 0 CuBr•SMe2 3.38 no reaction - 
17 Br 0 CuBr•SMe2 3.38 no reaction used 1.0 
equivalent of 
catalyst 
18 Br 0 CuBr•SMe2 3.38 no reaction - 
19 Br -78 none 3.38 0% used n-BuLi 
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Table 3.9 (continued) 
20 Br 0 CuBr•SMe2 3.38 no reaction NMR study 
with THF-d8 
 
Note: a Isolated material was de-iodinated quinoline 3.40. b Yield based on recovered starting material. 
To reconcile the incomplete conversions, isopropyl magnesium chloride lithium 
chloride complex was implemented and proved successful in consuming all starting 
material when followed by quench with ethyl chlorooxolate (Table 3.10). Unfortunately, 
challenges remained with development of de-halogenated quinoline which prevented 
scaling these reactions beyond a 1.0 g scale. 
Table 3.10  
Grignard reactions using isopropyl magnesium chloride lithium chloride complex 
 
Entry Scale %Yield Comments 
1 0.4 mmol 22%  
2 2.0 mmol 35%  
3 2.0 mmol 12%  
4 0.4 mmol 30% Used electrophile 3.36 
5 2.0 mmol 0% Used electrophile 3.36 
6 4.0 mmol 47%a  
 
Note: a Based on purity of 75% determined via NMR analysis 
The proceeding sodium borohydride reduction produced α-hydroxy ester 3.41 in 
77% yield (Scheme 3.10). Subsequent trans-halogenation to the 4-iodo quinoline 3.42 
followed by palladium (0) catalyzed Suzuki coupling to afford 4-phenyl quinoline 3.43 
were successful with an overall 63% yield. Ether formation via perchloric acid in tert-
butylacetate could achieve 71% conversion at best with normal phase purification able to 
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separate pure product in 71% yield based on recovered starting material. Saponification 
in aqueous sodium hydroxide then afforded the desired quinoline acetic acid 3.21 in a 
moderate 40% yield. 
 
Scheme 3.10 Late stage synthesis of biaryl quinoline 3.21. 
With an established synthetic route for the construction of the necessary quinoline 
scaffold, the procedures were altered in order to streamline the development of a 
candidate library. As shown in Scheme 3.11, the perchloric acid mediated tert-butyl ether 
synthesis was switched with the Suzuki coupling. This rearrangement implements a late 
stage derivatizing step where a wide variety of aromatics can be installed from a common 
intermediate. Ultimately, this allows for bulk preparation of bench-stable iodoquinoline 
3.45 leaving only two remaining steps and the necessity for one purification. 
 
Scheme 3.11 Final steps for quinoline library development. 
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Shown in Table 3.11 is a summary of a subset of biaryl quinolines that have been 
synthesized via the discussed route. Additionally, EC50 values for IN inhibition 
developed through two individual assays are presented. The 4-phenylquinoline (3.21a, 
R1=H) was utilized as the reference point for relative comparison of substituted phenyl 
rings. Substitution for a methyl group (3.21e, R1=CH3) resulted in a six-fold decrease in 
the EC50 value. Additionally, loss of potency occurred when methyl hydrogens were 
substituted with fluorine (3.21d, R1=CF3). There was a three-fold loss in potency 
observed between entries 4 and 5 (4-trifluoromethyl 3.21d and 4-methyl 3.21e, 
respectively). This suggests an incompatibility of the polar trifluoromethyl within the 
hydrophobic pocket. In addition, halogen substitution (entries 2 and 3) showed 
improvement in potency with para-chloro-4-phenylquinoline 3.21c having the most 
effective interaction among the series with an EC50 of 100 nM. 
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Table 3.11  
SAR study of para-substituted biaryl quinolines 
Entry Quinoline R1 %Yield 
3.44a 
%Yield 
3.21a 
EC50 Multimerization 
(µM) 
1 3.21a H 55% 40% 1.32±0.53  
2 3.21b F 67% 76% 0.49±0.04 
3b 3.21c Cl 63% 40% 0.10±0.02 
4 3.21d CF3 51% 99% 0.72±0.06 
5 3.21e CH3 49% 51% 0.24±0.11 
6 3.21f CN 80% 34%c 2.97±0.81 
7 3.21g COCH3 63%
d 57% 1.39±0.48 
11 3.21h C6H5 59% 77% No Activity 
12 3.21i NHCOCH3 67% 9% 8.41±0.73 
13 3.21j 
 
80% 78% 0.08±0.01 
14 3.21k 
 
72% 78% No Activity 
 
Note: a Isolated yield of homogenous material. b Follows original synthetic route with the yields reported associated with the Suzuki 
and hydrolysis step, respectivetly. c Required normal phase purification with dichloromethane-methanol. d Achieved 90% conversion 
by HPLC camparison of iodoquinoline 3.45 (4.6 min) and product 3.44g (5.7 min). 
Originally, we postulated that electron density at the aromatic ring was a 
significant factor but the presence of chlorine intriguingly interrupted this trend. We 
examined additional factors including size restrictions, steric interactions, and substrate-π 
interactions which may contribute significantly to protein affinity. Closer scrutiny of the 
trends revealed to us that electron density of the ring has minimal, although observable 
effect, with the size and steric interactions exhibiting the dominating factor for successful 
protein affinity. This was corroborated by entries 6-12 which contain substituents with 
increased sterics relative to entries 1-5. 
Still, steric interactions did not provide sufficient explanation for the increased 
potency in 3.21c. Further understanding for diversion from the standard trend can be 
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found in the stabilizing effect of chlorine-π interactions. A theoretical study elaborates on 
the significance of these interactions wherein chlorine participates in dispersive 
interactions with the π-systems of phenylalanine, histidine, and tryptophan residues.93 
The result of this interaction is a stabilizing effect of -2.01 kcal/mol, attributing to 
increased protein affinity. As shown in Figure 3.6 the chlorine resides within 4Å of 
tryptophan 132 allowing for this stabilizing Cl-π interaction to occur, providing evidence 
for the improved affinity. 
 
Figure 3.6 Three-dimensional and two-dimensional representation of the binding pocket. 
A. The computer model was generated by BIOVIA Discovery Studio® and denotes the distance between chlorine and W132 (blue 
dotted line). B. A two-dimensional representation of the binding pocket with the yellow and green sections representing the individual 
units of the integrase dimer. 
 In addition to the study of phenyl substitution, heterocyclic and bicyclic systems 
were also examined (Table 3.11; entries 11, 13, and 14). When testing biphenyl 3.21h no 
activity was observed. This supports the hypothesis that large substrates will exceed the 
available volume within the binding pocket. This is reiterated with para-cyano-4-
phenylquinoline 3.21f which showed no ability to bind within the pocket. The presence 
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of tryptophan 132 defines the available space in this pocket and the previously mentioned 
substrates, which exhibit rigid sp and sp2-hybridized carbon systems, exceed this three-
dimensional space and therefore have restricted access to the binding pocket. The most 
promising candidate from this series was the 2,3-benzo[b][1,4]dioxane 3.21j which 
showed an EC50 of 80 nM. 
3.5 Future Work 
Much of the presented work has utilized only quinoline substrates that contain no 
additional functionality on the western ring (positions 5-8). It can be postulated that 
certain functionalities, such as halogens bromine and iodine, would be implausible 
candidates for this method. Namely, the shortcoming would be derived in the Grignard 
reaction for the installation of the acetic acid residue. It is apparent that additional 
halogens would compete with the reaction, further reducing the yield of the desired α-
keto ester. Additionally, the Grignard reaction presents a time-consuming and low 
yielding step which develops a bottleneck to produce the iodohydrin in bulk quantities. 
To remedy this limitation, it would be of interest to revisit the first generation 
synthesis where development of the cyanohydrin presented significant challenges. 
Presented in Scheme 3.12 is the altered conditions to the original route. It was discovered 
that utilizing a lithium chloride catalyzed cyanosilylation was successful under ambient 
temperatures to produce a stable cyanosilane. Implementing Pinner Reaction conditions 
would then develop the needed α-hydroxy ester 3.46. From that point standard chemistry 
previously described can be implemented for library development. 
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Scheme 3.12 Alternative synthetic route for future substrate development. 
3.6 Summary and Conclusion 
Despite the marked improvements for treatment of HIV, the virus continues to 
produce resistance to standard treatment options. Additionally, the presented statistics 
show that it remains an aggressive virus that effects the lives of millions each year. 
Presented in this chapter is a method and proceeding discussion regarding the 
development of novel treatments containing a quinoline scaffold. A process for the 
construction of the quinoline core and subsequent functionalization has been established 
and subsequently utilized to afford a library of treatment candidates. Despite the progress 
with this work, deficiencies do exist and have been briefly described. Therefore, an 
alternative synthesis is required and proposed for the improvement and expansion to a 
more general method that is amenable to various functionality on the quinoline core. 
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3.7 Experimental 
3.7.1 Synthesis of Intermediates 
1H-benzo[d][1,3]oxazine-2,4-dione (3.17a): To a single neck 500 mL 
roundbottom flask was added anthranilic acid (72.9 mmol, 10 g) and 
tetrahydrofuran (2.441 mol, 200 mL) which resulted in a dark brown solution. 
Triphosgene (72.9 mmol, 21.64 g) was added to the mixture which resulted in a tan color 
suspension. The flask was equipped with a condensing column and the reaction was 
heated to 70 °C and stirred at 800 rpm for 12 hours. The reaction was cooled to room 
temperature and was poured into a 600 mL beaker containing 300 mL of distilled water 
and was stirred vigorously for one hour using an overhead mechanical stirrer. A white 
precipitate formed and was vacuum filtered through a Büchner funnel. The solid was 
collected and stirred in 100 mL of methanol for 30 minutes. The slurry was then collected 
via vacuum filtration through a Büchner funnel to afford 1H-benzo[d][1,3]oxazine-
2,4(1H)-dione (9.61 g, 81%) as a white solid. mp 249-250 ºC; IR (solid) cm-1 1724; 1H 
NMR (DMSO-d6, 400 MHz) δ: 11.75 (s, 1H, N-H), 7.92 (d, J = 7.9 Hz, 1H), 7.75 (dd, J 
= 8.0, 7.2, 1.5 Hz, 1H), 7.26 (d, J = 7.9 Hz, 1H), 7.17 (dd, J = 8.1, 0.9 Hz, 1H); 13C 
NMR (DMSO-d6, 100 MHz) δ: 160.3 (s), 147.5 (s), 141.9 (s), 137.4 (d), 129.4 (d), 124.0 
(d), 115.8 (d), 110.7 (s). 
6-bromo-1H-benzo[d][1,3]oxazine-2,4-dione (3.17b): mp >260 ºC; IR 
(solid) cm-1 3169, 1754, 1691; 1H NMR (DMSO-d6, 400 MHz) δ: 11.86 
(s, 1H, N-H), 7.99 (d, J = 2.3 Hz, 1H), 7.89 (dd, J = 8.7, 2.3 Hz, 1H), 7.10 (d, J = 8.7 Hz, 
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1H); 13C NMR (DMSO-d6, 100 MHz) δ: 158.8 (s), 146.7 (s), 140.6 (s), 139.3 (d), 130.5 
(d), 117.6 (d), 114.5 (s), 112.4 (s). 
6-iodo-1H-benzo[d][1,3]oxazine-2,4-dione (3.17c): mp >260 ºC; IR 
(solid) cm-1 3169, 1751, 1695; 1H NMR (DMSO-d6, 400 MHz) δ: 11.82 
(s, 1H, N-H), 8.13 (d, J = 1.6 Hz, 1H), 8.01 (dd, J = 8.5, 1.8 Hz, 1H), 6.96 (d, J = 8.5 Hz, 
1H); 13C NMR (DMSO-d6, 100 MHz) δ: 159.1 (s), 147.2 (s), 145.3 (s), 141.4 (d), 136.9 
(d), 118.1 (d), 113.1 (s), 86.5 (s). 
6-hydroxy-1H-benzo[d][1,3]oxazine-2,4-dione (3.17d): mp >260 ºC; 
IR (solid) cm-1 3269, 1771, 1695; 1H NMR (DMSO-d6, 400 MHz) δ: 
11.51 (s, 1H, N-H), 9.87(s, 1H, O-H), 7.22 (s, 1H), 7.20 (m, 1H) 7.03 (d, J = 8.4 Hz, 1H); 
13C NMR (DMSO-d6, 100 MHz) δ: 160.4 (s), 146.7 (s), 140.6 (s), 139.3 (d), 130.5 (d), 
117.6 (d), 114.5 (s), 112.4 (s). 
6-nitro-1H-benzo[d][1,3]oxazine-2,4-dione(3.17e): mp >260 ºC; IR 
(solid) cm-1 3169, 1747, 1695; 1H NMR (DMSO-d6, 400 MHz) δ: 12.35 
(s, 1H, N-H), 8.56 (d, J = 2.6 Hz, 1H), 8.52 (dd, J = 9.0, 2.6 Hz, 1H), 7.30 (d, J = 9.1 Hz, 
1H); 13C NMR (DMSO-d6, 100 MHz) δ: 159.1 (s), 147.0 (s), 146.5 (s), 142.9 (s), 131.7 
(d), 125.0 (d), 117.1 (d), 111.6 (s). 
7-bromo-1H-benzo[d][1,3]oxazine-2,4-dione (3.17f): mp >260 ºC; IR 
(solid) cm-1 3169, 1772, 1700; 1H NMR (DMSO-d6, 400 MHz) δ: 11.83 
(s, 1H, N-H), 7.83 (d, J = 8.4 Hz, 1H), 7.42 (dd, J = 8.4, 1.6 Hz, 1H), 7.30 (d, J = 1.6 Hz, 
1H); 13C NMR (DMSO-d6, 100 MHz) δ: 159.8 (s), 147.3 (s), 142.9 (s), 131.2 (d), 130.7 
(s), 126.9 (d), 118.2 (d), 110.2 (s). 
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7-nitro-1H-benzo[d][1,3]oxazine-2,4-dione (3.17g): mp >260 ºC; IR 
(solid) cm-1 3173, 1781, 1695; 1H NMR (DMSO-d6, 400 MHz) δ: 12.09 
(s, 1H, N-H), 8.16 (d, J = 8.6 Hz, 1H), 7.96 (dd, J = 8.6, 2.2 Hz, 1H), 7.86 (d, J = 2.2 Hz, 
1H); 13C NMR (DMSO-d6, 100 MHz) δ: 159.2 (s), 152.4 (s), 147.1 (s), 142.5 (s), 131.4 
(d), 117.8 (d), 115.9 (s), 110.7 (d). 
8-bromo-1H-benzo[d][1,3]oxazine-2,4-dione (3.17h): mp 99-201 ºC; IR 
(solid) cm-1 1716; 1H NMR (DMSO-d6, 400 MHz) δ: 11.08 (s, 1H, N-H), 
8.02 (dd, J = 7.9, 1.4 Hz, 1H), 7.95 (dd, J = 7.8, 1.4 Hz, 1H), 7.91 (dd, J = 
7.8 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz) δ: 159.6 (s), 147.0 (s), 140.6 (d), 140.0 
(s), 129.1 (d), 125.0 (d), 113.4 (s), 108.4 (s). 
 ethyl 4-hydroxy-2-methylquinoline-3-carboxylate (3.19a): To a 100 
mL single-necked round bottom flask was added 2H-
benzo[d][1,3]oxazine-2,4(1H)-dione (5 g, 30.6 mmol), ethyl 3-oxobutanoate (7.7 mL, 
61.3 mmol), and N,N-dimethylacetamide (50 mL). Sodium hydroxide (1.2 g, 30.6 mmol) 
was added to the flask, which resulted to an olive-green color. The reaction was equipped 
with a reflux condenser and stirred at 100°C for 12 hours. The reaction was cooled to 
ambient temperature then was poured into a 600 mL beaker containing 200 mL of 
distilled water and was vigorously stirred for 30 mins using an overhead mechanical 
stirrer. The white precipitate was vacuum filtered through a Büchner funnel and was 
rinsed with 50 mL of distilled water. The solid was collected and dried overnight under 
high vacuum to afford ethyl 4-hydroxy-2-methylquinoline-3-carboxylate (4.1 g, 57.85%) 
as a white solid. mp 224-228 ºC; IR (solid) cm-1 2873, 1717; 1H NMR (DMSO-d6, 400 
MHz) δ: 8.06 (dd, J = 8.1, 1.4 Hz, 1H), 7.68 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.54 (d, J = 
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8.0 Hz, 1H), 7.35 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 4.24 (q, J = 7.1, 2H), 2.34 (s, 3H), 1.28 
(t, J = 7.1, 3H); 13C NMR (DMSO-d6, 100 MHz) δ: 173.8 (s), 167.2 (s), 149.3 (s), 139.6 
(s), 132.7 (d), 125.5 (d), 125.0 (s), 124.2 (d), 118.4 (d), 115.3 (s), 60.7 (t), 18.6 (q), 14.6 
(q); HRMS Anal. Calcd. for C8H5NO3: C, 67.52; H, 5.67. Found C, 66.68; H, 5.73. 
ethyl 6-bromo-4-hydroxy-2-methylquinoline-3-carboxylate 
(3.19b): White Solid; mp >260ºC; IR (solid) cm-1 2904, 1704; 1H 
NMR (DMSO-d6, 400 MHz) δ: 12.04 (s, 1H, O-H), 8.13 (d, J = 2.3 Hz, 1H), 7.82 (dd, J 
= 8.8, 2.3 Hz, 1H), 7.51 (dd, J = 8.0, 1.0 Hz, 1H), 4.25 (q, J = 7.1, 2H), 2.39 (s, 3H), 1.28 
(t, J = 7.1, 3H); 13C NMR (DMSO-d6, 100 MHz) δ: 172.5 (s), 166.9 (s), 149.9 (s), 138.5 
(s), 135.4 (d), 127.6 (d), 126.5 (s), 121.1 (d), 116.8 (s), 115.5 (s), 60.9 (t), 18.7 (q), 14.6 
(q). 
ethyl 4-hydroxy-6-iodo-2-methylquinoline-3-carboxylate (3.19c): 
White Solid; mp >260ºC; IR (solid) cm-1 2904, 1704; 1H NMR 
(DMSO-d6, 400 MHz) δ: 12.04 (s, 1H, O-H), 8.13 (d, J = 2.3 Hz, 1H), 7.82 (dd, J = 8.8, 
2.3 Hz, 1H), 7.51 (dd, J = 8.0, 1.0 Hz, 1H), 4.25 (q, J = 7.1, 2H), 2.39 (s, 3H), 1.28 (t, J = 
7.1, 3H); 13C NMR (DMSO-d6, 100 MHz) δ: 172.5 (s), 166.9 (s), 149.9 (s), 138.5 (s), 
135.4 (d), 127.6 (d), 126.5 (s), 121.1 (d), 116.8 (s), 115.5 (s), 60.9 (t), 18.7 (q), 14.6 (q). 
ethyl 4,6-dihydroxy-2-methylquinoline-3-carboxylate (3.19d): 
White Solid; mp >260ºC; IR (solid) cm-1 3365, 1705; 1H NMR 
(DMSO-d6, 400 MHz) δ: 11.74 (s, 1H, O-H), 9.74 (s, 1H, O-H) 7.42 (d, J = 8.8 Hz, 1H), 
7.38 (d, J = 2.8 Hz, 1H), 7.16 (dd, J = 8.8, 2.8 Hz, 1H), 4.22 (q, J = 7.1, 2H), 2.36 (s, 3H), 
1.27 (t, J = 7.1, 3H); 13C NMR (DMSO-d6, 100 MHz) δ: 173.3 (s), 167.6 (s), 154.5 (s), 
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147.9 (s), 133.0 (s), 126.5 (s), 122.6 (d), 120.0 (d), 113.7 (s), 108.2 (d), 60.6 (t), 18.5 (q), 
14.6 (q). 
ethyl 4-hydroxy-2-methyl-6-nitroquinoline-3-carboxylate (3.19e): 
Yellow Solid; mp >260ºC; IR (solid) cm-1 1708; 1H NMR (DMSO-
d6, 400 MHz) δ: 8.79 (d, J = 2.6 Hz, 1H), 8.44 (d, J = 9.1, 2.7 Hz, 1H), 7.71 (d, J = 9.2 
Hz, 1H), 4.28 (q, J = 7.1, 2H), 2.43 (s, 3H), 1.29 (t, J = 7.1, 3H); 13C NMR (DMSO-d6, 
100 MHz) δ: 173.3 (s), 166.4 (s), 151.0 (s), 143.5 (s), 143.4 (s), 126.9 (d), 124.2 (s), 
122.0 (d), 120.4 (d), 116.5 (s), 61.1 (t), 18.7 (q), 14.6 (q). 
ethyl 7-bromo-4-hydroxy-2-methylquinoline-3-carboxylate 
(3.19f): White Solid; mp >260ºC; IR (solid) cm-1 3073, 1711; 1H 
NMR (DMSO-d6, 400 MHz) δ: 7.97 (d, J = 8.6 Hz, 1H), 7.71 (d, J = 1.8 Hz, 1H), 7.48 
(dd, J = 8.6, 1.8 Hz, 1H), 4.24 (q, J = 7.1, 2H), 2.38 (s, 3H), 1.27 (t, J = 7.1, 3H); 13C 
NMR (DMSO-d6, 100 MHz) δ: 173.3 (s), 167.0 (s), 150.2 (s), 141.0 (s), 127.8 (d), 127.1 
(d), 125.9 (s), 124.0 (s), 121.0 (d), 115.7 (s), 60.8 (t), 18.9 (q), 14.6 (q). 
ethyl 4-hydroxy-2-methyl-7-nitroquinoline-3-carboxylate (3.19g): 
Yellow Solid; mp >260ºC; IR (solid) cm-1 1722; 1H NMR (DMSO-
d6, 400 MHz) δ: 12.32 (s, 1H, O-H), 8.39 (d, J = 2.0 Hz, 1H), 8.28 (d, J = 8.8 Hz, 1H), 
8.08 (dd, J = 8.9, 2.2 Hz, 1H), 4.27 (q, J = 7.1, 2H), 2.44 (s, 3H), 1.29 (t, J = 7.1, 3H); 
13C NMR (DMSO-d6, 100 MHz) δ: 172.9 (s), 166.6 (s), 151.3 (s), 149.8 (s), 139.4 (s), 
128.4 (s) 127.9 (d), 117.8 (d), 116.7 (s), 114.7 (d), 61.1 (t), 18.9 (q), 14.6 (q). 
ethyl 8-bromo-4-hydroxy-2-methylquinoline-3-carboxylate (3.19h): 
White Solid; mp 133-135ºC; IR (solid) cm-1 3526, 3400, 1715; 1H NMR 
(DMSO-d6, 400 MHz) δ: 10.56 (s, 1H, O-H), 8.12 (dd, J = 8.0, 1.4 Hz, 
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1H), 8.02 (dd, J = 7.8, 1.4 Hz, 1H), 7.31 (dd, J = 7.8 Hz, 1H), 4.27 (q, J = 7.1, 2H), 2.51 
(s, 3H), 1.29 (t, J = 7.1, 3H); 13C NMR (DMSO-d6, 100 MHz) δ: 173.3 (s), 166.8 (s), 
150.4 (s), 137.5 (s), 136.7 (d) 126.6 (s), 125.5 (d), 125.2 (d), 116.5 (s), 111.3 (s), 61.1 (t), 
18.7 (q), 14.5 (q). 
3-bromo-2-methylquinolin-4-ol (3.34b): To a 100 mL roundbottom flask 
was added 2-methylquinolin-4-ol (1.2 g, 7.5 mmol), N-bromosuccinimide 
(1.3 g, 7.5 mmol), and acetic acid (34 mL, 7.5 mmol). The reaction was stirred at 60°C 
and within 15 minutes the white slurry obtained a yellow tint and increased in viscosity. 
The reaction was determined complete after 30 minutes via HPLC and TLC, was cooled 
to ambient temperature, and diluted with cold distilled water (20 mL). This mixture was 
filtered through a Hirsch funnel and the precipitate was washed with cold water (10 mL), 
saturated sodium bicarbonate (10 mL), and acetone (20 mL). The precipitate was dried by 
pulling air for 15 minutes and was collected to afford 3-bromo-2-methylquinolin-4-ol 
(1.6 g, 92%) as a yellow solid. No further purification was performed. mp >260 ºC; IR 
(solid) cm-1 2731 (br); 1H NMR (CDCl3, 400 MHz) δ: 8.10 (dd, J = 8.1, 1.2 Hz, 1H), 
7.67 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.35 (ddd, J = 8.0, 7.0, 1.0 
Hz, 1H), 2.56 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ: 171.4 (s), 149.3 (s), 139.4 (s), 
132.2 (d), 125.7 (d) 124.0 (d), 123.3 (s), 118.6 (d), 106.4 (s), 22.0 (q). 
3-bromo-4-chloro-2-methylquinoline (3.35b): To a 50 mL roundbottom 
flask was added 3-bromo-2-methylquinolin-4-ol (13.1 g, 55 mmol) and 
phosphorus oxychloride (25.6 mL, 275 mmol). The reaction was stirred at 80°C for 2 
hours before determining complete with HPLC. The reaction was cooled to ambient 
temperature and was slowly poured into a 250 mL beaker full of ice (about 100 g). The 
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residual material in the flask was rinsed with water and was added to the beaker. The 
beaker was maintained at 0°C while the solution was neutralized with sodium hydroxide 
pellets and vigorous stirring. Slow addition was required to prevent extreme exotherms. 
Once neutral, the solution contained a yellow precipitate. The slurry was stirred for an 
additional three hours at ambient temperature then filtered through a Buchner funnel. The 
precipitate was collected and dried under vacuum overnight to afford 3-bromo-4-chloro-
2-methylquinoline (13.8 g, 98%) as a yellow solid. No further purification was 
performed. mp 54-56 ºC; IR (solid) cm-1 2913; 1H NMR (CDCl3, 400 MHz) δ: 8.14 (d, J 
= 8.1 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.72 (ddd, J = 8.3, 6.7, 1.2 Hz, 1H), 7.51 (dd, J = 
7.4 Hz, 1H), 2.89 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ: 158.2 (s), 146.4 (s), 142.0 (s), 
130.3 (d), 129.1 (d) 127.5 (d), 125.9 (s), 124.5 (d), 119.8 (s), 27.4 (q). 
ethyl 2-(4-chloro-2-methylquinolin-3-yl)-2-oxoacetate (3.39): To a 
flame dried 50mL 3-neck roundbottom flask equipped with a low 
temperature thermometer was added 3-bromo-4-chloro-2-methylquinoline (1.0 g, 4 
mmol), copper(I) bromide-dimethyl sulfide complex (41 mg, 0.20 mmol), and 
tetrahydrofuran (7 mL). The solution was cooled to 0⁰C in an ice bath. 
Isopropylmagnesium chloride lithium chloride complex (7.7 mL, 10 mmol, 1M in THF) 
was added dropwise over 30 minutes via syringe pump. During addition, the solution 
changed from a clear, light yellow to a green/yellow solution to black. The reaction was 
stirred at 0°C for an additional five minutes following complete addition. An additional 
100 mL 3-neck roundbottom flask was prepared with ethyl 2-chloro-2-oxoacetate (0.728 
mL, 8 mmol) and tetrahydrofuran (7 mL) and was cooled to 0°C.  The Grignard cuprate 
was added to the 100 mL flask via cannula at a rate that kept the solution temperature 
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below 10°C. The reaction was stirred at 0°C for 15 minutes before determining complete 
via HPLC. The reaction was quenched with saturated ammonium chloride (10 mL) and 
was stirred for 15 minutes then transferred to a separatory funnel and the aqueous phase 
was removed. The organic phase was washed with saturated sodium bicarbonate (10 mL). 
The combined aqueous phase was extracted with ethyl acetate (10 mL). The combined 
organic phase was washed with brine (10 mL), dried over magnesium sulfate, vacuum 
filtered and concentrated in vacuo to afford a brown oil. The residue was 
chromatographed using via automated purification over 40 g of silica gel eluted with 
hexanes-ethyl acetate using a linear gradient. Product rich fractions were pooled and 
evaporated to afford ethyl 2-(4-chloro-2-methylquinolin-3-yl)-2-oxoacetate (700 mg, 
47%) as a yellow oil. IR (thin film) cm-1 1736, 1713; 1H NMR (CDCl3, 400 MHz) δ: 
8.21 (dd, J = 8.4, 0.9 Hz, 1H), 8.07 (d, J = 8.4, 1H), 7.84 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 
7.66 (ddd, J = 8.2, 7.0, 1.0 Hz, 1H), 3.98 (s, 3H), 2.69 (s, 3H); 13C NMR (CDCl3, 100 
MHz) δ: 186.8 (s), 161.2 (s), 155.5 (s), 148.5 (s), 141.0 (s) 132.1 (d), 129.2 (d), 128.9 (s), 
127.8 (d), 124.0 (d), 123.8 (s), 53.7 (q), 23.8 (q). 
ethyl 2-(4-chloro-2-methylquinolin-3-yl)-2-hydroxyacetate (3.41): 
To a 25 mL roundbottom flask was added ethyl 2-(4-chloro-2-
methylquinolin-3-yl)-2-oxoacetate (525 mg, 1.9 mmol), tetrahydrofuran (5 mL), and 
ethanol (50 µL). The solution was cooled to 0°C then sodium borohydride (71 mg, 1.9 
mmol) was added. The reaction was stirred at 0°C for 30 minutes before observing 
complete conversion by HPLC. The reaction was diluted with water (5 mL) and was 
neutralized with 1N HCl (1-2 mL). The aqueous phase was extracted with 
dichloromethane (two 3-mL portions). The organic phase was washed with brine (5 mL), 
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dried over sodium sulfate, gravity filtered, and concentrated in vacuo to afford a yellow 
oil (711 mg). The residue was chromatographed via automated purification over 12 g of 
silica gel eluted with a linear gradient of hexanes-ethyl acetate. Product rich fractions 
were pooled and evaporated to afford ethyl 2-(4-chloro-2-methylquinolin-3-yl)-2-
hydroxyacetate (409 mg, 77%) as a yellow solid. mp 54-56 ºC IR (thin film) 3074, 1745 
cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.24 (dd, J = 8.4, 0.9 Hz, 1H), 8.07 (d, J = 8.4, 1H), 
7.77 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.62 (ddd, J = 8.2, 7.0, 1.0 Hz, 1H), 6.00 (s, 1H, O-
H), 4.28 (qd, J = 7.2, 1.4; 1H), 2.80 (s, 3H), 1.22 (t, J = 7.1, 3H); 13C NMR (CDCl3, 100 
MHz) δ: 173.0 (s), 158.3 (s), 147.1 (s), 143.5 (s), 130.9 (d), 128.5 (d), 128.0 (s), 127.3 
(d), 125.2 (s), 124.7 (d), 69.3 (d), 62.9 (t), 23.9 (q), 14.0 (q). 
ethyl 2-hydroxy-2-(4-iodo-2-methylquinolin-3-yl)acetate (3.42): 
To a 25 mL roundbottom flask was added ethyl 2-(4-chloro-2-
methylquinolin-3-yl)-2-hydroxyacetate (409 mg, 1.5 mmol) and tetrahydrofuran (5.0 
mL). Hydrochloric acid (1.5 mL, 6.141 mmol, 4M in dioxane) was added to the flask and 
the reaction was stirred at ambient temperature for 40 minutes. The solution was 
concentrated in vacuo and the residue was diluted in acetonitrile (5.0 mL) then 
transferred to a 10-20 mL microwave vial. Sodium iodide (4.4 g, 29.2 mmol) was added 
and the vial was sealed. The reaction was heated to 90°C and monitored via HPLC. After 
3 hours the reaction was cooled to ambient temperature and the solvent was removed in 
vacuo. The red residue was diluted with ethyl acetate (10 mL) and was washed with 
saturated sodium bicarbonate (6 mL), 10% sodium thiosulfate (6 mL), and brine (6 mL). 
The organic phase was dried over magnesium sulfate, vacuum filtered, and concentrated 
in vacou to afford a yellow oil (693 mg). The product was utilized in the proceeding 
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reaction without purification. The reaction was determined complete via LRMS [m/z (I) 
= 280, m/z (VI) = 372]. The MS solution used was a 50/50 THF/MeOH solvent with 
trace NaCl and the samples were analyzed using the LXQ-ESI with direct injection. IR 
(thin film) 3061, 1741 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.24 (dd, J = 8.4, 0.9 Hz, 
1H), 8.07 (d, J = 8.4, 1H), 7.77 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.62 (ddd, J = 8.2, 7.0, 1.0 
Hz, 1H), 6.00 (s, 1H, O-H), 4.28 (qd, J = 7.2, 1.4; 1H), 2.80 (s, 3H), 1.22 (t, J = 7.1, 3H); 
13C NMR (CDCl3, 100 MHz) δ: 173.0 (s), 158.3 (s), 147.1 (s), 143.5 (s), 130.9 (d), 128.5 
(d), 128.0 (s), 127.3 (d), 125.2 (s), 124.7 (d), 69.3 (d), 62.9 (t), 23.9 (q), 14.0 (q). 
ethyl 2-(4-(4-chlorophenyl)-2-methylquinolin-3-yl)-2-
hydroxyacetate (3.43): To a 10-20 mL microwave vial was added 
(4-chlorophenyl)boronic acid (251 mg, 1.6 mmol), potassium 
carbonate (606 mg, 4.4 mmol), and tetrakis(triphenylphosphine)palladium (0) (84 mg, 
0.73 mmol). The vial was sealed immediately then evacuated and charged with nitrogen 
three times. Ethyl 2-hydroxy-2-(4-iodo-2-methylquinolin-3-yl)acetate (543 mg, 1.5 
mmol) in N,N-dimethylformamide (4 mL) and water (1 mL) was added to the vial via 
syringe. The reaction was heated to 90°C for one hour before determining complete via 
HPLC. The reaction was cooled to ambient temperature then diluted with distilled water 
(4 mL). The slurry was filtered through a Celite plug and the filtrate was collected. The 
aqueous phase was extracted with ethyl acetate (two 3-mL portions). The combined 
organic phase was washed with brine (5 mL), dried over magnesium sulfate, vacuum 
filtered, and concentrated in vacuo to afford a brown liquid. The residue was 
chromatographed via automated purification over 12 g of silica gel eluted with hexanes-
ethyl acetate on a linear gradient in 8 mL fractions. Product rich fractions were pooled 
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and evaporated to afford ethyl 2-(4-(4-chlorophenyl)-2-methylquinolin-3-yl)-2-
hydroxyacetate (329 mg, 63%) as an orange solid. mp 161-164 ºC IR (thin film) 3061, 
1741 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.05 (d, J = 8.4 Hz, 1H), 7.69 (ddd, J = 8.3, 
6.8, 1.4 Hz, 1H), 7.51 (ddd, J = 8.6, 6.6, 1.5 Hz, 1H), 7.40 (ddd, 8.2, 6.9, 1.1 Hz, 1H) 
7.31-7.29 (m, 3H), 5.22 (s, 1H), 4.21 (qd, J = 10.8, 7.2, 2H), 2.74 (s, 3H), 1.21 (t, J = 7.1, 
3H); 13C NMR (CDCl3, 100 MHz) δ: 173.8 (s), 158.1 (s), 147.9 (s), 147.0 (s), 134.6 (s), 
134.5 (s), 131.6 (d), 130.8 (d), 129.8 (d), 128.9 (d), 128.7 (d), 127.4 (s), 126.5 (d), 126.23 
(d), 126.21 (s), 69.8 (d), 62.7 (t), 23.9 (q), 14.1 (q). 
ethyl 2-(tert-butoxy)-2-(4-(4-chlorophenyl)-2-methylquinolin-3-
yl)acetate (3.44c): To a 5 mL conical vial was added ethyl 2-(4-(4-
chlorophenyl)-2-methylquinolin-3-yl)-2-hydroxyacetate (329 mg, 0.9 
mmol) and tert-butyl acetate (3.1 mL, 0.9 mmol) which developed an orange/yellow 
slurry. Perchloric acid (238 µL, 2.8 mmol) was then added which resulted in an 
immediate color change to a dark orange/brown solution. The reaction was stirred at 
ambient temperature for three hours and resulted in a 71% conversion by HPLC. The 
reaction was diluted with water (1 mL) and quenched via dropwise addition of saturated 
sodium bicarbonate until pH 7 was reached. The aqueous phase was extracted with ethyl 
acetate (three 3-mL portions). The combined organic phase was washed with saturated 
sodium bicarbonate (5 mL) and brine (5 mL), dried over magnesium sulfate, vacuum 
filtered, and concentrated in vacuo. The residue was chromatographed over 4 g of silica 
gel eluted with hexanes-ethyl acetate (25 mL 9:1→25 mL 4:1→25 mL 2:1→25 mL 1:1) 
in 3 mL fractions. Product rich fractions were pooled and evaporated to afford ethyl 2-
(tert-butoxy)-2-(4-(4-chlorophenyl)-2-methylquinolin-3-yl)acetate (271 mg, 71%) as a 
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yellow oil. IR (thin film) cm-1 1750; 1H NMR (CDCl3, 400 MHz) δ: 8.05 (d, J = 8.1 Hz, 
1H), 7.66 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 7.53 (m, 2H), 7.46 (m, 1H), 7.37 (ddd, 8.3, 6.8, 
1.2 Hz, 1H), 7.29-7.26 (m, 2H), 5.10 (s, 1H), 4.19 (dq, J = 10.8, 7.2 Hz, 2H), 2.85 (s, 
3H), 1.23 (t, J = 7.1, 3H), 1.00 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 172.4 (s), 159.4 
(s), 146.8 (s), 145.2 (s), 134.7 (s), 134.6 (s), 132.3 (d), 131.2 (d), 129.6 (s), 129.3 (d), 
128.8 (d), 128.7 (d), 128.3 (d), 126.3 (d), 126.1 (s), 125.9 (d) 76.1 (s), 70.8 (d), 61.4 (t), 
28.1 (q), 24.9 (q), 14.1 (q). 
2-(tert-butoxy)-2-(4-(4-chlorophenyl)-2-methylquinolin-3-yl)acetic 
acid (3.21c): To a 0.5-2.0 mL microwave vial was added a 0.3 molar 
solution of ethyl 2-(tert-butoxy)-2-(4-(4-chlorophenyl)quinolin-3-
yl)acetate (39 mg, 0.1 mmol) in ethanol (333 µL, 0.1 mmol). Aqueous sodium hydroxide 
(75 µL, 0.150 mmol, 2N) was added and the vial was sealed. The reaction was heated to 
60°C. After a total of 3.5 hours the reaction was neutralized with 1N HCl and the 
aqueous phase was extracted with ethyl acetate (0.5 mL). The organic phase was dried 
through a pasteurre pipette containing a magnesium sulfate plug and concentrated in 
vacuo. The residue was chromatographed over 4 g of silica gel elued with methanol-
dichloromethane (25 mL 1% MeOH→ 25 mL 2% MeOH→ 25 mL 3% MeOH→ 25 mL 
4% MeOH→ 25 mL 5% MeOH) in 3 mL fractions. Product rich fractions were pooled 
and evaporated to afford 2-(tert-butoxy)-2-(4-(4-chlorophenyl)quinolin-3-yl)acetic acid 
(14 mg, 40%) as a white solid. mp 122-125 ºC, IR (thin film) 1730, 3060 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ: 8.16 (d, J = 8.3 Hz, 1H), 7.71 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 7.68 
(m, 1H), 7.56 (dd, J = 9.2, 2.1, 1H), 7.54 (dd, J = 9.2, 2.1, 1H), 7.43 (ddd, J = 8.3, 6.7, 
0.8, 1H), 7.37 (dd, 8.3, 0.8 Hz, 1H), 7.29 (dd, J = 8.1, 2.2, 1H), 5.24 (s, 1H), 2.89 (s, 3H), 
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1.02 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 172.1 (s), 158.2 (s), 147.5 (s), 135.2 (s), 
133.8 (s), 132.8 (d), 130.9 (d), 130.3 (d), 129.3 (s), 128.8 (s), 128.3 (d), 127.7 (d), 126.7 
(d), 126.5 (d), 126.0 (s) 77.9 (s), 70.6 (d), 28.2 (q), 24.1 (q). 
ethyl 2-(tert-butoxy)-2-(4-iodo-2-methylquinolin-3-yl)acetate 
(3.45): To a 5.0 mL conical vial was added ethyl 2-hydroxy-2-(4-
iodo-2-methylquinolin-3-yl)acetate (91 mg, 0.25 mmol) and tert-
butyl acetate (817 µL, 0.25 mmol). Perchloric acid (44 µL, 0.74 mmol) was then added to 
the vial and the reaction was stirred at ambient temperature. After a total of 3 hours, the 
reaction was quenched with water (1 mL) and was neutralized to pH 7.0 with saturated 
sodium bicarbonate. The solution was extracted with ethyl acetate (three 1-mL portions) 
and the combined organic phase was washed with saturated sodium bicarbonate (1 mL) 
and brine (1 mL), dried over sodium sulfate, gravity filtered, and concentrated in vacou to 
afford a yellow oil (110 mg). The residue was chromatographed over 4 g of silica gel 
eluted with hexanes-ethyl acetate (25 mL 4:1→ 25 mL 2:1→ 25 mL 1:1) in 5 mL 
fractions. Product rich fractions were pooled and evaporated to afford ethyl 2-(tert-
butoxy)-2-(4-iodo-2-methylquinolin-3-yl)acetate (78 mg, 74%) as a yellow oil. IR (thin 
film) 1750 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.12 (dd, J = 8.4, 1.0 Hz, 1H), 7.95 (dd, 
J = 8.3, 0.8, 1H), 7.69 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.56 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 
5.93 (s, 1H), 4.18 (dq, J = 10.8, 7.1 Hz; 1H), 2.83 (s, 3H), 1.26 (s, 9H), 1.18 (t, J = 7.1 
Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ: 171.3 (s), 158.8 (s), 146.7 (s), 136.9 (s), 133.2 
(d), 130.1 (d), 129.4 (s), 128.8 (d), 127.5 (d), 120.5 (s), 80.2 (d), 76.7 (s), 61.6 (t), 28.3 
(q), 24.7 (q), 14.1 (q). 
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General Procedure for the Preparation of 4-Aryl Quinolines (3.44a-k): To a 0.5-2.0 
mL microwave vial was added ethyl 2-(tert-butoxy)-2-(4-iodo-2-methylquinolin-3-
yl)acetate (100 mg, 0.25 mmol), boronic acid (0.50 mmol), potassium carbonate (0.70 
mmol), and tetrakis(triphenylphosphine)palladium(0) (0.05 mmol). The vial was 
immediately sealed then evacuated and charged with nitrogen three times. 
Dimethylformamide (800 µL) and water (80 µL) were then added via syringe. The 
reaction was heated to 90ºC for a total of 3-16 hours and were monitored via HPLC and 
TLC. The reaction was cooled to ambient temperature then diluted with water (1 mL) and 
ethyl acetate (2 mL). The aqueous phase was removed and the organic phase was filtered 
through a Celite® plug. The filtrate was washed with water (five 1-mL portions), dried 
over magnesium sulfate, gravity filtered, and concentrated to afford a crude oil. The 
residue was chromatographed over 12 g of silica gel eluted with hexanes-acetone 
(9:1→4:1→2:1). Product rich fractions were pooled and evaporated to isolate the 4-aryl 
quinoline products. 
ethyl 2-(tert-butoxy)-2-(2-methyl-4-phenylquinolin-3-yl)acetate 
(3.44a): yellow oil; IR (solid) cm-1 1749; 1H NMR (CDCl3, 400 
MHz) δ: 8.05 (d, J = 8.4 Hz, 1H), 7.64 (ddd, J = 8.3, 4.4, 3.8 Hz, 1H), 
7.55-7.48 (m, 4H), 7.34-7.31 (m, 3H); 13C NMR (CDCl3, 100 MHz) δ: 172.6 (s), 159.4 
(s), 146.8 (s), 146.5 (s), 136.2 (s), 130.7 (d), 129.9 (d), 129.6 (s), 129.2 (d), 128.5 (d), 
128.45 (d), 128.4 (d), 128.0 (d), 126.7 (d), 126.3 (s), 125.7 (d), 76.0 (s), 70.8 (d), 61.3 (t), 
28.1 (q), 24.9 (q), 14.1 (q). 
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ethyl 2-(tert-butoxy)-2-(4-(4-fluorophenyl)-2-methylquinolin-3-
yl)acetate (3.44b): yellow oil; IR (solid) 1752 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ: 8.04 (d, J = 8.3 Hz, 1H), 7.66 (ddd, J = 8.3, 6.7, 
1.5 Hz, 1H), 7.50 (m, 1H), 7.37 (ddd, J = 8.3, 6.7, 1.5 Hz, 1H), 7.32-7.29 (m, 2H), 7.25-
7.21 (m, 2H), 5.12 (s, 1H), 4.19 (qd, J = 10.8, 7.1 Hz, 2H), 2.85 (s, 3H), 1.23 (t, J = 7.1 
Hz, 3H), 0.99 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 172.5 (s), 163.9 (s), 161.5 (s), 
159.4 (s), 146.8 (s), 145.5 (s), 132.6 (d, 3J =  8 hz), 132.1 (s), 131.6 (d, 3J =  8.0 hz), 
128.5 (s, 1J = 350 Hz), 129.3 (d), 128.6 (d), 126.4 (d), 125.9 (d), 115.6 (d, 2J = 21 Hz), 
115.1 (d, 2J = 21 Hz), 76.1 (s), 70.8 (d), 61.4 (t), 28.1 (q), 24.9 (q), 14.1 (q). 
ethyl 2-(tert-butoxy)-2-(2-methyl-4-(4-
(trifluoromethyl)phenyl)quinolin-3-yl)acetate (3.44d): yellow oil; 
1H NMR (CDCl3, 400 MHz) δ: 8.07 (d, J = 8.4 Hz, 1H), 7.82 (m, 
2H), 7.68 (m, 2H), 7.49 (m, 1H), 7.38 (ddd, J = 8.0, 6.4, 0.8 Hz, 1H), 7.22 (d, J = 8.2 Hz, 
1H), 5.03 (s, 1H), 4.20 (dq, J = 10.8, 7.1 Hz, 2H), 2.87 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H), 
1.00 (s, 9H) ; 13C NMR (CDCl3, 100 MHz) δ: 172.2 (s), 159.4 (s), 146.7 (s), 145.0 (s), 
140.2 (s), 131.4 (d), 130.7 (s, 2J = 32 Hz), 130.2 (d), 129.5 (d), 127.6 (s, 1J = 370 Hz), 
128.6 (d), 126.2 (d), 125.8 (s), 125.5 (d, 3J = 3.6 Hz), 124.9 (d, 3J = 3.6 Hz), 76.2 (s), 70.8 
(d), 61.5 (t), 28.0 (q), 24.8 (q), 14.1 (q).  
ethyl 2-(tert-butoxy)-2-(2-methyl-4-(p-tolyl)quinolin-3-yl)acetate 
(3.44e): yellow oil; IR (solid) 1750 cm-1; 1H NMR (CDCl3, 400 
MHz) δ: 8.03 (d, J = 8.4 Hz, 1H), 7.64 (ddd, J = 8.3, 6.2, 2.1 Hz, 1H), 
7.39-7.32 (m, 5H), 7.22-7.20 (m, 1H), 5.19 (s, 1H), 4.19 (dq, J = 10.7, 7.1 Hz, 2H), 2.84 
(s, 3H), 2.49 (s, 3H), 1.23 (t, J = 7.1 Hz, 3H), 0.98 (s, 9H); 13C NMR (CDCl3, 100 MHz) 
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δ: 172.7 (s), 159.4 (s), 146.8 (s), 146.7 (s), 138.2 (s), 133.1 (s), 130.6 (d), 129.8 (d), 129.7 
(s), 129.2 (d), 129.1 (d), 128.6 (d), 128.5 (d), 126.8 (d), 126.5 (s), 125.6 (d), 76.0 (s), 70.8 
(d), 61.3 (t), 28.1 (q), 24.8 (q), 21.4 (q), 14.1 (q). 
ethyl 2-(tert-butoxy)-2-(4-(4-cyanophenyl)-2-methylquinolin-3-
yl)acetate (3.44f): Black oil; IR (solid) 2230, 1747 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ: 8.07 (d, J = 8.4 Hz, 1H), 7.86 (dd, J = 5.1, 1.1 
Hz, 2H), 7.71-7.65 (m, 3H), 7.47-7.45 (m, 1H), 7.38 (dd, J = 8.1, 0.9 Hz, 1H), 4.98 (s, 
1H), 4.19 (dq, J = 10.8, 7.1 Hz, 2H), 2.87 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H), 0.99 (s, 9H); 
13C NMR (DMSO-d6, 100 MHz) δ: 172.1 (s), 159.3 (s), 146.8 (s), 144.4 (s), 141.4 (s), 
132.2 (d), 131.9 (d), 131.7 (d), 130.6 (d), 129.6 (d), 129.2 (s), 128.8 (d), 127.9 (d), 126.3 
(d), 125.4 (s), 118.4 (s), 112.6 (s), 76.2 (s), 70.8 (d), 61.6 (t), 28.0 (q), 24.9 (q), 14.1 (q). 
 
ethyl 2-(4-(4-acetylphenyl)-2-methylquinolin-3-yl)-2-(tert-
butoxy)acetate (3.44g): White Solid; mp 135-137ºC; 1H NMR 
(CDCl3, 400 MHz) δ: 8.14 (dd, J = 7.3, 1.3 Hz, 2H), 8.06 (d, J = 8.5 
Hz, 1H), 7.67 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 7.63 (dd, J = 8.8, 1.7 Hz, 1H), 7.45 (dd, 8.7, 
1.5 Hz, 1H), 7.36 (ddd, J = 8.2, 6.8, 1.1 Hz, 1H), 7.23 (dd, J = 8.4, 0.7 Hz, 1H), 5.05 (s, 
1H), 4.19 (qd, J = 10.8, 7.1 Hz, 2H), 2.85 (s, 3H), 2.73 (s, 3H), 1.24 (t, J = 7.1, 3H), 0.98 
(s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 197.6 (s), 172.3 (s), 159.4 (s), 146.8 (s), 145.3 
(s), 141.4 (s), 136.9 (s), 131.3 (d), 130.2 (d), 129.4 (d), 129.3 (s), 128.7 (d), 128.4 (d), 
127.9 (d), 126.2 (d), 126.0 (d), 125.7 (s), 76.1 (s), 70.8 (d), 61.5 (t), 28.1 (q), 26.7 (q), 
24.9 (q), 14.2 (q). 
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ethyl 2-(4-([1,1'-biphenyl]-4-yl)-2-methylquinolin-3-yl)-2-(tert-
butoxy)acetate (3.44h): Yellow oil; 1H NMR (CDCl3, 400 MHz) δ: 
8.06 (d, J = 8.4 Hz, 1H), 7.79-7.77 (m, 2H), 7.74 (m, 2H), 7.66 (ddd, 
J = 8.2, 6.6, 1.5, 1H), 7.58 (m, 1H), 7.53-7.49 (m, 2H), 7.44-7.35 (m, 
4H), 5.22 (s, 1H), 4.21 (dq, J = 10.8, 7.1 Hz, 2H), 2.86 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H), 
0.99 (s, 9H); 13C NMR (DMSO-d6, 100 MHz) δ: 172.6 (s), 159.5 (s), 146.8 (s), 146.3 
(s), 140.3 (s), 135.2 (s), 131.2 (d), 130.4 (d), 129.7 (s), 129.2 (d), 129.0 (d), 128.6 (d), 
127.8 (d), 127.1 (d), 127.0 (d), 126.7 (d), 126.5 (d), 126.3 (s), 125.8 (d), 76.1 (s), 70.9 
(d), 61.4 (t), 28.1 (q), 24.9 (q), 14.2 (q). 
ethyl 2-(4-(4-acetamidophenyl)-2-methylquinolin-3-yl)-2-(tert-
butoxy)acetate (3.44i): yellow oil; IR (solid) cm-1 1747, 1673; 1H 
NMR (CDCl3, 400 MHz) δ: 8.04 (d, J = 8.4, 1H), 7.93 (s, 1H, N-H), 
7.76 (d, J = 8.7, 2H), 7.64 (ddd, J = 8.3, 5.4, 3.1 Hz, 1H), 7.46 (dd, J 
= 9.3, 2.2 Hz, 1H), 7.36-7.34 (m, 2H), 7.28 (d, J = 2.1, 1H), 5.19 (s, 1H), 4.19 (dq, 10.8, 
7.1, 2H), 2.84 (s, 3H), 2.25 (s, 3H), 1.22 (t, J = 7.1, 3H), 0.97 (s, 9H); 13C NMR 
(DMSO-d6, 100 MHz) δ: 172.6 (s), 168.8 (s), 159.4 (s), 146.7 (s), 146.2 (s), 138.5 (s), 
131.6 (s), 131.4 (d), 130.6 (d), 129.8 (s), 129.3 (d), 128.3 (d), 126.7 (d), 126.4 (s), 125.8 
(d), 119.3 (d), 118.9 (d), 76.1 (s), 70.8 (d), 61.4 (t), 28.1 (q), 24.72 (q), 24.70 (q), 14.1 
(q). 
 ethyl 2-(tert-butoxy)-2-(2-methyl-4-(pyrimidin-5-yl)quinolin-3-
yl)acetate (3.44j): yellow oil; IR (solid) 1743 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ: 9.40 (s, 1H), 8.90 (d, J = 2.8 Hz, 1H), 8.69 (d, 
J = 2.8, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.73 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 7.44 (ddd, J = 
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8.5, 6.9, 1.2 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 5.04 (s, 1H), 4.16 (dq, 10.9, 7.1, 2H), 2.91 
(t, J = 7.1, 3H), 1.23 (s, 3H), 1.04 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 171.7 (s), 
158.7 (s), 158.5 (d), 158.4 (d), 156.8 (d), 146.8 (s), 139.3 (s), 130.7 (s), 130.6 (s), 129.9 
(d), 129.0 (d), 126.7 (d), 126.1 (s), 125.3 (d), 76.5 (s), 70.5 (d), 61.7 (t), 28.0(q), 24.9 (q), 
14.1 (q). 
ethyl 2-(tert-butoxy)-2-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-
2-methylquinolin-3-yl)acetate (3.44k): The product was isolated as 
a mixture of atropisomers. yellow oil; IR (solid) cm-1 1747, 1673; 1H 
NMR (CDCl3, 400 MHz) δ: 8.03 (d, J = 8.3, 1H), 7.64 (dt, J = 6.9, 
1.4 Hz, 1H), 7.47-7.35 (m, 2H), 7.04-6.96 (m, 2H), 6.84-6.78 (m, 1H), 5.25 (s, 1H), 4.38-
4.30 (m, 4H) 4.24-4.11 (m, 2H), 2.83 (s, 3H), 1.23 (t, J = 7.1 Hz, 3H), 1.01 (s, 9H); 13C 
NMR (CDCl3, 100 MHz) δ: [172.7, 172.5] (s), 159.4 (s), 146.8 (s), 146.1 (s), [143.7, 
143.6] (s), 143.5 (s), 143.0 (s), 129.8 (s), [129.2, 129.1] (d), [128.47, 128.46] (d), 
[126.82, 126.78] (d), [126.55, 126.46] (s), [125.68, 125.64] (d), 124.0 (d), 123.1 (d), 
120.0 (d), [119.95, 119.77] (d), 118.95 (d), [117.45, 117.29] (d), 116.7 (d), 115.5 (d), 
[76.02, 75.98] (s), [70.83, 70.80] (d), [64.49, 64.47] (t), [64.44, 64.36] (t), [61.38, 61.31] 
(t), 28.1 (q), 24.8 (q), 14.13 (q). 
General Procedure for Ethyl Ester Hydrolysis (3.21a-k): To a solution of ethyl ester 
quinoline (1.0 equiv.) and ethanol (3.5 mL) was added aqueous 50% sodium hydroxide (3 
equiv.). The reaction was heated to 60ºC and was stirred until 100% conversion was 
observed by HPLC. The solution was cooled to ambient temperature and was neutralized 
with 1N HCl to pH 5. The solution was extracted with chloroform-d6 (two 0.5-mL 
portions) and the combined organic phase was dried over magnesium sulfate, filtered, and 
 101 
examined via 1H-NMR. Carboxylic acid products requiring purification were 
chromatographed over 4g of silica gel eluted with dichloromethane-methanol (0% 
methanol→5% methanol→10% methanol). Product rich fractions were pooled and 
evaporated to afford desired acids(3.21a-3.21k). 
2-(tert-butoxy)-2-(2-methyl-4-phenylquinolin-3-yl)acetic acid 
(3.21a): yellow oil; IR (solid) 1719 cm-1; 1H NMR (CDCl3, 400 MHz) 
δ: 8.96 (s, 1H, O-H), 8.11 (d, J = 8.4 Hz, 1H), 7.73 (d, J = 6.7 Hz, 1H), 
7.66 (ddd, J = 8.3, 6.3, 2.0 Hz, 1H), 7.58-7.51 (m, 3H), 7.41-7.33 (m, 3H), 5.29 (s, 1H), 
2.88 (s, 3H), 0.97 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 173.2 (s), 158.5 (s), 148.2 (s), 
146.1 (s), 135.6 (s), 131.3 (d), 129.77 (d), 129.75 (d), 129.2 (s), 128.8 (d), 128.7 (d), 
127.9 (d), 127.8 (d), 126.8 (d), 126.3 (s), 126.2 (d), 70.7 (d), 28.1 (q), 24.1 (q). 
2-(tert-butoxy)-2-(4-(4-fluorophenyl)-2-methylquinolin-3-yl)acetic 
acid (3.21b): yellow oil; IR (Thin Film) 1730 cm-1 1724; 1H NMR 
(CDCl3, 400 MHz) δ: 8.17 (d, J = 8.2 Hz, 1H), 7.75 (dd, J = 5.7 Hz, 
1H), 7.66 (ddd, J = 8.0, 5.5, 1.6 Hz), 7.41-7.22 (m, 5H), 5.22 (s, 3H), 2.93 (s, 3H), 0.99 
(s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 174.0 (s), 164.1 (s), 161.7 (s), 159.0 (s), 147.5 
(s), 144.8 (s), 133.2 (d), 131.5 (d), 131.4 (s), 130.8 (s), 130.1 (d), 126.9 (d), 126.6 (d), 
115.9 (d), 115.1 (d), 76.7 (s), 70.7 (d), 28.1 (q), 23.4 (q). 
2-(tert-butoxy)-2-(2-methyl-4-(4-(trifluoromethyl)phenyl)quinolin-
3-yl)acetic acid (3.21d): yellow oil; IR (solid) 1730 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ: 10.33 (s, 1H, O-H), 8.18 (d, J = 8.4 Hz, 1H), 
7.90-7.82 (m, 3H), 7.70 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.41 (t, J 
= 8.2 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 5.14 (s, 1H), 2.94 (s, 3H), 1.00 (s, 9H); 13C 
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NMR (CDCl3, 100 MHz) δ: 173.3 (s), 158.8 (s), 146.9 (s), 145.3 (s), 139.5 (s), 131.8 (d), 
131.0 (s, 2J = 32 Hz), 130.3 (d), 130.0 (d), 129.9 (s), 127.2 (d), 126.8 (d), 126.3 (d), 125.9 
(s), 125.8 (d, 3J = 3.5 Hz), 125.3 (s), 124.9 (d, 3J = 3.5 Hz), 123.9 (s, 1J = 270 Hz), 77.2 
(s), 70.7 (d), 28.1 (q), 23.7 (q). 
2-(tert-butoxy)-2-(2-methyl-4-(p-tolyl)quinolin-3-yl)acetic acid 
(3.21e): clear, colorless oil; IR (solid) 3313, 1607 cm-1; 1H NMR 
(CD3OD, 400 MHz) δ: 7.83 (d, J = 8.1 Hz, 1H), 7.69 (m, 1H), 7.51 
(ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.35 (dd, J = 8.4, 1.0 Hz, 1H), 7.27-7.24 (m, 3H), 7.12 (m, 
1H); 13C NMR (CD3OD, 100 MHz) δ: 178.0 (s), 160.2 (s), 146.5 (s), 145.6 (s), 138.0 (s), 
133.9 (s), 133.3 (s), 131.2 (d), 130.2 (d), 128.7 (d), 128.4 (d), 127.8 (d), 126.56 (d), 
126.61 (s), 126.4 (d), 125.3 (d), 74.6 (s), 72.3 (d), 27.3 (q), 23.4 (q), 20.0 (q).  
2-(tert-butoxy)-2-(4-(4-cyanophenyl)-2-methylquinolin-3-yl)acetic 
acid (3.21f): white solid; mp >260 ºC; IR (solid) 3073, 2226, 1713 cm-
1; 1H NMR (CDCl3, 400 MHz) δ: 8.12 (d, J = 8.4 Hz, 1H), 7.85-7.83 
(m, 3H), 7.70 (dd, J = 7.4 Hz, 1H), 7.47 (d, J = 7.7 Hz, 1H), 7.41 (dd, 
7.7 Hz, 1H), 7.22 (d, J = 8.3 Hz, 1H), 5.07 (s, 3H), 2.89 (s, 3H), 0.98 (s, 9H); 13C NMR 
(CDCl3, 100 MHz) δ: 172.1 (s), 158.6 (s), 145.9 (s), 140.8 (s), 132.5 (d), 132.3 (d), 131.7 
(d), 130.5 (d), 130.2 (d), 129.5 (s), 127.8 (d), 126.8 (d), 125.9 (d), 125.5 (s), 118.3 (s), 
112.9 (s), 77.2 (s), 70.7 (d), 28.1 (q), 24.1 (q). 
2-(4-(4-acetylphenyl)-2-methylquinolin-3-yl)-2-(tert-butoxy)acetic 
acid (3.21g): Yellow oil; 1H NMR (CDCl3, 400 MHz) δ: 8.16-8.11 (m, 
3H), 7.85 (d, J = 7.2 Hz, 1H), 7.69 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.47 
(m, 1H), 7.39 (ddd, J = 8.0, 6.9, 1.0 Hz, 1H), 7.29 (d, J = 7.8 Hz, 1H), 
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5.19 (s, 1H), 2.89 (s, 3H), 2.72 (s, 3H), 1.01 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 
198.0 (s), 172.5 (s), 158.4 (s), 147.0 (s), 146.3 (s), 140.7 (s), 137.2 (s), 131.8 (d), 130.0 
(d), 128.9 (d), 128.7 (s), 128.1 (d), 127.7 (d), 126.5 (d), 126.3 (d), 125.7 (s), 77.7 (s), 70.7 
(d), 28.2 (q), 26.7 (q), 24.3 (q).  
2-(4-([1,1'-biphenyl]-4-yl)-2-methylquinolin-3-yl)-2-(tert-
butoxy)acetic acid (3.21h): white solid mp 198-200ºC; IR (solid) 
3356, 1600 cm-1; 1H NMR (CD3OD, 400 MHz) δ: 8.00 (d, J = 8.1, 1H), 
7.95 (m, 1H), 7.85 (dd, J = 5.7, 1.6 Hz, 1H), 7.83 (dd, J = 5.7, 1.6 Hz, 
1H), 7.75 (d, J = 7.1 Hz, 2H), 7.68 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 7.52-7.37 (m, 6H), 
5.22 (s, 1H), 2.92 (s, 3H), 0.97 (s, 9H); 13C NMR (CD3OD, 100 MHz) δ: 177.0 (s), 159.9 
(s), 146.6 (s), 145.5 (s), 141.2 (s), 140.2 (s), 135.1 (s), 133.0 (s), 131.6 (d), 130.8 (d), 
128.9 (d), 128.6 (d), 127.9 (s), 127.4 (d), 126.7 (d), 126.6 x2 (d), 126.4 (d), 125.9 (d), 
125.7 (d), 75.1 (s), 71.8 (d), 27.3 (q), 23.2 (q). 
2-(4-(4-acetamidophenyl)-2-methylquinolin-3-yl)-2-(tert-
butoxy)acetic acid (3.21i): yellow solid; mp 205-207ºC; 1H NMR 
(CD3OD, 400 MHz) δ: 7.99 (d, J = 8.4, 1H), 7.84 (dd, J = 8.3, 2.2 Hz, 
1H), 7.79 (dd, J = 8.3, 2.1, 1H), 7.73 (dd, J = 8.3, 4.1 Hz, 1H), 7.59 (dd, 
J = 8.3, 2.0 Hz, 1H), 7.46 (dd, J = 4.4, 0.8, 1H), 7.32 (dd, J = 8.3, 2.0, 1H), 5.26 (s, 1H), 
2.83 (s, 3H), 2.20 (s, 3H), 0.97 (s, 9H); 13C NMR (CD3OD, 100 MHz) δ: 174.7 (s), 170.5 
(s), 159.1 (s), 147.7 (s), 145.4 (s), 139.4 (s), 131.0 (d), 130.8 (s), 130.5 (d), 129.7 (d), 
126.6 (d), 126.4 (s), 126.3 (d), 119.4 (d), 119.0 (d), 75.9 (s), 70.5 (d), 27.0 (q), 22.7 (q), 
22.5 (q). 
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 2-(tert-butoxy)-2-(2-methyl-4-(pyrimidin-5-yl)quinolin-3-yl)acetic 
acid (3.21j): yellow oil; IR (solid) 1734 cm-1; 1H NMR (CDCl3, 400 
MHz) δ: 9.29 (s, 1H), 9.00 (s, 1H), 8.73 (s, 1H), 8.13 (d, J = 8.4 Hz, 
1H), 7.72 (dd, J = 7.6 Hz, 1H), 7.42 (dd, J = 7.9 Hz, 1H), 7.15 (d, J = 8.4, 1H), 5.26 (s, 
1H), 3.03 (s, 3H), 1.06 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 173.1 (s), 159.6 (d), 
155.6 (d), 146.5 (s), 139.8 (s), 130.8 (s), 130.1 (d), 128.7 (d), 126.9 (d), 126.5 (s), 125.1 
(d), 77.2 (s), 69.7 (d), 28.0 (q), 24.5 (q). 
2-(tert-butoxy)-2-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-
methylquinolin-3-yl)acetic acid (3.21k) The product was isolated as a 
mixture of atropisomers. yellow oil; IR (solid) 1717 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ: 8.22-8.20 (m, 1H), 7.67-7.63 (m, 1H), 7.54-7.31 
(m, 3H), 7.05-7.00 (m, 1H), 6.89-6.78 (m, 1H), 5.35 (s, 1H), 4.37-4.34 (m, 4H) 2.94 (s, 
3H), 1.00 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 173.7 (s), 158.9 (s), 148.5 (s), 
[144.05, 144.00] (s), 143.6 (s), 143.0 (s), [132.2, 132.1] (d), [130.9, 130.6] (s), 130.1 (d), 
[128.6, 128.5] (d), [128.4, 128.3] (s), [126.96, 126.93] (d), [126.7, 126.6] (s), [126.5, 
126.4] (d), 124.5 (d), 122.9 (d), 120.3 (d), 119.8 (d), [118.9, 118.8] (d), [117.6, 117.4] 
(d), [116.9, 116.8] (d), 115.5 (d), 76.9 (s), [70.77, 70.74] (d), [64.50, 64.48] (t), [64.46, 
64.44] (t), [28.19, 28.16] (q), [23.23, 23.17] (q). 
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CHAPTER IV – THEORETICAL AND EXPERIMENTAL INVESTIGATION OF A 
VINYL SULFOXIDE-CARBODIIMIDE ANNULATION VIA [3,3]-SIGMATROPIC 
REARRANGEMENT AND RING CLOSURE 
4.1 Introduction 
4.1.1 Importance of Vicinal Diamines 
1,2-Diamines have proven to exhibit a wide variety of applications within many 
fields of chemistry and biology. Biologically, vicinal diamines contain great importance 
among pharmacological applications and biochemical processes.94 These versatile 
compounds have also found use among supramolecular and host-guest chemistry. 
Furthermore, organic synthesis has extensively utilized vicinal diamines as intermediates 
for heterocycles, construction of nitrogen containing macrocycles, and chiral ligands for 
asymmetric synthesis (Figure 4.1).94 
 
Figure 4.1 Examples of vicinal diamines. 
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4.1.2 Vicinal Diamines in Organic Synthesis 
4.1.2.1 Chiral Auxiliaries in Diastereoselective Synthesis 
Significant progress has been made with the use of 1,2-diamines as chiral 
auxiliaries in diastereoselective synthesis. Most notably is the discovery of asymmetric 
olefination via the Wittig reaction utilizing chiral bicyclic phosphonamides. Hanessian 
and coworkers were able to produce olefinated ketones in greater than 80% optical purity 
and above when utilizing these chiral auxiliaries.95 A wide variety of processes have also 
been examined through the use of chiral 3-acyl-imidazolidin-2-ones. Among these 
include alkylation studies of 3-acyl-imidazolidin-2-ones96 (Scheme 4.1) and the use of 
imidazolidin-2-ones as chiral auxiliaries. The Davies group utilized dibutylboron enolates 
derived from chiral imidazolidin-2-ones in aldol reactions to produce 1,3-diols in 
homochiral form.97 There has also been significant progress in the use of boron-
containing chiral auxiliaries derived from 1,2-diphenylethylenediamine (Scheme 4.1). 
The resultant diazaborilidine has been extensively studied in enantioselective synthesis of 
syn- and anti-aldol reactions, enantio- and diastereoselective synthesis of anti-β-amino 
thioesters, anti-α-bromo β-hydroxy esters, and an Ireland-Claisen rearrangement of 
achiral allylic esters.98 
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Scheme 4.1 Vicinal diamines in diastereoselective synthesis. 
4.1.2.2 Chiral Ligands in asymmetric Synthesis 
Vicinal diamines have also found to have significant applications as chiral ligands 
in asymmetric synthesis. Some of the most influential reactions include aldehyde 
alkylations, aldol reactions, and Diels-Alder chemistry. Mukaiyama and coworkers 
performed studies employing chiral bipyrrolidines as a ligand for asymmetric alkylation 
of aldehydes to yield products in high optical purity (Scheme 4.2).99 These results were 
later applied to aldol reactions which utilized achiral silenol ethers and achiral aldehydes 
in the presence of chiral diamine-coordinated tin (II) triflate to afford enantiopure aldol 
products (Scheme 4.2).100 
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Scheme 4.2 Vicinal diamines as chiral ligands. 
A chiral aluminum catalyst, diazaaluminolidine, has been utilized by Corey and 
coworkers in Diels-Alder chemistry to afford enantiopure adducts.101 Further application 
of this concept was achieved by the Evans group through the use of Cu(II) bisimine 
ligands to yield product in 94% ee (Schem 4.3).102 
 
Scheme 4.3 Diels-Alder chemistry of the Evans group. 
4.1.3 Vicinal Diamines in Medicinal Chemistry 
Vicinal diamines exhibit significant biological applications for medicinal 
treatments. There are a variety of naturally occurring diamines that have potent 
antibacterial effects, including penicillins and cephalosporins.103 Synthetic diamino 
compounds have also been utilized as antifilarial and antitubercular agents.104 In the late 
1960s, an effective diamino platinum compound named cisplatin was reported for the 
effective antitumor properties.105 Since this discovery, the use of alternative 1,2-diamino 
 109 
platinum compounds have been employed in place of cisplatin due to decreased toxicity 
and ability to prevent tumors from developing resistances.106 Affinity for the µ, δ, and κ 
opioid receptor sites has also been expressed by vicinal diamines. Of particular interest is 
US-50,488, a diaminocyclohexane derivative, which has expressed high affinity for the κ 
receptor site.107 Further studies of the κ receptor site and improvements to diamino 
derivatives have been made due to a comparable decrease in dependency complications 
that can arise from opioids such as morphine which bind to the µ receptor site.108-109 
4.1.4 Vicinal Diamines in Natural Products 
Vicinal diamines have a significant presence among a wide range of natural 
products. The indications of these natural products include antibiotic activity, anti-cancer 
properties, and neurological inhibition/excitation characteristics. Commonly known 
antibiotics include penicillin and cephalosporins. Other antibiotics include edeines, 
peptides containing five amino acid residues,110 and tuberactomycin derivatives, peptides 
effective against tubercular bacilli.111 Chemotherapeutic agents used for treatment of 
malignant lymphomas and squamous cell carcinomas include the glycopeptide family 
which contain a 2,3-diaminopropanamide residue. These glycopeptides, which are 
characterized as bleomycins, have been found to possess DNA cleavage and degradation 
abilities112 and have beensynthetically altered to express an even higher affinity for DNA 
cleavage versus the naturally occurring bleomycins113. 
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Figure 4.2 Examples of vicinal diamines in natural products. 
The project being proposed will strictly focus on one particular motif containing a 
1,2-diamine structure. Specifically, the compound will be a cyclic urea that contains a 
five membered ring. This motif is of interest to our group as a precursor to the synthesis 
of cyclic guanidines. There are a wide variety of natural products that contain cyclic 
ureas and guanidines which include agelastatin A and dragmacidin E (Figure 4.3). A 
wide variety of synthetic techniques have been applied towards the synthesis of these 
vicinal diamines. There is a continuing demand for furthering this knowledge and 
proposed herein is another contribution to this growing database of methods. 
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Figure 4.3 Natural products containing a cyclic guanidine or cyclic urea. 
4.1.5 Synthetic Target 
The specific compound chosen as our inspiration is the alkaloid titled saxitoxin 
(STX). STX, a paralytic shellfish toxin, is found in a variety of marine dinoflagellates 
and freshwater cyanobacteria.114 Of particular note is the high toxicity of STX which can 
cause fatalities if 1 mg or more is ingested by a human. The lethal toxicity of STX arises 
from the high affinity for the receptor sites at sodium channels. Upon binding, the sodium 
channels are effectively blocked causing immediate paralysis in the victim.115 A deeper 
understanding of this highly toxic alkaloid can lead to pharmaceutical methods of 
treatment as well as better methods of detection and removal from water sources. STX 
can also provide an excellent opportunity for further studies of the function of sodium ion 
channels. Since the molecular interaction of STX within these channels is still not fully 
understood. Therefore, a facile synthesis that allows for minor modifications to be made 
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to the structure could provide opportunities for the discovery of improved STX target 
molecules. 
 Although the medicinal applications of this molecule hold significant interest, 
STX serves as an inspiration for method developments in the synthesis of cyclic ureas 
followed by the conversion to the guanidine moiety. STX provides a particularly unique 
motif due to the presence of a tricyclic system that is composed of two cyclic guanidines 
as well as a spirocyclic carbon located at C4 (Figure 4.4). Due to this dense heterocyclic 
skeleton, STX has presented a daunting challenge for the synthetic community. Despite 
this, Kishi,116 Jacobi,117 Fleming,118-119 Looper,120 and Nishikawa121 have all completed 
elegant total syntheses of this molecule. 
 
Figure 4.4 Structure of Saxitoxin. 
4.1.6 Prior Synthetic Methods of Sigmatropic Rearrangements 
4.1.6.1 The Marino Rearrangement 
To gain an understanding of the proposed work, previously performed syntheses 
of related sigmatropic rearrangements are reviewed for perspective. The Marino group 
has published a unique [3,3]-sigmatropic rearrangement of vinyl sulfoxides with 
dichloroketene. According to Scheme 4.4, this process proceeds in a stereoselective 
fashion to produce a functionalized cis-γ-butyro-lactone.122 
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Scheme 4.4 Marino rearrangement: vinyl sulfoxide-dichloroketene lactonization. 
Marino and coworkers also determined that this reaction proceeded via a [3,3]-
sigmatropic rearrangement as depicted by the proposed mechanism in. In this 
mechanism, the sulfoxide oxygen attacks the electrophilic sp-hybridized carbon in the 
dichloroketene (Scheme 4.5). The resultant zwitterion then undergoes bond 
reorganization and produces a thionium intermediate. The carboxylate anion then adds 
intramolecularly via a 5-exo cyclization to stereoselectively produce the lactone product. 
 
Scheme 4.5 Mechanism of the Marino rearrangement. 
The Marino group continued their studies of this lactonization reaction in the 
synthesis of physostigmine alkaloids and aflotoxins, both of which are heterocyclic 
natural products.123 This work expanded the research to include β-aminovinylsulfoxides 
and the incorporation of the double bond into a heterocyclic structure (Scheme 4.6). This 
work with β-aminovinylsulfoxides provides further insight into the applicability of our 
proposed synthesis. 
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Scheme 4.6 Total synthesis of physostigmine via the Marino rearrangement. 
4.1.6.2 The Overman Rearrangement 
Early studies of the Claisen rearrangement by Otto Mumm and Friedrich Moller 
led to an observed [3,3]-sigmatropic rearrangement of N-phenyl benzimidic acid allyl 
ester to yield N-allyl-N-phenyl benzamide (Scheme 4.7).124 The Overman group 
expanded upon this rearrangement using allylic trichloroacetimidates which resulted in a 
1,3-transposition of the alcohol and amine functions (Scheme 4.7).125 
 
Scheme 4.7 [3,3] Rearrangements involving nitrogen. 
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The Overman rearrangement can be performed under thermal conditions or in the 
presence of mercury(II) salts. This transformation is highly stereo- and regio-selective, 
with the (E)-alkene conformation as the favored product, and is irreversible due to the 
formation of the strong amide bond. The thermal rearrangement proceeds via a transition 
state in a six membered chair conformation and the mercury(II) catalyzed rearrangement 
proceeds via an iminomercuration-deoxymercuration mechanism (Scheme 4.8).126-128 
Both mechanisms result in the same product. 
 
Scheme 4.8 Thermal and mercury (II) catalyzed rearrangements. 
4.1.6.3 The Pfitzner-Moffat Oxidation 
The third reaction mechanism of importance to this proposal is the Pfitzner-
Moffat oxidation. In 1963, K.E. Pfitzner and J.G. Moffat synthesized aldehydes and 
ketones via oxidation of primary and secondary alcohols utilizing dimethyl sulfoxide and 
dicyclohexyl carbodiimide and catalytic amounts of anhydrous phosphoric acid.129 The 
main benefit of this mechanism is the mild reaction conditions which provides a desirable 
alternative to the use of chromium(VI) oxidants.130 
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 The mechanism of this oxidation is well understood. The reaction is indicated by 
protonation of the alkyl carbodiimide with an acid in the pKa range of 0.7-2.5 which will 
then activate the dimethylsulfoxide (DMSO) as shown in Scheme 4.9. The resultant 
sulfonium ion is attacked by the alcohol and produces an alkoxysulfonium ylide and a 
dialkyl urea byproduct. The ylide then decomposes intramolecularly to yield either the 
ketone or aldehyde depending on whether a primary or secondary alcohol was utilized 
(Scheme 9).131-132 
 
Scheme 4.9 Pfitzner-Moffat oxidation. 
4.1.6.4 Rearrangement of Allylic Phosphorimidates 
The Mapp group has disclosed the synthesis of carbon-nitrogen bonds through a 
[3,3]-sigmatropic rearrangement of allylic phosphorimidates to phosphoramidates 
(Scheme 4.10). Upon synthesis of the phosphorimidate, conversion to allylic amines can 
be achieved. Further investigations into this process confirmed the presence of the chair-
like transition state similar to that found in a typical Claisen rearrangement and the 
expansive scope this method has for preparation of a wide variety of allylic amines.133 
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Methods for the synthesis of carbon-nitrogen bonds are highly desired as many 
heterocyclic natural products contain them. 
 
Scheme 4.10 Rearrangements of allylic phosphorimidates. 
4.2 Research Hypothesis 
It is hypothesized that carbodiimides are competent electrophilic partners to engage 
vinyl sulfoxides in a [3,3]-sigmatropic rearrangement to synthesize cyclic and guanidines. 
The research questions to be addressed are: 
1. Can carbodiimides can be activated by exogenous acid for engagement with vinyl 
sulfoxides to synthesize cyclic ureas? 
2. Can molecular modeling guide the development of reaction conditions that will 
favor synthesis of cyclic ureas and guanidines? 
4.3 Research Design and Methods 
The overall goal of this project is to provide a new synthetic route for the 
development of cyclic ureas and guanidines. To achieve this, an investigation of a new 
carbon-nitrogen bond forming reaction between carbodiimides and vinyl sulfoxides will 
be conducted. It is proposed that the carbon-nitrogen bonds are formed through a [3,3]-
sigmatropic rearrangement followed by an intramolecular cyclization to produce a cyclic 
urea. Furthermore, vinyl sulfoxides containing endocyclic and exocyclic alkenes will be 
utilized to form fused bicyclic and spirocyclic structures, respectively. All previously 
discussed mechanisms have provided inspiration for the proposed synthesis. 
 118 
4.3.1 Overall Scheme 
The inspiration of this reaction sequence is based on the work of the Marino 
group. Marino’s work uses dichloroketene to achieve the same rearrangement while we 
propose to use of carbodiimides. We hypothesize that the sp hybridized carbon located in 
the center of the dialkyl carbodiimide has appropriate electrophilicity to undergo 
nucleophilic attack by the oxygen anion (Error! Reference source not found.). This 
intermediate will then undergo a [3,3]-sigmatropic rearrangement to form the first 
carbon-nitrogen bond and produce a reactive intermediate. We postulate that an 
intramolecular reaction will then occur via attack of the nitrogen on the sp2 carbon. 
 
Scheme 4.11 Proposed mechanism for cyclic urea synthesis. 
4.3.2 Carbodiimide Activation Studies 
The Pfitzner-Moffat oxidation discussed previously will serve as the model 
system. In the oxidation, the carbodiimide was activated using various weak acids 
including pyridinium salts of strong acids130 and phosphoric acid.129 It has been 
determined that only mildly acidic compounds can be utilized for carbodiimide 
activation.134 Initial studies will involve Brønsted acids of various pKa values. Shown in 
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Scheme 4.12 is a mechanistic hypothesis for the activation of carbodiimides via 
exogenous acids. 
 
Scheme 4.12 Mechanistic hypothesis for carbodiimide activation. 
In addition a list of potential candidates to be used as protonating agents and their 
respective pKa values are listed in Error! Reference source not found.. The selected 
acids will serve the purpose of determining the most effective pKa range for proper 
activation of the central carbon. 
Table 4.1  
Brønsted acids to be used and associated pKa values 
Acid pKa 
(CF3)2CHOH 9.3 
Pyr - OTf 5.2 
H3PO4 2.12 
Cl2CCO2H 1.29 
Pyr - HCl 0.72 
F3CCO2H -0.25 
CH3SO3H -2.6 
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Furthermore, it is imperative to consider the nucleophilicity of the conjugate base 
represented by (A-) that is produced (Scheme 4.13). If the conjugate base is a stronger 
nucleophile than vinyl sulfoxide, a competition exists such that the conjugate base may 
preferentially add to the activated carbodiimide. In this case, the counterion will be 
switched. For example, relatively acidic alcohols such as 1,1,1,3,3,3-hexafluoro-2-
propanol (pKa = 9.3) would likely produce an alkoxide ion that could act as a competing 
nucleophile. 
 
Scheme 4.13 Competing reaction of the conjugate base with the sulfoxide oxygen. 
The activation of carbodiimides is not limited to only Brønsted acids. The use of 
Lewis acids will also be examined. A variety of Lewis acids have been utilized for 
reaction with carbodiimides and include samarium diiodide,135 cupric triflate,136 metal 
chlorides,137 and boron (III) derivatives.138 Furthermore, the successful activation of 
carbodiimides has been observed through the use of lanthanide and yttrium catalysts.139 
4.3.3 Nuclear Magnetic Resonance and In Situ Infrared Spectroscopy Studies 
Carbodiimide protonation can be monitored effectively through the use of in situ 
IR spectrometry. The Mettler Toledo ReactIR will be utilized for solution phase IR 
studies. This analytical technique will provide evidence regarding protonation of the 
carbodiimide by monitoring the imide C=N bond stretch located at 2114 cm-1. The 
disappearance of the imide stretch will confirm protonation is occurring. Once 
protonation of the carbodiimide is observed, reaction progression with vinyl sulfoxides 
can also be monitored. If the carbodiimide is sufficiently activated, the appearance of a 
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C=O bond will be expected to appear between 1690-1620 cm-1 after the sulfoxide oxygen 
reacts and formation of the urea begins.  
 NMR will also be used as a tool to monitor both the protonation of the 
carbodiimide and the reaction of the sulfoxide. Prior to protonation, the sp hybridized 
carbon has a 13C shift located at δ 140 ppm.140 It is expected that an upfield shift of this 
diagnostic peak will occur should protonation be achieved. NMR can therefore be an 
effective method for relative pKa measurements of our carbodiimides according to 
Perrin’s NMR titration protocol.141 
 
Scheme 4.14 Carbodiimide protonation. 
NMR will be utilized for product analysis with attention on diagnostic peak shifts 
of vinyl sulfoxide. Of note are the vinyl hydrogens located on the sulfoxide. If the 
proposed rearrangement occurs, the cis-trans relationship will be eliminated and 
proximity to the nitrogen will decrease. Therefore, the coupling constant of the hydrogens 
in the trans- relationship will not be observed. Also, the vinyl hydrogens will become 
diastereotopic following ring closure and appearance of this relationship will be 
monitored. 
The proposed analytical techniques with further support from the Marino model 
system will be utilized as tools for confirmation of the proposed mechanism. Based on 
literature precedent of the Claisen rearrangement, stereochemistry of the reagents will be 
maintained due to the concerted synchronous characteristic. Therefore, if stereochemistry 
 122 
is maintained, it can be inferred that a chair-like transition state typical of the Claisen 
rearrangement is present. 
Another consideration for carbodiimide activation is the variation of the nitrogen 
substituents. Initial studies will involve the use of symmetric dialkyl carbodiimides that 
are readily available. Specifically, DIC and DCC have been employed during the reaction 
screening process. Once optimum reaction conditions have been determined, the 
incorporation of N-Benzyl protecting groups may be utilized as the R groups attached to 
nitrogen. This will be beneficial due to ease of removal and further functionalization via 
hydrogenolysis (Scheme 4.15). 
 
Scheme 4.15 Hydrogenolysis of benzyl protected nitrogens in the cyclic urea. 
Although it is preferred that symmetric dialkyl carbodiimides be used to prevent 
the production of regioisomers, as shown in Scheme 4.16, the electrophilicity of the 
central carbon could be further increased via preparation of dissymmetric carbodiimides. 
For instance, by altering R3 and R4 to be electron donating and electron withdrawing 
groups, respectively, a “push-pull” effect can be incorporated into the molecule to 
manipulate the electronics at the sp carbon. 
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Scheme 4.16 Expected regioisomers via dissymmetric carbodiimides. 
The preparation of dissymmetric carbodiimides will be performed via the 
Staudinger reaction between an isocyanate and iminophosphorane. The general reactions 
portraying this reagent preparation are shown in Scheme 4.17. 
 
Scheme 4.17 Aza-Wittig preparation of dissymmetric carbodiimides. 
4.3.4 Stereochemistry of the Sulfoxide 
The application of chiral sulfoxides to asymmetric synthesis has found an 
increasing interest among the synthetic community.142-144 The initial reaction screening 
will involve the use of phenyl vinyl sulfoxide but further application of the project can be 
found via a wide variety of enantiopure sulfoxides. Once the sulfoxide has been activated 
by the carbodiimide, it is expected that the intermediate will be ordered according to a 
Zimmerman-Traxler chair-like transition state. This transition state, shown in Figure 4.5, 
provides explanation for the rearrangement and the stereochemistry of the final product. 
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Figure 4.5 Zimmerman-Traxler Transition State. 
The example provided utilizes an (E)-olefin and contains a sulfoxide with an (S) 
stereocenter. This transition state places the carbon-nitrogen double bond within the chair 
conformation. This allows the nitrogen to participate in the rearrangement by 
suprafacially engaging in the exposed face of the vinyl sulfoxide. It is then expected that 
the reactive intermediate will selectively produce the trans-geometry of the cyclic urea. 
 Following initial studies with phenyl vinyl sulfoxide, a variety of geometrically 
pure sulfoxides (R1 = Ph, p-tol, t-Bu; R2 = H, CH3, Ph) will be prepared via the Horner-
Wittig olefination (Scheme 4.18).145 
 
Scheme 4.18 Vinyl Sulfoxide Horner-Wittig Olefination. 
4.3.5 Sulfoxide Substituents 
The synthesis of fused and spirocyclic ring systems containing urea or guanidine 
moieties has significant application to the realm of natural product total synthesis. The 
urea cyclization can be extended to the synthesis of these bicyclic systems. This can be 
achieved through the incorporation of substituents in the vinyl positions of the sulfoxide. 
According to the expected rearrangement, it is proposed that both spirocyclic and fused 
ring structures can be obtained. The use of either an endocyclic or exocyclic vinyl 
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sulfoxide could be used to yield a fused or spirocyclic ring system, respectively (Scheme 
4.19). 
 
Scheme 4.19 Fused and spirocyclic ring synthesis. 
To examine this synthesis, the vinyl sulfoxides must first be prepared. A general 
procedure has previously been performed by Parham and Edwards via oxidation of 
cyclohexenyl phenyl sulfide which is prepared through an SN2 displacement of 
cyclohexenyl p-toluenesulfonate with thiophenol146 (Scheme 4.20). 
 
Scheme 4.20 Proposed Synthesis of cyclic vinyl sulfoxides. 
NMR will be utilized to determine whether the product is formed according to 
significant shifts in 13C and 1H signals. Of note is the spirocyclic carbon that will be 
formed as shown in Scheme 4.19. As an sp2 carbon in the starting material, the predicted 
location in 13C NMR is near δ 150 ppm. Upon formation of product, the sp3 carbon would 
then be predicted to shift much further downfield near δ 60 ppm. 
4.3.6 Alternative Electrophiles 
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The primary goal of this prospectus is to present new methodology for the 
synthesis of cyclic ureas via the use of dialkyl carbodiimides. Alternative electrophiles 
can be utilized in a similar fashion. Of particular interest are isocyanates, isothiocyanates, 
and trichloroacetimidates which would produce oxazolidinones, thiazolidinones, and 
oxazolines, respectively. These three heterocyclic substructures have shown to be useful 
in not only pharmaceuticals but a wide variety of chemical applications.147-149 Our 
proposed synthesis would provide a method for easy access to these crucial moieties. 
4.3.7 Vinyl Sulfinimines 
There is also a possibility of utilizing other variants of the vinyl sulfoxide. In 
2005, Marino and coworkers reported an extension of their original work with vinyl 
sulfoxides to also include vinyl sulfilimines as a method for chemoselective synthesis of 
γ-butyrolactones (Scheme 4.21)150. 
 
Scheme 4.21 Synthesis of γ-butyrolactams via vinyl sulfilimines and dichloroketene. 
The benefit to this functional group is the ability to use alternative electrophiles to 
produce the same cyclic urea as presented in the original proposal. This can be achieved 
by reaction of the vinyl sulfilimine with an isocyanate (Scheme 4.22). 
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Scheme 4.22 Synthesis of cyclic ureas via vinyl sulfilimines and isocyanates. 
The main difficulty with this alternative process is the production of two 
constitutional isomers. According to the possible products, there appears to be 
competition between the oxygen of the isocyanate and the nitrogen of the sulfilimine to 
act as the ring closing nucleophile. It is proposed that alteration of the R2 group may 
increase the nucleophilicity of the nitrogen which will improve the yield of the major 
product. A variety of both electron withdrawing and electron donating groups will be 
utilized to observe effective product yield. Analysis of these products will mostly involve 
13C and 1H NMR shifts and IR absorption bands. The most significant changes that will 
be observed can be easily detected via IR. As previously stated, the urea product will 
have a signature peak between 1690-1620 cm-1. 
4.3.8 Computational Methods 
A major component of this work involved the use of theoretical models as a tool 
for the guidance of synthetic methodology to achieve the previously discussed cyclization 
reaction. In collaboration with Professor Dean Tantillo at the University of California: 
Davis, I have developed computational methods for the prediction of the chemical 
outcomes. All reported data was acquired with Gaussian 09151 using the Density 
Functional Theory (DFT)152-155 B3LYP /6-31G+(d,p) functional and basis set unless 
otherwise specified. Considering this project consists of a [3,3]-sigmatropic 
rearrangement, implementation of the B3LYP functional is preferred based on its 
reported success with modeling sigmatropic rearrangements.156-158 
 All initial calculations for the development of transition states were performed in 
the gas phase and later optimized in diethyl ether using the solvation model density 
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(SMD)159 continuum solvation model when specified. Transition-states were 
characterized by vibrational states and were subsequently connected to starting materials 
and products via intrinsic reaction coordinate (IRC) calculations.160-163 All energies are 
reported in Gibbs Free Energy at 298 K and structures have been modeled via Cylview 
visualization and analysis software.164 
4.3.8.1 Experimental Approach 
To begin with the theoretical studies, it was determined that exploration of the 
Marino rearrangement would be necessary. It would serve as the model system where the 
mechanism could be established and utilized for comparison with carbodiimide 
electrophiles. Additionally, it would provide support for the proposed rearrangement 
described in the original work by Marino and co-workers.122 First, all starting materials 
would be optimized under specified conditions. Once complete, the sum of the energy for 
the starting materials will act as the zero-point energy for the system. Following this, the 
molecules will be reacted via a transition state (TS) calculation. An IRC will be 
performed on the identified TS which will determine if the TS is plausible by connecting 
to starting materials and potential intermediates/products. This system of steps will be 
repeated until the final product is reached. The mechanistic hypothesis is presented in 
Scheme 4.23. 
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Scheme 4.23 Mechanistic hypothesis to be studied computationally. 
Once the mechanism for the Marino rearrangement has been established 
computationally, the carbodiimide system can be examined. For the purpose of reducing 
computational demand, the carbodiimide system utilized for all experiments is 
dimethylcarbodiimide. Although this is not a previously proposed carbodiimide for the 
experimental portion, it is best to begin with simpler models then increase complexity 
after a suitable model has been established. 
4.4 Results and Discussion 
4.4.1 Solvent System Studies 
A solvent screen has been performed for the reaction of phenyl vinyl sulfoxide 
with dicyclohexyl carbodiimide (DCC) or diisopropyl carbodiimide (DIC) at various 
temperatures (Table 4.2). This was performed to first identify the potential for 
carbodiimides to react without the need for further activation by an acid. This study was 
conducted due to the significant effect solvents can have on reactions. By varying 
between polar protic, polar aprotic, and non-polar aprotic solvent systems, reaction 
progression can be affected. For example, hydrogen bonding and dipole interactions with 
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ionic solutes can alter the activation energy needed for the reaction. Considering the vinyl 
sulfoxide is performing nucleophilic attack on the carbodiimide, it would be best to have 
polar aprotic solvents because the oxygen anion can better act as the electron donor. It is 
also important to consider the dielectric constants as an indicator of the solvents ability to 
support charge separation. With this reaction containing charged reactants and 
intermediates, it would be desirable to use solvents with high dielectric constants. 
Following this screening process, it was concluded that the electrophilicity of the central 
carbon will need to be increased to promote reaction. 
Table 4.2  
Solvent Screen and the associated dielectric constant 
Entry Solvent 
Temperature 
(°C) 
Dielectric 
Constant 
1 DCM 25 
10.36 
2 DCM 60 
3 DCM 25 
4 DCM 80 
5 THF 25 
7.58 6 THF 60 
7 THF 80 
8 DMF 25 
36.7 9 DMF 60 
10 DMF 80 
11 Acetone 25 20.7 
12 Nitroethane 25 28.06 
13 Ethylene Carbonate 25 90.5 
14 Benzene 25 2.27 
15 Benzene/TFA 25 - 
16 Dichloroacetic acid 25 8.2 
17 DCM/DCA 25 - 
18 HMPA 25 30 
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4.4.2 In Situ Infrared Results 
Preliminary results with 1,1,1,3,3,3-hexafluoro-2-propanol  have shown 
successful decrease in the absorption band at 2114 cm-1 upon addition of 1.0 equivalent 
of 1,1,1,3,3,3-hexafluoro-2-propanol. This implies the protonation of the nitrogen and 
subsequent conversion of the πCN double bond to a σCN single bond (Figure 4.6). 
 
Figure 4.6 Waterfall plot ReactIR graph showing protonation of diisopropyl 
carbodiimide. 
This result implies that the conjugate base of hexafluoroisopropanol has sufficient 
nucleophilicity for reaction with the activated carbon (Scheme 4.24). This reaction is 
indicated by the new signal appearing at 1694 cm-1 which is due to the imide C=N stretch 
of the pseudo-urea, 4.113. 
 
Scheme 4.24 Conjugate base addition to activated DIC. 
DIC absorption Band: 2114 cm-1 
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This result indicated that other acids with different pKa strengths may produce 
similar results. Therefore, both Lewis and Brønsted acids were reacted with DIC to 
observe activation of the central sp hybridized carbon (Table 4.3 and Table 4.4). There 
was greater success with the use of Brønsted acids with all experiments showing decline 
of the C=N stretch at 2114 cm-1. Further investigations with the Lewis acids will be 
required which include increased equivalents for cupric acetate as well as increased 
temperature. 
Table 4.3  
Lewis acid activation studies via ReactIR 
Entry Acid Equivalence Solvent Time (hr) Temp. ReactIR 
1 Cu(OAc)2 0.05 DMF 8 hr ambient no change 
2 Cu(OAc)2 0.20 DMF 8 hr ambient no change 
3 HgCl2 1.0 EtOAc 8 hr ambient no change 
4 Cu(OTf)2 0.05 DMF 2 hr ambient no change 
5 Cu(OTf)2 1.0 DMF 3 hr ambient C=N loss 
 
Table 4.4  
Brønsted acid activation studies via ReactIR 
Entry Acid Equivalence Solvent Time Temp. ReactIR 
1 DCA 2.0 DCM 5 min ambient C=N loss 
2 (CF3)2CHOH 9.5 (CF3)2CHOH 3 min ambient C=N loss 
3 (CF3)2CHOH 1.0 DCM 8 hr ambient C=N loss 
4 PyrOTf 1.0 DMF 4 hr ambient C=N loss 
5 PyrHCl 1.0 DMF 4 hr ambient C=N loss 
 
ReactIR spectra showed complete loss of the imide stretch when using stronger 
Brønsted acids such as trifluoromethanesulfonic acid (Figure 4.7). A promising result is 
the loss of the imide stretch without appearance of signals implying the nucleophilic 
attack of the conjugate base at the electrophilic carbon center. Furthermore, the use of 
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cupric triflate in 1.0 equivalent afforded decline in the imide stretch intensity but did not 
fully remove the signal. This implicates that there is likely a coordination of the copper 
with DIC but no bonds are being broken (Figure 4.8). 
 
Figure 4.7 Waterfall plot ReactIR graph showing protonation of diisopropyl carbodiimide 
with trifluoromethansulfonic acid. 
 
Figure 4.8 Waterfall plot ReactIR graph showing coordination of diisopropyl 
carbodiimide with cupric triflate. 
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Finally, as a control experiment to ensure that what is being observed correlates 
with previous work, the Pfitzner-Moffatt oxidation conditions were examined. The results 
of DIC reacting with aqueous phosphoric acid confirm that complete loss of the imide 
stretch is to be expected with activation of the carbodiimide (Figure 4.9). 
 
Figure 4.9 Waterfall plot ReactIR graph showing protonation of diisopropyl carbodiimide 
with phosphoric acid. 
4.4.3 Computational Results 
4.4.3.1 Marino Rearrangement 
TS1 4.104 was identified via transition state calculations and the TS was 
confirmed with IRC calculations (Figure 4.10). It was observed that the TS had an 
extremely low energy barrier of 1.8 kcal/mol which implies this portion of the 
mechanism to be plausible. In addition, the identified intermediate (Int1 4.105) was 
within a shallow energy well with a decrease of only 0.5 kcal/mol. With the IRC 
successfully implemented, it was decided to take this step and perform the same 
calculations with the M06-2X functional. This is a crucial comparison to provide 
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evidence that the system can by repeated with alternative methods without significant 
deviation from the original results. Although an IRC was not performed with M06-2X, all 
three structures were reoptimized and showed minimal deviation from the energy levels 
calculated using B3LYP. 
 
Figure 4.10 TS1 identification of the Marino rearrangement. 
Furthermore, the system was examined using diethyl ether as solvent. Ether was 
chosen as the solvent due to Marino reporting its use in the original publication. When 
beginning this set of calculations, the identification of TS1 4.104 was unsuccessful. It 
was postulated that the solvent promotes a “concerted” mechanism where no TS exists 
between the sulfoxide attack and sigmatropic rearrangement. To support this hypothesis, 
a single point energy calculation was performed on TS 4.104 and intermediate 4.105 
identified in the vacuum system. The observed result was a 5.0 kcal/mol higher energy 
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for intermediate1, supporting the hypothesis that solvent has eliminated the presence of 
TS1 4.104. 
With the first intermediate and TS identified in the gas phase, an attempt to 
discover the second transition state which involves the [3,3]-sigmatropic rearrangement 
was attempted. Although TS 4.114 was identified, it was observed to have unexpected 
vibrations which implied an alternative reaction pathway. Essentially, an imaginary 
frequency was observed but the vibrations are associated with unexpected bond 
formation/cleavage considering it is desired to see a sigmatropic rearrangement (Figure 
4.11). 
 
Figure 4.11 Ball and stick model of TS2 4.114. 
An IRC was performed on this TS which confirmed the hypothesis that this would 
lead to an alternative pathway. What is of interest is that neither products of the IRC 
connect to the starting intermediate. Rather, two individual products 4.115 and 4.39 were 
formed which implies the possibility of a bifurcation from the associated transition state 
(Figure 4.12). The forward IRC shows promise in the formation of the desired γ-lactone 
but has the unexpected cyclobutene product in the reverse direction. Another significant 
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observation of this IRC is the lack of an additional transition state as previously 
hypothesized. The slight shoulder in the forward IRC represents the final step of the 
mechanistic hypothesis wherein the ring-closing step occurs. 
 
Figure 4.12 IRC of TS2 4.114. 
In response to this result, it was attempted to work from the reverse direction to 
see if a connection could be made to the pre-[3,3]sigmatropic rearrangement TS (Figure 
4.13). TS2a 4.116 was identified and proceeded to the lactone product 4.39 in the forward 
IRC. The reverse IRC produced an intermediate 4.117 that had no significant difference 
in structure from TS2a. 
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Figure 4.13 IRC of TS2 starting from the post [3,3] rearrangement. 
The issue presented here is no IRC connects int1 with a TS or other structure that 
undergoes the [3,3] rearrangement. It is postulated that this is due to the remainder of the 
reaction occurring in a “downhill” process. Once TS1 4.114 is achieved there is never 
another significant increase in the energy and therefore no presence of additional energy 
wells. Though a TS2 has been identified (4.116) that then proceeds to the lactone 
product, there is no IRC that connects the post [3,3] intermediate with a pre [3,3] 
intermediate. Based on additional calculations containing solvent, there is enough 
supporting evidence to hypothesize that the rearrangement is therefore a concerted 
process wherein only one true TS exists prior to the sigmatropic rearrangement and 
subsequent lactone formation. 
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4.4.3.2 Carbodiimide Studies 
After reaching a conclusion with the Marino rearrangement, study of the 
carbodiimide system was started based on the mechanistic proposal bearing resemblance 
to the Marino rearrangement (Scheme 4.25). 
 
Scheme 4.25 Proposed mechanism for the carbodiimide annulation. 
To begin, an experiment to discover the first transitions state was implemented in 
the gas phase. Once identified, an IRC was performed to determine the first intermediate 
and confirm the connection to starting materials (Figure 4.14). Two observations from the 
IRC provided intriguing results. First, the intermediate produced was an unexpected 
dissociation of the transition state to urea 4.126 and vinyl sulfide 4.125. The second 
observation was the energy requirement to reach TS1 4.119. With an energy barrier of 45 
kcal/mol, it can be concluded that without exogenous acid activation the barrier is too 
high and this reaction would not occur. This provides further support of the experimental 
results which show no reactions occurring during the solvent screen. 
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Figure 4.14 IRC for unprotonated TS1 4.119. 
With it established that exogenous acid activation was necessary, a study 
containing a protonated carbodiimide 4.127 was implemented. TS 4.128 was identified 
and an IRC was performed (Figure 4.15). A promising observation of this IRC is the 
energy barrier of 19 kcal/mol. This is a significant decrease from the unprotonated 
carbodiimide and presents a plausible energy barrier to overcome. Despite this, the 
resultant dissociation for the development of vinyl sulfide 4.125 and protonated urea 
intermediate 4.129 was still observed. 
 141 
 
Figure 4.15 IRC for protonated TS1 4.128. 
With these results, it was decided to continue forward with the identification of 
the next TS in the reaction. Considering the first intermediate is a significant deviation 
from the original proposed mechanism the following step was designed with influence for 
the next needed transition state by placing the negatively charged nitrogen near the 
external position of the alkene (Figure 4.16). The identified TS 4.130 was then utilized in 
an IRC with promising results for the development of the second intermediate 4.131. 
With this potential reaction pathway established, a combined IRC was produced to show 
the connection from starting materials to the current intermediate 4.131 (Figure 4.17). 
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Figure 4.16 IRC for TS2 4.130. 
 
Figure 4.17 Combined IRC for the protonated carbodiimide system. 
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4.5 Summary and Conclusions 
This chapter has demonstrated the important role that vicinal diamines exhibit 
within a variety of synthetic and medicinal applications. The role of these diamines in 
natural products has also been exemplified and expanded to include cyclic ureas and 
cyclic guanidines. It has been realized through the implementation of in-situ reaction 
monitoring that an exogenous acid is capable of activating the carbodiimide. 
Furthermore, activation with hexafluoroisopropanol (pKa = 9.3) developed a conjugate 
base that participated in subsequent nucleophilic attack of the carbodiimide which gave 
insight to the necessary acid strength. Once appropriate conditions have been identified 
for conversion to cyclic ureas, chiral phosphoric acids can be implemented to study 
asymmetric synthesis. 
Additionally, theoretical modeling provided support for experimental 
observations. Notably, Bronsted acid activation drastically reduced the activation energy 
for nucleophilic attack from PVS. Without this activation, it was clear that no reaction 
would occur which was validated by initial condition screenings with un-activated 
diisopropylcarbodiimide. Additional modeling will be needed to identify a completed 
reaction pathway and further studies utilizing Lewis acid activated systems will need to 
be examined. 
4.6 Experimental 
4.6.1 General Methods 
Solvent Screen General Procedures: To a 6 mL conical vial equipped with a spin vane 
was added the carbodiimide (1.64 mmol) and solvent (1.64 mL). Vinyl sulfoxide (215 
µL, 1.64 mmol) was then added to the reaction. When applicable (Error! Reference 
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source not found.) the acid catalyst was then added (0.820 mmol). The reaction was then 
stirred at the temperature outlined in Error! Reference source not found.. All reactions 
were monitored using TLC with a developing solvent of 4:1 Hexanes:Acetone. Plates 
were visualized using UV followed by phosphomolybdic acid dye. 
Entry Solvent Carbodiimide Acid Temp. 
(ºC) 
Time (hr) TLC 
1 CH2Cl2 DCC - ambient 22 no change 
2 CH2Cl2 DCC - 60 22 no change 
3 CH2Cl2 DCC - ambient 16 new spots 
4 CH2Cl2 DCC - 80 16 no change 
5 THF DCC - ambient 22 no change 
6 THF DCC - 60 22 no change 
7 THF DCC TFA ambient 16 new spots 
8 THF DCC - 80 16 no change 
9 DMF DCC - ambient 22 no change 
10 DMF DCC - 60 22 no change 
11 DMF DCC TFA ambient 16 new spots 
12 DMF DCC - 80 16 no change 
13 CH2Cl2 DCC DCA ambient 16 new spots 
14 THF DCC DCA ambient 16 new spots 
15 DMF DCC DCA ambient 16 new spots 
16 Acetone DCC - ambient 16 no change 
17 Nitroethane DCC - ambient 16 no change 
18 Ethylene 
Carbonate 
DCC - ambient 16 no change 
19 Benzene DCC - ambient 8 no change 
20 Benzene DCC TFA ambient 8 no change 
21 DCA DIC DCA ambient 0.5 new spots 
22 CH2Cl2 DIC DCA ambient 0.5 new spots 
 
4.6.2 Synthesis of Intermediates 
Reaction of diisopropyl carbodiimide with 1,1,1,3,3,3-hexafluoro-2-propanol: NGJ-1-
080. To a 4 mL vial equipped with a stir bar was added DIC (50.9 µL, 0.328 mmol) and 
DCM (328.0 µL, 84.9 mmol). The ReactIR probe was submerged into the solution and 
the mixture was stirred. One reading per minute was taken for a total of 3 minutes before 
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1,1,1,3,3,3-hexafluoro-2-propanol was added (17.3 µL, 0.164 mmol). The reaction was 
stirred for 3 hr. at room temperature with no observed decrease in peak intensity at 2114 
cm-1. Another 0.5 eq. of the hexafluoro-2-propanol (17.3 µL, 0.164 mmol) was added for 
a total of 1.0 eq. A continual decrease in peak intensity at 2114 cm-1 and appearance of a 
new peak at 1694 cm-1 was observed during a time period of 4.5 hr. Phenyl vinyl 
sulfoxide (43.1 µL, 0.328 mmol) was added and the solution was stirred for an additional 
8 hr. No further changes were observed.
 146 
  
Supplementary data (NMR, IR, MS, and Elemental Analysis) for Chapter 2 compounds is 
provided in the supporting text titled “Supplementary Spectral Data”. 
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Supplementary data (NMR, IR, MS, and Elemental Analysis) for Chapter 3 compounds is 
provided in the supporting text titled “Supplementary Spectral Data”. 
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